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Abstract  
Background – Feline upper respiratory tract aspergillosis (URTA) is an emerging 
mycosis with worldwide distribution. It occurs in two forms – sino-orbital and sino-
nasal. Sino-orbital aspergillosis (SOA) is an invasive fungal infection with high 
mortality due to difficulty in its treatment. SOA is commonly caused by cryptic 
species in Aspergillus section Fumigati that are often resistant to antifungal triazoles 
but are usually susceptible to caspofungin. Caspofungin, an echinocandin, is a 
lipopeptide antifungal that inhibits glucan synthase and prevents the synthesis of β-
1,3-glucans in the fungal cell wall. It is indicated for the treatment of refractory 
invasive aspergillosis in humans and has been used successfully in cats with sino-
orbital aspergillosis. Pharmacokinetic data is lacking in cats and cannot be 
extrapolated from other studies as cats possess several genetic polymorphisms and 
unique metabolic pathways compared to other species.  
Aims – To determine the pharmacokinetics of caspofungin acetate in healthy adult 
cats and determine an optimal dosing regimen that can be utilised in a clinical 
setting.  
Materials and Methods – Eight adult healthy cats were administered caspofungin 
(1mg/kg IV) over 1hr (Day 1). Six cats subsequently received caspofungin (1mg/kg 
IV) daily for an additional 6 days (Day 2-7). Blood was collected at 0 h, 0.5 h, 0.75 h, 
1 h, 1.25 h, 1.5 h, 2 h, 3 h, 6 h, 9 h, 12 h and 24 h after drug administration (Day 1), 
before the next dose (Days 2–7), and 24 h after final dosing (Day 8). Plasma 
caspofungin levels were determined using HPLC-tandem mass spectrometry. 
Nonlinear mixed-effects pharmacokinetic modelling and simulation was used to 
investigate caspofungin population pharmacokinetics and explore dosing regimens in 
cats using caspofungin minimum effective concentrations (MECs). In the final 
pharmacokinetic model an optimum maximum concentration (Cmax): MEC ratio of 10-
20 was used to guide caspofungin efficacy. Simulations were performed for dosing 
regimens (doses 0.25 – 1 mg/kg and 6 – 72 h dosing intervals) with and without the 
inclusion of a loading dose. 
Results - Using a 1 mg/kg dose Cmax was 14.8 µg/mL, Cmax at steady state was 19.8 
µg/mL, Cmin was 5 µg/mL and Cmax: MEC was >20 in 42.6% of cats after multiple 
doses. An optimal Cmax: MEC ratio was achieved in caspofungin simulations using 
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0.75 mg/kg q 24 h or 1 mg/kg q 72h. However, at 1 mg/kg q 72h, Cmin was < MEC 
(i.e. <1 μg/mL) in over 95% of the population. Using a daily dose of 0.75 mg/kg, the 
Cmax: MEC was optimal and Cmin was > 2.5 μg/mL for more than 95% of the 
population. Using a loading dose of 1 mg/kg and daily dose of 0.75 mg/kg thereafter, 
the Cmax: MEC was optimal and Cmin was > 2.5 μg/mL for 98% of the population. 
Conclusion and clinical importance – Mean plasma caspofungin concentrations were 
> 1.0 µg/ml for the duration of the 24 h sampling period, which exceeds the MIC 
effective against most Aspergillus species. Caspofungin given at 1 mg/kg IV q 24h is 
safe in cats. Based on the modelling data, a daily caspofungin dose of 0.75 mg/kg 
daily (with or without the use of a 1mg/kg loading dose) is likely to achieve target 
therapeutic concentrations, meet the proposed Cmax: MEC window and provide 
consistent exposure between doses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
TABLE OF CONTENTS 
 
Acknowledgements………………………………………………………………………..ii 
Abstract……………………………………………………………………………………..iii 
Table of contents.…………………………………………………………………………iv 
List of figures……………………………………………………………………………...vi 
List of tables…………………………………………………………………………….....vi 
List of abbreviations...…………………………………………………………………...vii 
 
Chapter 1. INTRODUCTION………………………………………………………………1 
 1.1 Introduction …………………………..………………………………………..1 
 1.2 Aim ..……………………………………………………………………………..4 
Chapter 2. LITERATURE REVIEW……………………………………………………….5 
2.1. Idiosyncrasies of feline drug metabolism………………………………..5 
2.2. Overview of pathogenic fungi...…………………………………………..10 
 2.2.1. Pathogenic Aspergillus species…………………………………...12 
 2.2.2. Structure of filamentous fungi……………………………………..13    
2.3. Antifungal therapy in small animal veterinary medicine……………..14 
 2.3.1. Amphotericin B……………………………………………………...16 
 2.3.2. Azole Antifungal drugs……………………………………………..17 
  2.3.2.1. Itraconazole……………………………………………….19 
  2.3.2.2. Voriconazole………………………………………………20  
  2.3.2.3. Posaconazole……………………………………………..20  
 2.3.3. Pyrimidines………………………………………………………….21 
 2.3.4. Echinocandins………………………………………………………22 
  2.3.4.1. Mechanisms of action……………………………………22 
 vi 
  2.3.4.2. Pharmacokinetics of echinocandins……………………23   
  2.3.4.3. Clinical efficacy of echinocandins………………………25 
  2.3.4.4. Adverse events associated with echinocandins………27  
2.4. Future directions and novel antifungal therapies……………………..28 
2.5. Conclusion……………………………………………………………………31 
Chapter 3. MATERIALS AND METHODS……………………………………………..32 
3.1. Animals………………………………………………………………………..32 
3.2. Drug Administration ………………………………………………….…….32 
3.3. Blood Collection ……………………………………………......................33 
3.4. Analytical Method …………………………………………………………..34  
3.5. Non-compartmental Pharmacokinetic Analysis …………………..…..35 
3.6. Population Pharmacokinetic Analysis and Dose Regimen 
Simulations ……………………………………………………………………….35  
3.6.1. Methods Software .……………………………….........................35 
3.6.2. General Modelling Strategy ……………………………………….36 
3.6.3. Covariate Model Building ………………………………………….37 
3.6.4. Model Evaluation …………………………………………………..37 
3.6.5. Caspofungin Dose Regimen Simulations ……………………….38  
Chapter 4. RESULTS……………………………………………………………………..39 
4.1. Safety………………………………………………………………………….39 
4.2. Non-compartmental Pharmacokinetic Analysis ………………………39  
4.3. Pharmacokinetic Modelling ……………………………………………….41 
4.4. Caspofungin Dose Regimen Simulations ……………………………...44  
Chapter 5. DISCUSSION…………………………………………………………………49 
REFERENCES……………………………………………………………………………..55 
APPENDIX I………………………………………………………………………………..84 
 vii 
Leshinsky, J., McLachlan, A., Foster, D. J. R., Norris, R., & Barrs, V. R. (2017). Pharmacokinetics of caspofungin 
acetate to guide optimal dosing in cats. PLoS ONE, 12(6), e0178783. 
http://doi.org/10.1371/journal.pone.0178783 ; Supplementary material included.  
APPENDIX 2 ……………………………………………………………………………102 
CANCIDAS â (Caspofungin acetate) Product Information (S-WPC-MK0991-IV-102016)  
 
List of figures 
Figure 2.1 Diagram of the azole structures…………………………………….......19 
Figure 4.1 Mean plasma concentration-time curve for intravenous (IV) 
caspofungin acetate (1 mg/kg)……………………………………………40  
Figure 4.2 Mean plasma concentration-time curve for IV caspofungin acetate (1 
mg/kg) after reaching steady state……………………………………….41  
Figure 4.3 Visual predictive check plot for 1000 simulations of the final 
pharmacokinetic model and observed data……………………………..43  
Figure 4.4  Plots of caspofungin concentration over time…………………………..46 
Figure 4.5  Plots of caspofungin Cmax:MEC over time……………………………….47  
Figure 4.6 Plots of caspofungin Cmax:MEC ratio over time utilising a 1mg/kg 
loading dose on day 1 followed by 0.75 mg/kg daily thereafter……….48  
 
List of tables  
Table 2.1  Pathogenic fungal species of companion animals……………………..11 
Table 2.2  Spectrum of activity of antifungals against common fungi…………….15  
Table 2.3  Summary of the susceptibility of some of the “cryptic” Aspergillus 
species within section Fumigati…………………………………………..16  
Table 2.4 Pharmacokinetics of echinocandins in adult humans………………….24 
Table 4.1  Pharmacokinetic parameters following administration of a single 
1mg/kg dose of caspofungin acetate IV and after reaching steady state 
after consecutive daily dosing of 1mg/kg IV……………………………40  
Table 4.2  Population pharmacokinetic parameters for cats………………………42  
 viii 
Table 4.3  Summary of caspofungin model-independent pharmacokinetic 
parameters and exposure indices from simulations which result in 
maximum % animals 10<Cmax:MEC<20 ratio for the three dosing 
regimens…………………………………………………………………….44  
List of abbreviations  
5FC  Flucytosine 
ABLC  Amphotericin B lipid complex  
AMB  Amphotericin B  
AFG  Anidulafungin 
ATP  Adenosine triphosphate  
AUC   Area under the concentration time curve  
BVS  Between subject variability 
CAS  Caspofungin  
CBC  Complete blood count  
CI  Confidence interval  
CL  Clearance  
FLC  Fluconazole 
ISA  Isavuconazole  
ITC  Itraconazole  
IV  Intravenous  
MEC  Minimum effective concentration  
MFG  Micafungin 
MIC  Minimum inhibitory concentration  
NAT  N-acetyltransferase  
OJB  Objective function value 
PCR   Polymerase chain reaction  
POS  Posaconazole 
PPV  Population parameter variability 
RVC  Ravuconazole 
SNA  Sino-nasal aspergillosis   
SOA  Sino-orbital aspergillosis  
TPMT  Thiopurine S-methyltransferase  
UGT   Uridine diphosphate glucuronosyltransferases 
URTA  Upper respiratory tract aspergillosis  
USG   Urine specific gravity  
V  Volume of distribution  
VPC   Visual predictive check  
VRC  Voriconazole 
 1 
Chapter 1  
INTRODUCTION  
1.1 Introduction  
Fungal infections are less common than bacterial infections in veterinary medicine 
[1-3]. Consequently, there are fewer anti-microbial drugs available for the treatment 
of mycoses. However, due to the increased incidence of systemic fungal infections in 
human medicine, there has been an increased drive to explore new anti-fungal 
agents since the 1990s. The incidence of systemic mycoses in veterinary medicine, 
seems to be similarly increasing [2]. Pinner, Teutsch (4) reported that by the late 
1990s fungal infection was the seventh most common cause of infection-related 
death in humans. This increase has been attributed to immunosuppression from 
immunodeficiency virus infections, haematopoietic stem cell and organ transplants, 
chemotherapy and haematological malignancies [3, 5, 6]. The development of fungal 
infections in critically ill patients has also been described in advanced liver cirrhosis 
and chronic pulmonary obstructive disease [7]. Global warming, leading to extension 
in the geographical range of pathogenic fungi has been implicated in the increased 
prevalence of mycotic disease in mammals [8].  
 
Feline upper respiratory tract aspergillosis (URTA) is an emerging infectious disease 
with worldwide distribution [9]. The first case of feline URTA was reported in 
Australia in 1982 [10] and over 60 cases have since been reported in the veterinary 
literature, particularly in the last 5 years [9-24]. There are two anatomical forms of 
URTA in cats, sino-orbital aspergillosis (SOA) and sino-nasal aspergillosis (SNA), 
which are the result of colonisation of the upper respiratory tract with Aspergillus spp. 
Significant morbidity in affected cats occurs as a result of subsequent inflammation 
and tissue destruction [9]. SNA in cats is usually non-invasive and confined to the 
nasal passages and paranasal sinuses, similar to disease seen in canine SNA, 
although there have been reports of invasive SNA occurring in cats [25, 26]. SOA 
accounts for more than 65% of cases of feline URTA. The nasal passages are the 
primary site of infection; however SOA represents an extension of the disease to 
involve the orbit resulting in the development of mass lesions that can also extend 
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into the nasopharynx [15, 25]. Purebred cats, in particular brachycephalic breeds of 
Persian lineage, are over represented in cases of URTA and appear to be at 
increased risk [15, 21, 25, 27, 28].  Although invasive fungal infections are most 
commonly described in immuno-compromised individuals, SOA is associated with 
disease in apparently immuno-competent cats and carries a more guarded prognosis 
compared to SNA [9].  
 
Aspergillus species are ubiquitous saprophytic fungi that are found in soil, water and 
decaying vegetation [29]. Sporulation occurs in decaying matter, producing a large 
number of small conidia, which are aerosolised and disseminate through the air via 
wind currents. The respiratory tract of both humans and animals is thus exposed to 
Aspergillus conidia on a daily basis. Aspergillus fumigatus is the most common 
Aspergillus species encountered by humans and animals [29]. In dogs and cats, it is 
most frequently associated with SNA [9, 30, 31]. SOA, on the other hand, is caused 
by cryptic species of Aspergillus in section Fumigati [9, 31]. Cryptic species, such as 
those within the A. viridinutans complex, are closely related groups of species that 
are indistinguishable from each other by morphological methods and require 
molecular methods for identification [32, 33].   In order to accurately identify fungal 
pathogens in humans and animals, molecular methods of identification are 
recommended, as correct species identification may facilitate improved treatment 
outcomes in cases of aspergillosis [25, 29, 34, 35]. 
 
Novel fungal species, and in particular cryptic species, are emerging pathogens of 
humans and companion animals. Barrs, van Doorn (31) described a novel 
heterothallic species in Aspergillus section Fumigati, Aspergillus felis, that was 
isolated from human patients with invasive pulmonary aspergillosis, cats with URTA 
and a dog with disseminated invasive aspergillosis. A. fumigatus section Fumigati 
contains more than 63 species, many of which cannot be clearly distinguished 
morphologically from one another or from A. fumigatus [35, 36]. A. felis is a member 
of the A. viridinutans complex, which contains other species capable of causing 
illness in cats include A. udagawae, A. wyomingensis and A. parafelis [18, 23, 26].  
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As well as causing invasive disease these fungal species are often refractory to 
conventional anti-fungal therapeutic regimens. A. felis isolates have high minimum 
inhibitory concentrations of antifungal triazoles [31]. Isolates of A. felis can also 
exhibit in vitro cross-resistance to itraconazole and voriconazole, and to itraconazole, 
voriconazole and posaconazole [31, 37]. Optimal treatment protocols for cats with 
SOA have not yet been identified and are currently based on treatment responses 
from a small number of affected cats who required systemic antifungal therapy for at 
least six months. 
 
The aim of systemic anti-fungal therapy is to eradicate the fungal organism without 
causing patient impairment. However, many antifungal agents have a narrow 
therapeutic index and adverse reactions can be problematic. Each agent is unique in 
its therapeutic role, toxicity profile and drug interactions. To maximise effectiveness, 
it is important to understand the pharmacokinetic and pharmacodynamics profile of 
each drug [38]. Treatment failures may also be attributed to their immense plasma 
concentration variance within and among individuals [39].  Despite the development 
of novel antifungal agents for treatment of human aspergillosis, some patients 
remain difficult to treat. This can be a direct result of drug interactions, antifungal 
resistance, fungal misidentification or organ dysfunction preventing the use of some 
agents [40].  
 
Most antifungal drugs used in small animal veterinary medicine are not approved for 
use in companion animal species. They are used off-label, with indications and 
dosing regimens often extrapolated from human medicine [41]. This approach is not 
optimal due to the species differences in pharmacokinetics and susceptibility to toxic 
effects. Cats, in particular, are deficient in several drug conjugation pathways and 
have unique drug metabolism and disposition compared to dogs and humans, as 
well as genetic polymorphisms, which increases their risk of toxicity and make dose 
extrapolation potentially dangerous [42]. 
 
Caspofungin is an echinocandin approved in many countries for use in human 
medicine for the treatment of invasive aspergillosis that is refractory to other 
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antifungal therapy [43]. Caspofungin has a unique mechanism of action compared to 
the traditional antifungal agents such as amphotericin B and azoles [38, 44]. As 
echinocandins exert their antifungal activity directly on the fungal cell wall, adverse 
effects in mammalian species are expected to be low [45]. Drug-drug interactions 
and enhanced toxicity due to echinocandins are of minimal risk compared to triazole 
antifungals [1, 41].  
 
Caspofungin was well tolerated and effective in a cat with sino-orbital aspergillosis 
[9]. A German Shepherd with disseminated invasive aspergillosis caused by A. 
deflectus was treated with caspofungin for over a year with no adverse effects 
documented [46]. The pharmacokinetics of micafungin, another echinocandin, have 
been studied in mice, rats and dogs [47]. Recently, the pharmacokinetic profile of a 
novel long acting echinocandin (CD101, biafungin) was investigated in mice, rats, 
dogs, cynomolgus monkeys and chimpanzees [48]. However, pharmacokinetic 
studies of other echinocandins, including caspofungin, have not been described in 
either the cat or dog. Current dosing regimens are extrapolated from human 
treatment recommendations. The pharmacokinetics of caspofungin in healthy cats 
needs to be described before clinical investigation in cats with naturally occurring 
fungal disease can be performed.  
 
This review presents a brief overview of feline drug metabolism and pathogenic 
Aspergillus species, in particular those responsible for feline URTA. Current 
knowledge on anti-fungal drugs, with an emphasis on the echinocandin class, is also 
presented.  
 
1.2. Aim  
The objective of this study was to determine the pharmacokinetics of caspofungin 
acetate in healthy adult cats and to devise an optimal dosing regimen for the 
treatment of aspergillosis in a clinical setting. 
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Chapter 2 
LITERATURE REVIEW 
2.1 Idiosyncrasies of feline drug metabolism 
 
There has been considerable research undertaken to improve our understanding of 
drug metabolism and disposition in cats compared to other species; particularly 
deficiencies in drug metabolism pathways [49-68]. Xenobiotic metabolism plays a 
central role in the therapeutic and toxic effects that these pharmaceutical compounds 
may possess. If a species lacks the preferred metabolic pathway for the drug, 
elimination times will be prolonged and alternate metabolite production will be 
difficult to predict [69]. The metabolic pathways that have been studied in cats 
include glucuronidation (uridine diphosphate glucuronosyltransferases (UGTs)), 
acetylation (N-acetyltransferase isoform (NATs)), methylation (thiopurine 
methyltransferase) and active transporters (ATP-binding cassettes). Court (42) 
reviewed the pharmacokinetic evidence of species differences for drug metabolism 
among cats, dogs and humans; drugs that undergo metabolic conjugation, including 
glucuronidation, sulfation or glycination, such as aspirin, propofol and paracetamol 
can be cleared more slowly in cats [42, 69].  
 
Glucuronidation deficiency is one of the most widely appreciated pharmacological 
idiosyncrasies of cats. If glucuronide synthesis is the major pathway of inactivation 
and other pathways are less efficient, there may be toxic accumulation of substances 
[69]. The elimination of many drugs, toxins and endogenous compounds into urine 
and/or bile is facilitated by conjugation with glucuronic acid; this process is catalysed 
by UGT enzymes expressed in the liver, kidney and intestinal mucosa, which are the 
primary sites of drug metabolism. Glucuronidation deficiency in cats mainly affects 
compounds with a simple planar phenolic structure [55, 70]. In humans and some 
other species, it has been shown that these compounds are mainly metabolised in 
the liver by UGT1A6 and UGT1A9 [56]. There does not appear to be a related 
UGT1A isoform expressed by the feline liver, and a mutation in the UGT1A6 gene 
results in a non-functional protein [53, 57, 71]. Additionally, the human liver 
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expresses five different UGT1A isoforms whereas cats only express two different 
UGT1A isoforms [57].  
 
UGT1A1 is conserved in all species as it is essential for the glucuronidation and 
clearance of bilirubin. UGT1A2, the other isoform expressed in the feline liver is 
believed to be related to human UGT1A3 and UGT1A4, which glucuronidate drugs 
containing carboxyclic acid and amines [57]. Deficiency in functioning UGT1A6, the 
UGT isoform primarily responsible for paracetamol metabolism, causes shifting of 
paracetamol metabolism to the less efficient sulfation pathway contributing to toxicity 
in cats [57]. Other UGT isoforms, such as UGT2B7 and UGT2B15, are important for 
glucuronidation of other drugs (Court 2013). van Beusekom, Fink-Gremmels (53) 
showed that cats are also deficient in UGT2B7 and this may account for reduced 
morphine glucuronidation in cats [42].  
 
Benzoic acid poisoning and hepatotoxicity has been shown in cats. The likely result 
of their UGTB isoforms is an inability to glucuronidate benzoic acid and benzyl 
alcohol, which are frequently added to drugs as preservative [54, 69]. Cats are able 
to glycinate benzoic acid, although this is a much slower process than 
glucuronidation and toxic accumulation tends to occur [72]. Although deficient 
glucuronidation is often cited as the cause of drug toxicity or slowed clearance in 
cats, there is only direct evidence of paracetamol, chloramphenicol, clofibrate, 
morphine, orbifloxacin and valporate being poorly glucuronidated [50, 51, 56, 73-77].  
 
The ATP-binding cassette (ABC) transporters are a group of transmembrane 
proteins that derive energy from ATP to transport various molecules across cell 
membranes [60].  These transporters modulate drug absorption, distribution and 
elimination according to their level of expression in the intestine, liver, kidney, and at 
biological barriers such as the blood-brain barrier [78]. There are four members of 
this group of transporters that are known to be responsible for transporting drugs 
commonly used in veterinary patients, including ABCB1 (MDR1 or P-glycoprotein), 
ABCC1 (multidrug resistance-related protein-1) and ABCC2 (multidrug resistance-
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related protein-2). Some of the commonly used drugs in veterinary medicine that rely 
on ABC transporters include fluoroquinolones, loperamide and cimetidine [78].  
 
Permeability glycoprotein (P-glycoprotein) has been shown to influence the 
pharmacokinetics of many substrates including macrocyclic lactones in mammals, by 
actively transporting absorbed substrates back across a variety of cell membranes 
[79]. P-glycoprotein is found in all mammalian species and is widely distributed in 
tissues. However, a defect in the gene that codes for P-glycoprotein can result in 
accumulation of substrates and compromise protective barriers such as the blood 
brain barrier, causing toxicity [80]. A defect in the MDR1 gene, which encodes for P-
glycoprotein, is associated with ivermectin sensitivity in herding dogs [81, 82]. 
Although a similar defect has not yet been described in cats, there have been 
anecdotal reports of ivermectin toxicity in cats, which could be due to the same 
mechanism [82]. The tissue distribution of P-glycoprotein in cats has been 
investigated. Van Der Heyden, Chiers (66) found similar distribution of P-
glycoprotein in the liver, colon, adrenals and brain to humans and canines; however, 
it is not equally distributed in the kidney. This may have implications for feline renal 
susceptibility to toxic substances.  
 
Fluoroquinolone antibiotic toxicity in cats is associated with temporary or permanent 
blindness [83, 84]. Ramirez, Minch (61) suggested that this toxicity is due to 
deficiency in the ABCG2 transporter resulting in inefficient efflux of fluoroquinolones 
from the feline eye. Like other ABC transporters, ABCG2 pumps substrates out of 
the cell, thus protecting the host from toxicity. Four amino acid changes have been 
identified in the feline ABCG2, and it is unknown if a combination of these or a single 
amino change is responsible for the defective function of the ABCG2 transporter [60, 
61]. 
 
Mealey (60) hypothesises that deficient ABCG2 function in cats could lead to 
shunting of paracetamol metabolism away from sulfation and towards cytochrome 
P450-mediated pathways, thus further contributing to paracetamol toxicity in cats 
rather than a pure deficiency in UGT1A6 [57]. Defective ABCG2 function in cats may 
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have other physiological consequences as have been demonstrated in ABCG2 
knockout mice and humans with functional polymorphism of ABCG2 [60]. ABCG2 
has a role in protecting erythrocytes from oxidative damage, thus their deficiency 
may also be responsible for drug-induced erythrocyte damage such as the 
development of Heinz bodies and/or methaemoglobinaemia with paracetamol [60].  
 
Arylamine drugs, such as sulphonamide antibiotics, hydralazine and procainamide, 
are metabolised through the N-Acetylation pathway. N-acetylation is catalysed by the 
N-acetyltransferase enzymes NAT1 and NAT2. Canid species, including domestic 
dogs, lack both of the genes encoding these enzymes [68]. Cats lack NAT2 but still 
express NAT1 with lower enzyme activity than other species [49]. NAT2 deficiency 
has been associated with low acetylation in the feline liver of various sulphonamides 
and is also proposed to contribute to the mechanism of paracetamol toxicity n cats 
as well as dogs [42, 49]. N-acetylation is the major mechanism of metabolism of 
caspofungin acetate in humans and “pre-clinical” species (mice, rats, rabbits and 
monkeys), thus toxicity due to deranged acetylation in cat livers could be a limiting 
factor in its use [45, 85].        
 
Cats are particularly sensitive to the myelosuppressive effects of thiopurine drugs 
such as azathioprine [62, 67, 86]. S-methylation by thiopurine S-methyltransferase 
(TPMT) is an important detoxification mechanism for several chemotherapeutic and 
immunosuppressive drugs, including azathioprine [42]. Salavaggione, Yang (62) 
demonstrated that feline erythrocytes have significantly lower TPMT activity, which is 
a reflection of low enzyme activity in other tissues, compared to humans and dogs. 
There was also large individual variation in the level of TMPT activity [62]. The low 
activity of thiopurine S-methyltransferase may help to explain the sensitivity of cats to 
thiopurine drugs [62]. The reason for low TMPT levels in cats is unknown; however, 
several polymorphisms in the coding sequence that affect enzyme protein levels and 
activity for the feline TMPT gene have been identified and could explain this finding 
[42, 62].       
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Acetylsalicylic acid (aspirin) has been used to treat acute pain and inflammation and 
as an antithrombotic agent for decades in cats, dogs and humans. However, it is 
eliminated in cats at a much slower rate relative to other mammals and therefore can 
only be used at doses 2-4 x lower and frequencies 4-6 x longer in cats than dogs 
[42]. In experimental human studies it has been shown that acetylsalicylic acid is 
rapidly converted to salicylic acid in the circulation and excreted in urine unchanged 
or after conjugation with glucuronic acid or glycine [87]. Unlike humans and dogs, 
cats have been shown to be deficient in the conjugation of salicylate with glycine to 
form salicylurate, and this is the likely mechanism of slow elimination rather than 
deficient glucuronidation [42, 73]. Poor glycine conjugation may therefore be the 
underlying cause for the slow elimination of aspirin in cats.  
 
The hepatic cytochrome P450 enzymes play an important role in hepatic drug 
detoxification and other life processes such as cholesterol metabolism, bile-acid 
biosynthesis, and vitamin D3 synthesis and metabolism [88, 89]. Mutations in human 
cytochrome P450 genes can cause inborn errors in metabolism [71, 88]. Cytochrome 
P450 subfamilies are important in phase one metabolism of drugs. CYP1A, 2C, 2D 
and 3A subfamilies are important for the oxidative metabolism of many drugs in 
animals [63, 71, 89-92]. The CYP450 pattern of cats has only been investigated 
recently;  CYP2C (corresponding to CYP2C9 in humans) activity in cats is extremely 
low and there is a difference between male and female cats in CYP2D and 3A 
activities [63]. Shah, Sanda (63) also compared CYP1A clearance reactions and 
found that its activity in cats was much higher than in dogs and humans, implying 
faster elimination rates of CYP1A substrates (e.g. theophylline) in cats. CYPD2E and 
CYP2D6 have also been explored recently and their low activity in cats are thought 
to further contribute to feline sensitivity to drugs such as paracetamol and volatile 
anaesthetic agents as compared to dogs and humans [52, 58, 65]. Many of the 
drugs used in veterinary medicine for dogs and cats have the same dose regime, but 
do not take into account the differences in CYP450 metabolism. These preliminary 
studies of CYP-mediated drug metabolism in cats show that we should carefully 
assess known CYP substrates prior to extrapolating dose regimes from other 
species for their use in cats.    
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Drug metabolism and disposition differences in cats are still largely unknown, 
although increasingly more evidence is arising to suggest that these differences are 
significant. Physiological differences in cats such as a simple, shorter digestive tract, 
which has a slower transit time and greater permeability, may also affect the 
absorption of drugs [93, 94] Therefore, it is important that pharmaceuticals undergo 
individual species pharmacokinetic and pharmacodynamic investigation prior to their 
widespread and long-term use.    
 
2.2 Overview of Pathogenic Fungi 
 
Fungi are eukaryotic organisms of the kingdom fungi [95, 96] with a definitive cell 
wall composed of chitin, a structural polysaccharide (N-actelyglucosamine) that is 
absent in vertebrates [96, 97]. Fungi can be classified as dermatophytes, yeasts, 
dimorphic pathogens, oelomycetes, zygomycetes, oomycota phaeohyphomyocetes 
and hyalohyphomycetes [96]. Table 2.1 contains a list of fungal species known to be 
responsible for disease in cats and dogs [41, 95, 96, 98-100].  
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Table 2.1. Pathogenic fungal species of companion animals. 
 
 
There are two groups of systemic mycoses: dimorphic and opportunistic. Dimorphic 
species are characterised by their divergent morphological structure under specific 
environmental conditions [95]. These fungal pathogens are able to overcome 
physiological and cellular defences of the normal host by changing their 
morphological form [96]. Dimorphic fungi have a variable geographical distribution; 
with the primary site of infection often being the respiratory system due to inhalation 
of conidia [96].  
 
Opportunistic systemic mycoses occur most commonly in debilitated animals, whose 
normal defence mechanisms are impaired. Organisms within this group include 
yeasts, the zygomycetes, Aspergillus spp., the other hyalohyphomycetes and 
phaeohyphomyocetes. Phaeohyphomyocetes are fungal moulds that 
characteristically produce melanin-pigmented hyphal elements in tissue and in 
culture [101]. The hyalohyphomycetes are non-pigmented and are transparent or 
hyaline in tissues [101]. Both are ubiquitous saprophytic agents that often cause 
infection in immunocompromised hosts after traumatic implantation from the 
environment or via the respiratory system [99, 102]. Opportunistic fungal infections 
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causing disseminated disease, e.g. disseminated aspergillosis or mucormycosis 
have been reported in immune-compromised cats secondary to diabetes mellitus, 
viral infection (feline leukaemia virus, feline immunodeficiency virus, feline 
panleukopaenia virus), and in those treated with glucocorticoids or antibiotics [103, 
104].   
 
Localised infection, for example with Aspergillus spp. and Cryptococcus spp., 
particularly of the sinuses and nasal cavity occurs frequently in companion animals 
[100]. Other filamentous fungi implicated in feline rhinitis include Penicillium spp., 
Scedosporium apiospermum, Alternaria alternate and zygomycetes such as Pythium 
insidiosum [100, 105-107].  
 
2.2.1 Pathogenic Aspergillus species 
Aspergillus fumigatus is the most important pathogenic filamentous fungus in 
humans. Cryptic species from Aspergillus section Fumigati are involved in 3 to 6% of 
invasive aspergillosis cases [32]. The actual prevalence may be higher due to lack of 
recognition of cryptic species by conventional diagnostic approaches. Other 
pathogenic Aspergillus spp. been implicated in aspergillosis in humans include A. 
flavus, A. niger, A. terreus, A. versicolor, A. nidulans  and their cryptic species, as 
well as A. calidoustus, [108].   
 
The species within Aspergillus section Fumigati that are most commonly associated 
with clinical disease in humans, apart from A. fumigatus, are A. lentulus, A. 
udagawae, A. felis-clade, A. thermomutatus (Neosartorya pseudofischeri), A. 
novofumigatus, and A. hiratsukae [32, 34, 35, 109]. Feline URTA is most commonly 
due to infection by members of Aspergillus section Fumigati [25, 110]. A. fumigatus 
is commonly identified as the pathogen involved in feline SNA [13, 21, 25, 110, 111]. 
Feline SOA, on the other hand, is most commonly caused by cryptic species, which 
have a lower thermotolerance and different secondary metabolite profiles that may 
contribute to their virulence [112, 113]. In addition, these cryptic species often exhibit 
decreased susceptibility to triazole and other antifungals, and are associated with 
high mortality rates [32, 33, 35, 36, 113, 114].  
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Antifungal susceptibility was tested for thirteen A. felis isolates from cats by Barrs, 
van Doorn (31). In these tests, after incubation at 38oC, caspofungin displayed a 
minimum effective concentration (MEC) of less than 0.06 µg/ml in all but one isolate, 
which was 2 µg/mL. The majority of isolates had minimum inhibitory concentrations 
(MICs) greater than 0.06 µg/mL of amphotericin B and the azoles tested; with 
voriconazole having 9/13 isolates having MICs greater than 1 µg/mL [31]. Further 
susceptibility testing carried out by Lyskova, Hubka (33) has further shown that 
isolates of A. felis have relatively high MICs for voriconazole, itraconazole and 
amphotericin B. The MICs for posaconazole, caspofungin, anidulafungin and 
micafungin are, however, very low and likely consistent with a more favourable 
clinical outcome [33]. 
 
2.2.2 Structure of filamentous fungi 
Antifungal agents generally target various components of the cell wall, thus in order 
to understand the pharmacodynamics of these agents it is important to appreciate 
the components of the fungal cell wall. For example, echinocandins inhibit glucan 
synthase whereas triazoles inhibit the synthesis of ergosterol. Hyphal growth is the 
life force of filamentous fungi, and is important for all aspects of colonisation, 
reproduction, morphogenesis and recognition of environmental signals [115]. 
Hyphae are broadly distinguished as septate or aseptate [115].  
 
Each hypha has a cell wall, which is an extracellular matrix made up of an outer 
layer of polysaccharides and glycoproteins, and an inner layer of carbohydrate 
polymers including chitin, glucans and galactomannan [97, 116, 117]. Chitin is a 
structural polysaccharide (N-acetylglucosamine) that is absent in vertebrates [96, 
97]. The nuclear envelope is a porous double membrane containing abundant RNA 
[115]. Within the cell wall, the plasma membrane contains ergosterol, a cell 
membrane sterol that is frequently targeted by anti-fungal agents [95]. Ergosterol 
regulates permeability of the cell membrane and the activity of membrane-bound 
enzymes [118]. Chitin synthesis is stimulated by low ergosterol content and inhibited 
by high concentrations causing patchy chitin formation [118]. 1,3-β-D-glucan is an 
essential cell wall homopolysaccharide found in the carbohydrate layer of the fungal 
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cell wall. This carbohydrate layer also contains β-1,6-glucan and chitin [116, 117, 
119].  
 
1,3-β-D-glucans are not present in mammalian cell walls. 1,3-β-D-glucan synthase is 
a multi-subunit enzyme complex responsible for fungal cell wall synthesis, 
maintenance and remodelling [116]. Glucan synthase is a heteromeric enzyme 
complex comprising one large integral membrane protein, encoded by either the 
FKS1 or FKS2 genes, and one small subunit more loosely associated with the 
membrane, specified by Rho1 [120-122]. FKS1p is involved in cell wall remodelling 
and growth [120]. The FKS2 gene product is needed for sporulation [120-123]. 
Additional components, such as Pma1 have also been identified and may be 
involved in cell wall integrity [124].  
 
2.3 Antifungal therapy in Small Animal Veterinary Medicine 
Compared to antibacterial drugs the range of antifungal drugs is limited, particularly 
in veterinary medicine where the cost of newer, non-generic drugs is often 
prohibitive. Prior to the widespread availability of antifungal tri-azoles, amphotericin B 
was used for first-line treatment for invasive fungal infections in both human and 
veterinary medicine [1, 5]. The azole group of drugs have similar mechanisms of 
action and share other properties such as pharmacokinetics, tissue penetration and 
adverse effect profiles. Echinocandins are a fairly new class of antifungal that are 
gaining popularity in veterinary medicine. Table 2.2 is a schematic representation of 
the antifungals available for off-label use in companion animal veterinary medicine 
and their activity spectrums against some of the common fungal organisms 
extrapolated from available data [1, 2, 31, 34, 35, 38, 125-140]. Table 2.3 shows the 
susceptibility patterns of Aspergillus cryptic species in section Fumigati [32, 114, 
141-145].  
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Table 2.2. Spectrum of activity of antifungals against common fungi.  
The data has been extracted from the listed references [1, 2, 31, 34, 35, 38, 125-140].  
 
(+) indicates activity against organism, (-) indicates no activity against organism, (±) indicates variable 
activity against organism. No entry indicates unknown activity. Antifungals: Amphotericin B (AMB), 
Fluconazole (FLC), Itraconazole (ITC), Voriconazole (VRC), Isavuconazole (ISA), Ravuconazole 
(RVC), Posaconazole (POS), Caspofungin (CAS), Micafungin (MFG), Anidulafungin (AFG), 
Flucytosine (5FC)  
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Table 2.3. Summary of the susceptibility of some of the “cryptic” Aspergillus species 
within section Fumigati [33, 34, 40, 99, 126, 127, 129, 134, 146, 147]. 
Species  Amphotericin B  Voriconazole Posaconazole Itraconazole Caspofungin  
A. viridinutans - - + - + 
A. felis  + ± ± ± + 
A. thermomutatus + - + - + 
A. udagawae  ± ± + + + 
A. hiratsukae  + + + + + 
A. lentulus  - - ± - +/± 
A. novofumigatus + - - - + 
(-) indicates no activity against organism; (+) indicates activity against organism; (±) 
indicates variable activity against organism.   
 
2.3.1. Amphotericin B 
Amphotericin B (AMB), a polyene macrolide antibiotic produced from Streptomyces 
nodosus, was discovered in 1956. AMB forms micelles with fungal ergosterol, 
forming channels in the fungal membrane and altering cell permeability, allowing 
leakage of ions and cellular components from the fungi and resulting in cell death [1, 
5, 148]. It also activates macrophages and enhances macrophage-killing capacity 
[5]. This immunomodulatory effect may explain its effectiveness against fungi lacking 
cell wall ergosterol, such as Pythium insidiosum [41].  
 
AMB has been utilised as first line therapy for many systemic fungal infections in 
humans, dogs and cats [1]. Resistance to AMB is rare, although high MIC values 
have been observed for some moulds, including Aspergillus terreus and A. flavus, A. 
lentulus and A. fumigatiaffinis [35, 41, 141, 149-152]. This may be related to 
decreased cell wall ergosterol, however the mechanism is not well understood [153]. 
AMB is minimally absorbed from the gastrointestinal tract, and therefore requires 
intravenous administration. However, it causes cumulative nephrotoxicity due to 
direct toxicity to epithelial cell membranes, and renal vasoconstriction causing 
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reduced renal blood flow and glomerular filtration rate [1, 5, 41, 154]. New 
formulations of AMB were subsequently developed; liposomal preparation, lipid 
complex and colloidal dispersion with cholesterol sulphate [1]. These preparations 
are less nephrotoxic, however are considerably more expensive [1, 41].  
 
While AMB formulations are commonly used, evidence-based research is lacking in 
veterinary medicine. According to Sykes and Papich (41), amphotericin B lipid 
complex (ABLC) is the most commonly used formulation in companion animal 
medicine for systemic mycoses. Disruption of lipid complexes by phospholipases 
occurs only at sites of inflammation or infection, leading to the release of AMB [1, 
155]. In research dogs, ABLC was found to be eight to ten-times less nephrotoxic 
than conventional AMB; however, its toxicity profile in cats has not been determined 
[156]. Experimental studies in healthy beagle dogs showed six-times higher plasma 
concentrations of liposomal amphotericin B (AmBisome) than original AMB, no 
azotaemia and minimal renal effects on histopathology [157]. Barrs, Fliegner (9) 
reported the successful use of liposomal amphotericin (AmBisome) in cases of sino-
orbital and sino-nasal aspergillosis in combination with itraconazole and 
posaconazole. This formulation was also reportedly used in another cat with sino-
orbital aspergillosis which was refractory to azole treatment. The cat was euthanized 
one month after starting treatment due to seizures associated with intracranial 
extension of infection [15]. This evidence suggests that the new preparations of AMB 
have improved efficacy and a better safety profile; however, no pharmacological 
studies have been conducted in cats and therefore caution is still warranted in this 
species.  
 
2.3.2. Azole antifungal drugs 
Azole antifungals, similar to amphotericin B, also target ergosterol in the fungal cell 
wall.  However, in contrast to AMB, azoles inhibit sterol 14α-demethylase, a 
cytochrome P450-dependent fungal enzyme involved in the synthesis of ergosterol 
from lanosterol [41]. This leads to ergosterol reduction and accumulation of 
anomalous and potentially lethal sterols in the cell membrane [1]. Most of the 
adverse effects and drug interactions with this class of drugs are a direct result of 
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cross-inhibition of mammalian cytochrome P450 enzymes [1, 41]. Azoles, imidazoles 
and triazoles, are a group of synthetic aromatic compounds that are structurally 
similar with a five-membered azole ring and a complex side chain [158]. Imidazoles 
are now largely used for topical use whereas triazoles are recommended for 
systemic disease. Imidazoles such as ketoconazole were previously used for 
systemic mycoses, due to good oral bioavailability, however this drug was 
deregistered in Australia and the US in 2013 due to its significant toxic effects in 
humans [1, 41, 159-161]. Cats are also highly susceptible to the side effects of 
ketoconazole; including hepatotoxicity and suppression of steroid hormone synthesis 
[162]. Triazoles are metabolised more slowly and have less impact on mammalian 
sterol synthesis than the imidazoles [41].  
 
“Triazole”, as shown in Figure 2.1, refers to either one of a pair of isomeric chemical 
compounds with the molecular formula C2H3N3, having a five-membered ring of two 
carbon atoms and three nitrogen atoms [163]. The structural differences of the azole 
rings result in different binding affinities for the cytochrome P-450 (CYP) enzyme 
system [163]. The triazole antifungal drugs include itraconazole and fluconazole, as 
well as the newer drugs, voriconazole and posaconazole. Itraconazole 
(C35H38Cl2N8O4) is an equimolar racemic mixture of four diastereoisomers (two 
enantiomeric pairs), each possessing three chiral centres, it is structurally similar to 
ketoconazole (C26H28Cl2N4O4) [163]. Itraconazole has three nitrogen atoms in its 
azole ring, which help with tissue penetration, prolong half-life and increase 
specificity for fungal enzymes [158]. Posaconazole (C37H42F2N8O4) is a synthetic 
structural analogue of itraconazole, with fluorine in place of a chlorine and a furan 
ring in place of the dioxolane ring [131, 163]. Voriconazole (C16H14F3N5O) was 
developed from fluconazole (C13H12F2N6O), a fluorinated bistriazole, by substituting 
the fluoropyrimidine ring for one of the azole groups and an added α- methyl group, 
which provides activity against Aspergillus spp. and other moulds; unlike fluconazole 
to which Aspergillus spp. are intrinsically resistant [135, 163, 164].  
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Figure 2.1. Diagram of the azole structures 
  
 
2.3.2.1 Itraconazole  
Itraconazole is one of the most widely used azoles in both human and veterinary 
medicine. It is often used as first-line systemic treatment for Aspergillus spp. 
infection in dogs and cats [1, 41, 165-167]. The most common adverse effects 
associated with itraconazole are gastrointestinal signs and hepatotoxicity [1, 41, 165-
168]. Itraconazole is available in both capsules and oral suspension. The oral 
suspension has enhanced bioavailability in cats and requires a dose reduction 
compared to the capsule in order to minimise hepatotoxicity, 1-1.5mg/kg per day and 
10mg/kg per day respectively [1, 41, 168]. Itraconazole, like ketoconazole, can inhibit 
the metabolism of other P450 cytochrome drugs and interfere with P-glycoprotein 
transport of ivermectin [1, 41]. 
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2.3.2.2 Voriconazole 
Voriconazole is used for first-line treatment of invasive aspergillosis in humans [169]. 
It is also used to treat other mould infections, particularly if they are refractory to 
other treatments, including some Scedosporium spp., and Fusarium spp. [20, 41]. 
The major draw-back of voriconazole is its cost and neurological side effects, as well 
as gastrointestinal and hepatic effects. In humans, it has been reported to cause 
reversible photophobia and blurred vision, hallucinations and peripheral 
neuropathies [170-172]. Toxicity has not been documented in dogs, which may be 
due to its limited use associated with high cost of treatment [173-175]. 
Gastrointestinal signs were reported in a pharmacokinetic study of voriconazole in 
dogs [176]. Sykes and Papich (41) also describe inappetence, increased serum liver 
enzymes activities and CNS signs such as ataxia and staring, as well as tachypnoea 
and pyrexia in dogs. Cats appear to be highly sensitive to the effects of voriconazole 
with several case reports detailing adverse events such as reduced appetite, 
lethargy, hypokalaemia, arrhythmias, CNS signs including ataxia, hind limb paresis, 
blindness, staring off into space and vestibular signs, and in one case death [9, 20, 
177, 178]. Voriconazole, like itraconazole and ketoconazole, also inhibits CYP3A 
and can therefore increase plasma concentrations of other drugs [179]. A recent 
pharmacokinetic study of voriconazole in cats, suggested that a dose of 12.5 mg/cat 
every 72 hours compared to 5 mg/kg twice daily, as for  dogs and humans, may be 
safe and effective [180]. The authors, however, recommended close therapeutic 
drug monitoring in order to minimise adverse effects.   
 
2.3.2.3 Posaconazole   
Posaconazole is a promising antifungal agent for a number of refractory deep 
mycoses in animals. It is reported to have the lowest minimum inhibitory 
concentration against isolates of Aspergillus Section Fumigati of the available azoles 
and may be effective when other azole treatments have failed [35, 164, 181]. 
Posaconazole is highly protein bound (>98%) and undergoes hepatic metabolism 
with only minimal drug interaction via the cytochrome P450 enzyme pathways [131, 
182]. Initial studies in various species have shown that its bioavailability is promoted 
by concurrent feeding of a fatty meal; however, alterations in gastric acidity do not 
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affect its absorption [138, 183, 184]. Posaconazole (Noxafil, Merck) is available in an 
oral suspension, delayed release tablets and as an intravenous injection; however, 
its availability in all forms is limited outside of the United States. Posaconazole is well 
tolerated after oral administration of suspension in cats, however mild liver enzyme 
elevations have been noted [9, 15, 19, 185-187].  
 
Published data on the pharmacokinetics of posaconazole in cats has recently 
become available. This has shown that although it is well tolerated with minimal side 
effects, it has low oral bioavailability and as such, a greater oral dose is required to 
reach therapeutic serum levels, which may predispose to adverse effects [188]. It 
has also been shown to be well tolerated long term in critically-ill people with 
refractory invasive fungal infections [189, 190].  
 
The metabolism of posaconazole is mediated by uridine diphosphate (UDP) – 
glucuronyltransferase (UGT) enzyme pathways, particularly UGT1A4 [191]. It is also 
a substrate and inhibitor of P-glycoprotein, however the role of gene polymorphism in 
the pharmacokinetics of posaconazole have not yet been explored [191]. Other 
newly available azoles, include ravuconazole and isavuconazole [192, 193]. 
Isavuconazole has shown promise for the treatment of invasive Aspergillus 
fumigatus when there is cross-resistance with other azoles [134, 192, 194]. 
 
2.3.3. Pyrimidines 
The pyrimidines (5-FC), such as flucytosine, have been used to treat azole resistant 
infections of Cryptococcus spp. in cats and in Candida spp. infection [2]. Flucytosine 
is often used in combination with azoles or AMB as an effective treatment for 
cryptococcosis in cats and dogs [195, 196]. They are inactive against most 
Aspergillus spp. The drug interferes with DNA/RNA synthesis when it is deaminated 
into 5-fluorouracil within the fungal cell. Unfortunately, there is rapid development of 
resistance with this antifungal and it has significant side effects such as 
myelosuppression, gastrointestinal upset, acute hepatic injury, renal failure, 
hypersensitivity and central nervous system signs [2].  
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2.3.4. Echinocandins 
2.3.4.1 Mechanisms of action 
Echinocandins are large semisynthetic lipopeptides which have been chemically 
modified from the natural products of fungi [123]. Drugs within this class include 
caspofungin acetate, micafungin and anidulafungin, which received FDA approval in 
2002, 2005 and 2006, respectively. A novel long-acting echinocandin (CD101 IV) is 
currently in phase two trials and shows promise as a once-weekly outpatient 
treatment for systemic mycoses, including potentially resistant pathogens [48, 197]. 
Each echinocandin is structurally different and has been derived from different fungal 
species; caspofungin is derived from pneumocandin B of Glarea lazoyensis, and 
anidulafungin comes from echinocandin B0 of Aspergillus nidulans [123]. These 
differences account for the variation in their pharmacokinetic profiles and drug 
interactions, despite similar spectrums of activity [123]. Their specific anti-fungal 
activity is determined by the position and confirmation of the N-linked acyl lipid side 
chains of the cyclic hexapeptides. Caspofungin has a fatty acid side chain, whereas 
micafungin has a complex aromatic and anidulafungin has an alkoxytriphenyl side 
chain [123].  These side chains interact with the phospholipid bilayer of the fungal 
cell membrane.  
 
Echinocandins inhibit glucan synthase within the fungal cell wall via non-competitive 
inhibition of 1,3,β-D-glucan synthase, and to a lesser extent the 1,6,β-D-glucan 
synthase within the fungal cell wall [1, 41, 119, 123]. Specifically, echinocandins 
target the FSK1 gene product that encodes for the Fks1p subunit within 1,3,β-D-
glucan synthase [119, 123]. The precise binding site in regards to the enzyme 
complex is unknown. Inhibition of 1,3,β-D-glucan synthase leads to compromise of 
the osmotic integrity of the cell wall and cell lysis. A second mechanism of action is 
thought to be due to disruption of cell wall mannoproteins, allowing for greater 
immune system recognition [1]. Hohl, Feldmesser (198) also demonstrated that b-
glucan exposure due to echinocandin-induced morphological hyphal changes 
increase the dectin-1-mediated inflammatory responses by macrophages.   
Caspofungin is fungicidal against Candida spp and fungistatic against Aspergillus 
spp., Cryptococcus neoformans and zygomycetes are resistant [41, 123, 140, 199]. 
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Yeast forms of fungi are not susceptible as they contain α-glucan within the cell wall, 
which is not targeted by echinocandins [1, 41]. The activity of the echinocandins is 
largely dependent on the proportion of the fungal cell wall comprised of glucan, 
which varies between fungal species [123]. As single agent therapy, echinocandins 
have minimal effect on Fusarium spp., zygomycetes and Scedosporium spp., as 
there is limited glucan within the cell wall. However, utilising caspofungin in 
combination with amphotericin B has been successful in the treatment of 
zygomycosis in murine models, as well as human patients [200, 201]. Caspofungin 
also has an enhanced effect in the treatment of aspergillosis and candidiasis when 
combined with azoles; such as itraconazole, posaconazole and voriconazole [202-
209].  
 
2.3.4.2 Pharmacokinetics of echinocandins 
Due to their poor oral bioavailability (e.g. <0.2% for caspofungin) echinocandins are 
available as intravenous preparations only [85]. However, they are highly protein 
bound (e.g. 96-97% for caspofungin) allowing for good distribution into the lung, liver 
and spleen [85, 210]. Their high molecular weight, as well as level of protein binding 
limits their ability to penetrate the central nervous system and ocular fluid [210, 211]. 
Their urinary concentrations are low, and they are not metabolized or excreted via 
the renal system [85, 212, 213].  
 
Echinocandins exhibit dose-dependent linear pharmacokinetics after intravenous 
administration in all studied species; including humans, rodents, lagomorphs, dogs, 
cynomolgus monkeys and chimpanzees. In humans and rats, studies have shown 
that they are taken up by the red blood cells (micafungin) and the liver (caspofungin 
and micafungin) following initial distribution and are slowly degraded primarily in the 
liver, as well as the adrenal glands and spleen [210]. Degradation of caspofungin to 
inactive metabolites occurs by peptide hydrolysis in these species, as opposed to 
oxidative reactions and N-acetylation [45, 85, 210, 214]. Catechol-O-
methyltransferase pathways in the liver metabolise micafungin in rats and humans 
[123]. The degradation products of caspofungin in rats and humans are eliminated 
over a number of days via the biliary system [210, 215].  Anidulafungin is unique 
 24 
among the echinocandins as it has been shown that it is eliminated almost 
exclusively by slow degradation in bile rather than by hepatic metabolism in rats 
[216].  
 
As can be seen in Table 2.4, pharmacokinetic parameters including maximum 
concentration, elimination pathways, elimination half-life, volume of distribution and 
clearance rates are different for each echinocandin drug administered to the same 
host. Adult human data is provided for comparison, as comparable pharmacokinetic 
data for other mammalian species is lacking. Anidulafungin, for example, has a lower 
maximum concentration with longer half-life, as well as larger volume of distribution 
and faster clearance than caspofungin and micafungin. Steady-state concentrations 
for caspofungin are achieved significantly later than with micafungin [123, 217]. 
 
Table 2.4. Pharmacokinetics of echinocandins in adult humans 
Variable  Caspofungin  Micafungin Anidulafungin 
Cmax (mg/ml) 7.64 4.95 2.07-3.5 
Bioavailability (%) <10 <10 2-7 
T1/2 (h) 9-11 11-17 24-26 
Vd (L/kg)  0.14 0.22-0.24 0.5 
AUC (µg.h/mL) 87.9-114.8 111.3 44.4-53 
Protein Binding (%) 96-97 99.8 >99 
Clearance (ml/min/kg)  0.14-0.17 0.12-0.3 0.24 
Time to Steady State 2 weeks 4-5 days 1 day* 
Cmax = maximum concentration; T1/2 = elimination half-life; Vd = volume of distribution; AUC = area 
under the plasma concentration-time curve. Table modified from Chen, Slavin (123) and Kofla and 
Ruhnke (217). Data for 50mg single dose IV in an average 70kg adult. *steady state achieved after 
single loading dose (100mg IV).  
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The echinocandins do not serve as major substrates, inducers or inhibitors of 
cytochrome P450 or the P-glycoprotein transport system [121]. Deranged P-
glycoprotein in mammals increases the risk of toxicity due to active transportation of 
substrates back across cell membranes [79]. Drug-drug interactions and enhanced 
toxicity due to echinocandins is of minimal risk, compared to triazole antifungals that 
interact with P-glycoprotein [1, 41]. Sandhu, Lee (215) showed that the OATP-1B1 
transporter pathway is responsible for hepatic uptake of caspofungin. This also 
transports bile and several other drugs such as rifampin and cyclosporine.  The use 
of rifampin with caspofungin necessitates increasing the daily dosage, as it initially 
inhibits and then induces hepatic uptake of caspofungin by OATP-1B1, which 
decreases steady state concentrations [218, 219].   
 
2.3.4.3 Clinical efficacy of echinocandins  
The spectrum of activity of the echinocandins is best measured by determining the 
minimum effective concentration (MEC) rather than the MIC. As echinocandins are 
fungistatic against filamentous fungal organisms such as Aspergillus spp., their 
effectiveness is measured by the lowest drug concentration causing blunt 
attenuation of hyphal structures viewed microscopically, known as the MEC [123].  
The MEC is the recommended endpoint for determining in vitro activity of 
caspofungin against Aspergillus spp., and has been adopted in more recent 
susceptibility studies [128, 199, 220-222]. Pfaller, Boyken (221) determined the in 
vitro activity of caspofungin, anidulafungin and micafungin against Aspergillus flavus, 
Aspergillus fumigatus, Aspergillus niger and Aspergillus terreus isolates, of which 
99% were inhibited by <0.06 μg/ml of antifungal drug. Alcazar-Fuoli, Mellado (35) 
also showed that all tested strains of Aspergillus section Fumigati, are susceptible to 
both caspofungin and micafungin (MECs ≤1.3μg/ml). Echinocandin susceptibility is 
determined utilising CLSI and EUCAST reference susceptibility broth microdilution 
(BMD) methods [221, 223].  
 
Echinocandin resistance is an emerging risk factor for treatment failure in human 
patients affected by aspergillosis, although it is considered a rare phenomenon. 
Similar to the mechanism of azole resistance; echinocandin resistance of moulds 
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has been associated with point mutations in hot spots of the FKS1 gene encoding 
the major subunit of 1,3-β-D-glucan synthase [224]. Resistance to caspofungin has 
been described for clinical isolates of Candida, and more recently, breakthrough 
infection with Aspergillus spp. with elevated MEC have also been reported in human 
patients [225, 226]. Laboratory manipulated strains of Aspergillus fumigatus with 
mutations in the ECM33 gene, encoding cell wall proteins important for fungal cell 
wall organisation, have been shown to be intrinsically resistant to caspofungin and 
are hypervirulent in mice [227]. Scientific studies surrounding antifungal resistance 
concentrate on Aspergillus fumigatus as it is the most common isolate causing 
human infection. There have also been clinical reports of resistance to 
echinocandins in humans infected with A. fumigatus and A. flavus previously 
exposed to this class of drugs, as well as breakthrough infections [226, 228]. Clinical 
resistance is multifactorial and attributed to host factors, virulence factors of the 
pathogen, and/or the pharmacodynamics and pharmacokinetics of antifungal drugs 
[153, 229, 230].  Cryptic species in Aspergillus section Fumigati, many of which are 
emerging pathogens, require further investigation as many are intrinsically resistant 
to one or more antifungal drugs [35].   
 
 Various models have looked at how best to describe the clinical efficacy of 
echinocandins and predict clinical outcome. Parameters examined include 
percentage of time greater than the MEC, 96-h area under the plasma concentration 
curve to MEC ratio, and peak (Cmax) in plasma to MEC ratio [231-235]. Andes, 
Marchillo (232) found that the peak concentration to MEC ratio was the most 
appropriate tool to monitor therapeutic dosing in a murine model of candidiasis 
treated with aminocandin. However, Li, Sun (233) found that none of these 
pharmacokinetic parameters were significantly correlated with outcomes in paediatric 
human patients with aspergillosis or candidiasis that were treated with caspofungin. 
In a murine model of invasive pulmonary aspergillosis in which caspofungin dose 
escalation and dose fractionation were evaluated, Cmax: MEC ratio was the 
parameter most strongly associated with reduced fungal burden with an optimal 
value of 10-20. Mice dosed with 1 mg/kg daily or 2 mg/kg every second day had a 
significantly lower fungal burdens than mice dosed with 1 mg/kg every 6 hours [231]. 
At higher doses of 4 mg/kg, correlating to a Cmax: MEC > 20 there was a paradoxical 
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effect on fungal growth resulting in increased burdens in mice. Although not proven 
in clinical trials, the paradoxical growth effect of caspofungin at Cmax: MEC > 20 in 
vivo has led to concerns about possible reduced clinical efficacy using dosing 
regimens where the Cmax greatly exceeds the MEC [231]. However, the in vivo 
significance of this is yet to be determined, as the doses exhibiting this effect exceed 
clinical recommendations. 
 
In humans, caspofungin is indicated for treatment of invasive aspergillosis that is 
refractory to other antifungal therapy [7, 116, 121, 236-240]. The echinocandins do 
not appear to have cross-resistance to other antifungal agents and are generally 
effective against azole-resistant moulds and Candida spp. [116, 241]. Caspofungin is 
also recommended for use in patients that are unable to tolerate other antifungals 
due to hepatic or renal insufficiency [41]. Caspofungin is also approved as empirical 
therapy for presumed Candida spp. or Aspergillus spp. infections in febrile 
neutropenic patients [116].  
 
 2.3.4.4 Adverse events associated with echinocandins  
As echinocandins exert their antifungal activity on the fungal cell wall their adverse 
side effects in mammalian species are expected to be low [45].  Adverse events 
reported in humans are minimal and include fever, gastrointestinal signs, phlebitis 
and headache [1, 41, 214]. Histamine-mediated signs including anaphylaxis, rashes, 
facial swelling, pruritus, bronchospasm and cardiac arrhythmias have been reported 
in humans during caspofungin infusion but are rare [208, 242]. Echinocandin induced 
cardiomyopathies due to focal direct myocyte injury in human patients and 
experimental rat models receiving echinocandins via a central line have also been 
rarely reported [243, 244]. Manifestations of acute anaphylaxis are species-
dependent and directly related to the locations of the largest population of mast cells, 
which are the heart and lungs in humans, gastrointestinal tract and liver in dogs, and 
lungs in cats [245-252]. Thus, the establishment of a safety profile of echinocandins 
in cats is a crucial aspect of determining their pharmacokinetic profile.  
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Caspofungin administered in excessive doses was shown to cause hepatic necrosis 
in one pre-clinical trial in humans, and subsequent studies have reported a low 
incidence of serious hepatoxicity [123, 253]. All echinocandins can cause liver 
enzyme elevations, however only micafungin causes focal alteration in hepatocytes 
and can cause hepatocellular tumours [254]. Discontinuation of micafungin is 
recommended if liver enzyme elevations are documented [254]. Mistry, Migoya (214) 
concluded that no dosage reduction is necessary in human patients with mild hepatic 
disease when treated with caspofungin, however recommended a 25% dose 
reduction in moderate hepatic disease.  
 
Caspofungin, administered at 1mg/kg once daily IV, was well tolerated and effective 
in a cat with sino-orbital aspergillosis caused by A. felis [9]. A German Shepherd with 
A. deflectus infection was treated with caspofungin for over a year with no adverse 
effects attributable to its use [46]. The same dog also received anidulafungin upon 
clinical relapse, however developed a severe diffuse urticarial reaction [46]. 
Micafungin, in combination with ABLC was also trialled in this dog but there was no 
clinical response [46]. High-dose anidulafungin has been associated with the 
development of pulmonary oedema in neutropenic rabbits with pulmonary 
aspergillosis, although no adverse effects were reported using recommended doses 
[255]. Studies performed in rabbit models of invasive aspergillosis have also shown 
that neutropenia leads to significantly slower clearance of antifungals and higher 
plasma concentrations at the end of dosing intervals compared to healthy subjects, 
which may predispose to the paradoxical growth effect or toxicity [234].  A cat with 
sino-orbital aspergillosis due to A. udagawae was treated with a combination of AMB 
and micafungin and no adverse effects were reported [18]. Among companion 
animals, the pharmacokinetics of micafungin and the novel echinocandin CD101 
(biafungin), but not caspofungin, have been determined in dogs, but no echinocandin 
pharmacokinetics have been evaluated in cats [47, 48]. 
 
2.4. Future directions and novel anti-fungal therapies  
Despite the development of novel antifungals, fungal infections in some patients 
(including humans, cats and dogs) remain difficult to treat. Echinocandins are a 
 29 
promising antifungal class for patients with aspergillosis refractory to other 
treatments. In particular, they exhibit excellent clinical efficacy when combined with 
other drug classes and have a favourable toxicity profile. However, development of 
other drugs with novel fungal targets is still required. The cost and time associated 
with research and development of novel anti-microbials often delays their clinical 
use. Criteria used to select optimal new antifungal drugs include potency when 
compared to AMB, safety compared to fluconazole, antifungal activity in vitro and in 
vivo, as well as differences in mode of activity [256].  
 
The emergence of resistance to commonly used anti-fungal drugs has also spurred 
the requirement for the development of novel agents, as well as a better 
understanding of the ones currently in use. Potential novel therapies include 
pradimicins-benanomicins, nikkomycins, sordarins, cationic peptides, 
polyaminocarboxylates [256, 257]. A number of compounds with unidentified 
mechanisms of action are also being investigated which include dication-substituted 
carbazoles, furans, benzimidazoles, glycyrrhizin and a cyclic beta-amino acid related 
to cispentacin [256]. Pradimicins-benanomicins bind to cell wall mannoproteins, 
through calcium dependence, and have been shown to cause lysis and cell death via 
osmosis in animal models of aspergillosis [256].  In human trials this class of 
antifungal caused unacceptable hepatotoxicity, although future development with a 
better toxicity profile may allow for clinical use.  Nikkomycins are competitive chitin 
synthase inhibitors. Other chitin inhibitors such as recombinant human chitinase also 
have efficacy in animal models of aspergillosis, but have greater synergistic activity 
with other antifungal compounds such as AMB [256]. Allylamines and 
thiocarbamates, including terbinafine, are reversible, non-competitive inhibitors of 
squalene epoxidase, which converts squalene to lanosterol and therefore prevents 
the production of ergosterol [256]. Although terbinafine has long been available as 
an anti-fungal agent, its usefulness as a single agent is limited. Further development 
of this class may also provide better in vivo effectiveness for aspergillosis. Sordarins 
have a novel mechanism of action, inhibiting protein synthesis in pathogenic fungi, 
and has synergistic effect against Aspergillus spp. and Scedosporium spp. when 
combined with AMB and azoles [256].  The cationic peptides have antifungal activity 
against a number of pathogenic fungi, including Aspergillus spp.; however their 
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clinical applicability remains to be determined [256]. Polyaminocarboxylates exert 
their effect by interfering with fungal zinc metabolism [257]. Another novel class of 
glucan synthase inhibitors, triterpenoid antifungals have also been developed, with 
broad in vitro and in vivo activity against a broad spectrum of Aspergillus [258].    
 
Invasive aspergillosis in humans is treated with a combination of antifungal drug 
therapy and immune augmentation strategies, as disease occurs most commonly in 
immune-compromised hosts. This approach could be employed in veterinary 
medicine for patients with known immune-deficiencies. Another approach may be to 
further boost the immune system of immune-competent patients, for example cats 
with sino-orbital aspergillosis secondary to A. felis, in order to enhance fungal 
clearance. Current strategies for enhancing immune-competence in humans include 
improving phagocytic function, providing cytokines and stimulating innate pathogen 
recognition pathways. For example, granulocyte colony-stimulating factor (G-CSF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and macrophage 
colony stimulating factor have been shown to increase fungicidal activity of 
phagocytes in vitro against Aspergillus spp. [259, 260]. In cases of invasive 
aspergillosis caused by Aspergillus fumigatus, GM-CSF may be recommended in 
neutropenic patients as host defence depends on both neutrophil and macrophage 
function [259]. Recombinant interferon γ augments innate and Th1-dependent 
immunity contributing to host defence against aspergillosis, however its use has not 
been validated and is limited to a small number of case reports in the human 
literature [259]. The stimulation of toll-like receptors (TLRs) can activate specialized 
anti-fungal effector functions and inflammatory responses. The activation of TLR-4 in 
neutrophils is a proposed secondary mechanism of action of liposomal AMB in the 
treatment of Aspergillus fumigatus [261].  
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2.5. Conclusion 
Despite the introduction of a number of novel antifungal treatments since the turn of 
the century, the prognosis for animals with systemic fungal infections, especially 
filamentous fungi, remains poor. Cats are deficient in numerous drug conjugation 
pathways, which potentially limits the range of drugs that can be utilised. Defective 
glucuronidation of phenolic substances, such as paracetamol, is the best-understood 
conjugation defect in cats. It has also been demonstrated that cats are deficient in 
other conjugation pathways, such as N-acetylation by NAT2, S-methylation by TPMT 
and active transporters (ATP-binding cassettes). These deficiencies can lead to slow 
elimination times and toxic accumulation of drugs. Thus, in cats, pharmacokinetic 
and safety profiles cannot necessarily be directly extrapolated from other species for 
drugs that are metabolised by these variable pathways.  
 
Antifungal therapy must be tailored to the individual patient and organism involved 
[2]. Pharmacological variables contribute significantly to the overall therapeutic 
outcome, including the mechanism of drug action, route of administration, absorption 
and side effects.  There is a large amount of work that still needs to be done to better 
understand the molecular causes of pharmacokinetic differences in cats compared to 
other species. As new therapies emerge for the treatment of systemic fungal 
infections, it is important to establish the metabolism, bioavailability, elimination 
routes and toxic effects in cats to optimise therapeutic outcomes.  
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Chapter 3  
MATERIALS AND METHODS  
3.1. Animals 
Eight clinically healthy adult domestic shorthair cats were used in this study weighing 
4.4 ± 0.56 kg. The mean age of the cats was 3.94 ± 1.84 years.  There were four 
desexed female cats and four desexed male cats. Results of complete blood count 
(CBC), serum biochemical analyses and urine specific gravity (USG) performed 5 
days prior to the study were within reference values for the commercial laboratory 
(IDEXX Laboratories, Inc). The cats were acclimatized to the clinical environment for 
three days prior to the start of the study and were housed individually in a dedicated 
ward of the Valentine Charlton Cat Centre located at the University Veterinary 
Teaching Hospital - Sydney.  The room was environmentally controlled (room 
temperature (19 – 21 oC), humidity (30-50%), 12-hour light/dark cycle). The cats 
were fed a commercial dry and wet food diet and had water ad libitum. A veterinary 
examination was performed upon arrival, and cats were handled every four hours 
during the acclimatization period. During the study period a full physical examination 
was performed twice daily, as well as visual examination (for food, water, eating, 
drinking, urination and defecation) every four hours. The study was approved by the 
Animal Ethics Committee (AEC) of The University of Sydney (Approval no. 
2015/775, 6th March, 2015).  
 
3.2. Drug Administration    
For blood collection, a 20-gauge 8 cm triple-lumen central venous catheter 
(MILACATHÒ, MILA International, Inc., Kentucky, USA) was aseptically inserted into 
the jugular vein using a modified Seldinger technique, and secured with a Kitty 
Kollar®. An Elizabethan collar was also placed to prevent the cats removing the 
catheter. The cats were sedated with IV medetomidine (10 μg/kg; Domitor®, Pfizer 
Animal Health Australia, West Ryde, NSW) and butorphanol (0.1 mg/kg; Ilium 
Butorgesic®, Troy Laboratories Pty Limited, Glendenning, NSW) for jugular catheter 
placement twenty-four hours prior to starting the study. This dose was repeated after 
20 min if no effect was seen, and alfaxalone (0.5 mg/kg; AlfaxanÒ, Jurox, 
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Rutherford, NSW) was administered if the desired level of sedation was not achieved 
after a further 20 min. For IV drug administration, a peripheral catheter (22G IV 
radiopaque catheter; OPTIVA®, Smiths Medical International Ltd, Lanchashire, UK) 
was placed into the cephalic vein with a T-connector (T-Connector with Spin Lock, 
Codan US Corporation, Santa Ana, CA) extension.  
 
The treatment consisted of caspofungin acetate (Cancidas®, Merck Sharp & Dohme 
(Australia) PTY Limited, South Granville, NSW) for IV infusion (1 mg/kg), 0.2 mg/mL 
with sterile saline solution (0.9% sodium chloride, Abbott Laboratories, Abbott Park, 
IL), and given as an infusion over one hour. Upon completion of the infusion 2 mL of 
sterile saline was flushed through the line. In six cats (3 male neutered, 3 female 
neutered) drug administration was repeated for a further 6 days at the same time 
each day for the multi-dose component of the study.     
 
3.3. Blood Collection  
Blood Samples (1.0 mL) were taken with 3 mL syringes (Becton Dickison, North 
Ryde, NSW) via the catheter in the jugular vein immediately before drug 
administration (time 0), and after IV administration at 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 6, 
9, 12, and 24 h. Blood samples were immediately placed in lithium heparin-coated 
tubes (Sarstedt Australia Pty. Ltd., Mawson Lakes, SA).  At the time of each sample 
collection, 1 mL of blood was withdrawn into a heparinised syringe to remove the 
saline solution out of the extension system, another 1.3 mL was collected as sample, 
the withdrawn blood was then replaced, and the system was flushed with 0.5 mL of 
0.9% sterile saline.  The central venous catheter was flushed with heparinised saline 
solution (0.5 mL) every 4 h between subsequent blood sample collections. Samples 
were centrifuged at 12, 000 xg for 5 min (IDEXX StatSpin VT Centrifuge, IDEXX 
Laboratories Inc.) within 10 min of collection, and plasma was removed with 
disposable polyethylene transfer pipettes and stored in micro tubes (Sarstedt 
Australia Pty. Ltd., Mawson Lakes, SA), labelled according to collection time, at -80 
°C until assay.  
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In six cats this blood sampling technique was repeated on day 7 of the study, after a 
further 6 days of dosing at 1 mg/kg q24 h. A blood sample (1.0 mL) was also 
collected prior to daily infusion (48, 72, 96 and 120 h). A further 2 mL of blood was 
collected at 24 h post final infusion for repeat biochemical analysis.    
 
3.4. Analytical Method   
Assay of caspofungin in feline plasma samples was undertaken in the Clinical 
Pharmacology Division, SydPath, St Vincent’s Hospital, Sydney, using high 
performance liquid chromatography (HPLC) tandem mass spectrometry.  
  
Blood samples were prepared for assay using protein precipitation by adding 
methanol (80 µL) to 20 µL of calibrators, controls (drug free) and unknown samples 
using a stable isotope of caspofungin as internal standard (in methanol). The 
analytical reference standard was supplied by Merck Sharp & Dohme (Whitehouse 
Station, New Jersey 08889, USA). Chromatography and analysis was performed on 
a Shimadzu UPLC coupled to an 8050 tandem mass spectrometer in positive ion 
ESI mode, monitoring the transition monitoring the transition 547.6 > 538.5 and 
internal standard transition 549.5> 86.2. A Waters BEH C18 column was used with 
gradient elution with mobile phase A (water containing 0.1 % formic acid) and mobile 
Phase B (acetonitrile containing 0.1 % formic acid). The mobile phase gradient 
involved 100% A for 0.5 mi and a linear gradient to 0% A by 4.5 min. After raising the 
gradient to 100% B at 4.5 min it was held there for 0.5 min before returning to initial 
conditions for a further 1 min, making a total run time of 6 min.  
 
The method was validated in accordance with the US FDA Guidelines for industry for 
bioanalytical method validation utilising pooled plasma from six untreated cats with 
known concentrations of caspofungin reference standard [262]. Linearity was 
demonstrated from 0.1 to 10.0 µg/mL.  
 
Data for demonstration of accuracy and precision (four replicates on three occasions 
of spiked controls at 0.2 and 9.0 µg/mL) showed total precision of 12.0 and 4.3 % 
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(expressed as co-efficient of variation) respectively.  Accuracy was 103.4 and 96.7 % 
respectively. Carry-over was demonstrated to be no more than 1.0 % of the lowest 
standard in blank matrix following injection of the highest standard (10.0 µg/mL). 
 
3.5. Non-compartmental Pharmacokinetic Analysis  
Non-compartmental analysis was performed using the observed plasma caspofungin 
concentration-time data in Microsoft Excel.  The area under the plasma 
concentration–time curve to the final measured concentration value (AUC0-t) was 
determined using the trapezoidal rule [263]. The elimination rate constant (kel) was 
calculated using the log-linear slope of the terminal portion of the concentration–time 
profile [263]. The AUC was extrapolated to infinity (AUC0-∞) using the last observed 
concentration divided by kel [263].  The elimination half-life (t1/2) was calculated as 
ln2/kel. The clearance (CL) was calculated as CL = (F*Dose)/AUC0-∞ ,where F = 1 
due to intravenous administration, and volume of distribution (V) was estimated 
using the equation V = CL/kel. At steady-state, the area under the plasma 
concentration–time curve over the dosing interval (AUCss,0-τ,  τ = 24 h) was 
calculated using the trapezoidal rule. The accumulation ratio was determined using 
the equation AUCss,0-τ / AUC0-t.  Results of pharmacokinetic analyses were reported 
as the median and standard deviation.  
 
3.6. Population Pharmacokinetic Analysis and Dose Regimen 
Simulations1  
 
3.6.1. Methods Software 
Pharmacokinetic model development employed nonlinear mixed-effects modelling 
using NONMEM version 7.3 [264], with the Wings for NONMEM 7.3 interface 
(http://wfn.sourceforge.net) and IFort compiler. Modelling was performed using a Dell 
                                               
1 Population pharmacokinetic analysis, modelling and simulations were performed by Assoc. Prof. David 
Foster, PhD. School of Pharmacy and Medical Sciences, Australian Centre for Pharmacometrics, Sansom 
Institute for Health Research, University of South Australia, Adelaide, South Australia, Australia.  
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PowerEdge R910 server with 4 by 10 core Xeon 2.26-Ghz processors running 
Windows Server 2008 R2 Enterprise 64- bit software. Data manipulation and post-
run processing of NONMEM output was conducted using the R data analysis 
language (Version 3.2.2) and the packages ggplot2, GGally, foreign, tidyr, Hmisc, 
gdata, doBy, plyr, grid, stringr with associated dependencies [264-275]. 
 
3.6.2. General Modelling Strategy 
The base pharmacokinetic model was developed in a step-wise manner. 
Pharmacokinetic models were coded using the built-in ADVAN subroutines of 
NONMEM.  Linear kinetic models with 1 and 2 compartments were evaluated. The 
First Order Conditional Estimation (FOCE) method was used to fit models. The base 
model was selected on the basis of mechanistic plausibility, visual inspection of 
goodness-of-fit diagnostic plots, the precision of parameter estimates (se%<30% for 
fixed, <50% for random effects parameters), and the lowest value of the Akaike’s 
information criterion (AIC; Equation 1) in accordance with the number of parameters 
and the final NONMEM derived objective function value (OBJ). The base model was 
also required to pass the covariance step. 
 AIC = OBJ + 2 ∗ number	of	parameters	 Equation 1 
Unless stated otherwise, population parameter variability (PPV) was represented 
using an exponential error model (Equation 2): 
 P9 = TVP ∗ 	𝑒=> Equation 2 
where Pj is the individual value for the parameter in the jth individual, TVP is the 
typical population value of P and ηj is an independent random variable with a mean 
of zero and variance ω2. PPV was systematically examined on each fixed-effect 
parameter. Models with and without covariance for P were investigated using the 
OMEGA BLOCK functionality of NONMEM.  
 
A combined proportional (θprop) and additive (θadd) residual unexplained error model 
of the caspofungin concentrations (C) was used, where estimation of a THETA was 
employed and epsilon was fixed to zero (Equation 3): 
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 𝐶@9 = 𝐶A@9 + BθDEFDG ∗ 𝐶A@9G + θHIIG Equation 3 
Cij is the ith concentration measured in the jth individual, 𝐶A@9 is the model predicted Cij, 
and θDEFD and θHII  are parameters representing the proportional and additive 
residual error, respectively. The influence of the additive component of the error was 
also examined by a comparison with a proportional only error model.  
 
All base models were investigated with allometric scaling for total body weight (TBW) 
referenced to 4 kg and an exponent fixed of 0.75 for clearance parameters and 1 for 
volumes, although during base model development models was explored without 
allometric scaling on any parameter [276]. 
 
3.6.3. Covariate Model Building 
The base model was screened for the influence of cat sex, guided by plots of 
individual parameter random effects versus sex if shrinkage was low. Sex was only 
retained in the model if there was a significant improvement in OBJ at the p<0.01 
level. 
 
3.6.4. Model Evaluation 
Visual Predictive Checks (VPC) were used to assess the appropriateness of the 
candidate base and final models, faceted for any included covariates as appropriate. 
For the VPC’s, the median, 5th and 95th percentiles of the prediction-corrected 
observations were compared against the empirical 95% confidence intervals (CI) of 
the median, 5th and 95th percentiles of caspofungin concentrations from 1000 
simulations of the original dataset. The predictive performance of the model was 
considered acceptable if the median, 5th and 95th percentile of the prediction-
corrected observed data lay inside the CI’s of the prediction-corrected simulated data 
for the majority of the time.  
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3.6.5. Caspofungin Dose Regimen Simulations 
The final pharmacokinetic model for caspofungin in cats was used to perform dosing 
simulations designed to examine Cmax: minimum effective concentration (MEC) ratios 
following intravenous infusions of caspofungin. Simulations were performed utilising 
total drug in plasma rather than unbound drug, as published data available for MEC 
values have only been reported for the total drug. Based on data from a murine 
model of invasive pulmonary aspergillosis  an optimum Cmax: MEC ratio of 10-20 was 
chosen as a marker of caspofungin dose efficacy [231]. Simulations were performed 
for dosing regimens of 0.25 mg/kg at 6 h intervals; 0.5 mg/kg at 6 h, 12 h and 24 h 
dosing intervals; 0.75 mg/kg and 1 mg/kg at 24 h, 48 h and 72 intervals; 2 mg/kg at 
48 h and 72 h dosing intervals. Loading dose regimen simulations were also 
considered based upon the results of the constant dose regimens. A MEC value of 1 
µg/mL was chosen based on the epidemiological cut-off value (ECV) of caspofungin 
for wild type A. fumigatus sens. str [277] and on antifungal susceptibility MEC data 
on clinical human and feline isolates of A. felis [31] and A. udagawae [34, 144, 278]. 
The duration of infusion was adjusted to 1, 2 and 4 h in the 1 mg/kg and 2 mg/kg 
simulations. Concentrations were simulated at 0.1 h intervals for 1000 standard 4 kg 
cats for each dose regimen for a total of 7 days of dosing.  The percentage of 
animals with a Cmax: MEC >10, > 20 and 10-20 was calculated over the entire 7 d of 
dosing. Maximising the percentage of animals with a Cmax: MEC of 10-20 was the 
criteria for “goodness” of a regimen. Supplementary pharmacokinetic parameters 
were also derived from the model parameters: AUCss (determined from dose and 
clearance), distribution (t1/2α) and terminal (t1/2β) half-life (calculated from the 
individual values of the pharmacokinetic parameters for each animal), Cmax (derived 
directly from the data as the concentration at the end of each infusion).   
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Chapter 4 
RESULTS 
4.1 Safety 
All cats completed the pharmacokinetic study and no changes were seen on 
complete blood counts and multiple biochemical analyses after consecutive daily 
dosing. Physical examination parameters were normal throughout the study except 
for minor transient hyperthermia in one cat (range 39.6-39.8 °C, reference range 37.5 
–39.1°C) during the first caspofungin transfusion only, and mild transient diarrhoea 
that resolved within 24 h of the final caspofungin infusion on Day 8 in another. No 
adverse effects at the injection site were noted. One of the single dose cats had 
extravasation of its caspofungin infusion, there were no adverse effects associated 
with this. The caspofungin plasma concentration data was excluded for this cat.  
 
4.2. Non-compartmental pharmacokinetic analysis  
 
The mean and 95% CI of calculated pharmacokinetic parameters for the single and 
multi-dose study are presented in Table 4.1. The mean plasma drug concentration-
time curve for single dose intravenous caspofungin acetate administration is 
presented in Figure 4.1. Caspofungin displays first-order-elimination at the dose 
administered, and the terminal half-life (T1/2) following a single intravenous dose is 
long (median 15.5 h, range: 12.8 – 18.6 h).  Peak concentration (Cmax) of intravenous 
caspofungin for cats was recorded at 1 hour, at the time of completion of infusion 
(range 1 – 1.5 h) and ranged from 11.37 to 17.20 mg/L (mean of 14.15 mg/L). The 
volume of distribution (VD) had a mean value of 0.09 L/kg (range of 0.07 – 0.13 
L/Kg) and the clearance (CL) was 4.1 mL/kg/hr (range of 2.8 – 4.9 mL/kg/hr).  
 
The mean trough concentration after achieving steady state was 5.88 mg/L (range 
3.56 – 7.78 mg/L) after 3 days of intravenous dosing. The volume of distribution (VD) 
had a mean value of 0.06 L/kg (range of 0.05–0.08 L/kg). Peak concentration was 
seen 1-1.5 h after administration (mean of 1 h) and ranged from 14.9 to 24.3 mg/L 
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(mean of 19.10 mg/L). The steady state accumulation ratio was 1.39.  
Figure 4.1. Mean plasma concentration-time curve for intravenous (IV) caspofungin 
acetate (1 mg/kg) delivered over 1 h.  
 
Table 4.1. Pharmacokinetic parameters following administration of a single 1 mg/kg 
dose of caspofungin acetate IV over 1hr and after reaching steady state after 
consecutive daily doses of 1 mg/kg IV.  
Parameter (units)  Single Dose Mean                                                
(1 mg/kg, n=7)a (95% CIs)  
Steady State Mean                                                
(1 mg/kg, n=6) (95% CIs)  
Tmax (h) 1.1 (0.9, 1.25) 1.13 (0.9, 1.34) 
Cmax (μg/mL) 14.38 (12.4, 16.35)  19.73 (15.79, 23.67)  
Css,trough (μg/mL) 
 
5.88 (4.39, 7.38) 
AUC(0-∞) 251.32 (200.95, 301.69)  349.98 (233.11, 466.85)  
T1/2 (h)  15.5 (13.1, 17.8) 14.5 (11.1, 17.9) 
CL/F (mL/hr/kg) 4.12 (3.45, 4.78)  3.16 (2.05, 4.27)  
V/F (L/kg) 0.09 (0.07, 0.11)  0.06 (0.05, 0.08)  
Accumulation ratio   1.52 
a Data from one cat was excluded due to extravasation of caspofungin during infusion. 
Cmax, maximum concentration; AUC0-∞, area under the plasma concentration–time curve extrapolated to infinity; Css, trough, 
minimal concentration prior to each daily dose; T1/2, elimination half-life; CL/F, apparent clearance; V/F, apparent volume of 
distribution.  
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Figure 4.2. Mean plasma concentration-time curve for intravenous (IV) caspofungin 
acetate (1 mg/kg) after reaching steady state.  
 
 
4.3. Pharmacokinetic modelling  
The two-compartment linear model provided the best description of the plasma 
concentration-time profiles of caspofungin in cats compared to a 1-compartment 
pharmacokinetic model, the objective function value is greater than 200 (∆OBJ 
>200). The two-compartment base model included proportional and additive residual 
error terms, and random effects on clearance (CL) and the central volume of 
distribution (V1).  Clearance and V1 were highly correlated. This was best described 
using a scale factor for the PPV on V1 as a function of the population parameter 
variability (PPV) on CL (∆OBJ >100) in order to prevent very high shrinkage on V1.  
Inclusion of PPV on the peripheral volume of distribution (V2) and the inter-
compartmental clearance (Q) had no effect on the OBJ (∆OBJ >0.1), gave very low 
estimates for PPV and resulted in the failure of the covariance step. Removal of 
allometric scaling for weight resulted in a worsening of model fit (∆OBJ >6), and so 
was retained in the final model. No covariates demonstrated evidence of predictive 
performance, and none were included in the final model. The population 
pharmacokinetic parameter estimates of the final pharmacokinetic model for 
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caspofungin in cats are presented in Table 4.2.  
 
Table 4.2. Population pharmacokinetic parameters for caspofungin in cats.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All model parameters were estimated with very good precision (7-21% RSE). The 
inter-individual variability for clearance was low (18%), and both had minimal 
shrinkage (<1%). There was good agreement between the observed and predicted 
population as well as individually predicted concentrations, with no evidence of bias, 
consistent with unbiased plots of conditional weighted residuals versus concentration 
and time after dose. 
Parameter (units) Estimate %RSE 
Structural 
CL (mL/h) * (WT/4)0.75 17.5 7 
V1 (mL) * (WT/4) 214 8.6 
V2 (mL) * (WT/4) 143 8.3 
Q (mL/h) * (WT/4)0.75 150 20 
   
Between subject variability (BSV) %CV (% shrinkage) 
CL 18 (0) 21 
V/F BSV scale factor 1.05 (na) 8.4 
   
Residual unexplained variability (RUV) 
Proportional (%CV) 7.8 18 
Additive (SD, µg/mL) 0.61 20 
CL, clearance; V1, central volume of distribution; V2, peripheral volume of 
distribution; Q, inter-compartmental clearance; RSE, relative standard error. 
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The visual predictive check based on 1000 simulations of the final pharmacokinetic 
(PK) model suggested acceptable fit of the model to the caspofungin plasma 
concentration-time data. Figure 4.3 shows the visual predictive check for simulations 
based on initial 24 hours and final dose at day 7. 
 
Figure 4.3. Visual predictive check plot for 1000 simulations of the final 
pharmacokinetic model and observed data. Solid lines represent the median and 
dashed lines represent the upper and lower 95% confidence intervals of the 
observed data (black) and prediction intervals of the final model (red). Circles 
represent the raw observed data. 
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4.4 Caspofungin Dose Regimen Simulations 
Table 4.3 summarises the caspofungin model-independent pharmacokinetic 
parameters and exposure indices from the “best” simulations, as well as the regimen 
employed in the original study (1 mg/kg every q24 h). While increasing the infusion 
duration from 1 h to 2 h or 4 h had some impact on the observed Cmax, this has 
minimal impact of the different dose regimens in the ability to achieve target 
exposures.  As a result, only the results from 1 h caspofungin infusions are 
presented here. Other dose regimens and infusion durations are presented in the 
supplementary table accompanying appendix 1. Doses above 1 mg/kg resulted in 
excessively high exposures, which were less able to meet the target Cmax:MEC ratio.   
 
Table 4.3. Summary of Caspofungin model-independent pharmacokinetic 
parameters and exposure indices from simulations which result in the maximum % 
animals 10<Cmax:MEC<20 ratio for three dosing regimens (0.75 mg/kg q24 h, 1 
mg/kg q24 h and and 1 mg/kg q72 h) 
  
 45 
 
Metric Regimen Mean Median SD Minimum Maximum 
Distribution t1/2 (hr) 
 
0.388 0.387 0.0287 0.28 0.481 
Terminal t1/2 (hr) 
 
14.5 14.5 0.963 12 19.4 
AUC0-τ,ss (μg.h/L)* 1mg/kg 232 230 40.7 125 436 
AUC0-τ,ss (μg.h/L)* 0.75mg/kg 173 170 30.7 88.8 287 
First dose 
      
Cmax first dose (μg/mL) 1mg/kg 14.8 15 2.11 8.55 23.8 
Cmax first dose (μg/mL) 0.75mg/kg 11 10.8 1.61 6.01 16.6 
AUC > MIC first dose 
(μg.h/L)** 
q24h 1mg/kg 133 133 22 69 227 
AUC > MIC first dose 
(μg.h/L)** 
q72h 1mg/kg 163 159 36.4 75.9 313 
AUC > MIC first dose 
(μg.h/L)** 
q24h 
0.75mg/kg 
93.2 92.5 16.6 42.7 148 
Last dose 
      
Cmax last dose (μg/mL) q24h 1mg/kg 19.8 19.6 3.23 10.9 34.2 
Cmax last dose (μg/mL) q72h 1mg/kg 15.4 15.3 2.38 9.27 23.8 
Cmax last dose (μg/mL) q24h 
0.75mg/kg 
14.7 14.2 2.42 7.94 22.9 
AUC > MIC last dose 
(μg.h/L)*** 
q24h 1mg/kg 1350 1340 253 662 2560 
AUC > MIC last dose 
(μg.h/L)*** 
q72h 1mg/kg 472 464 102 227 891 
AUC > MIC last dose 
(μg.h/L)*** 
q24h 
0.75mg/kg 
958 945 191 424 1650 
* AUCss,0-Ƭ = the AUC within an inter-dosing interval (0- Ƭ), at steady-state, which is also equivalent 
to the AUC0-∞ if only a single dose were given. This is identical for regimens that employ the same 
total dose (i.e. the 1 mg/kg q24 h and 1 mg/kg q72 h). 
**AUC > MEC first dose: this is the AUC > MIC for the first dosing interval.  For the q24 regimens 
this is 24 h. For the q72 h regimen this is 72 h.  The AUC > MEC in the first 24 h for the q72 h 1 
mg/kg regimen will be identical to that for the q24h 1mg/kg regimen as they both employ the same 
1 mg/kg dose. 
***AUC > MEC last dose: this is the cumulative AUC>MIC during the entire 7-day dosing period. 
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In the typical 4kg cat, a 1 mg/kg daily caspofungin dose results in a Cmax of 
14.8 µg/mL after the first dose, while this is 19.8 µg/mL at steady-state, with trough 
concentrations of caspofungin approximately 5 µg/mL.  In contrast, when given every 
three days, a 1 mg/kg dose reaches a mean Cmax of 15.4 µg/mL and the average 
trough caspofungin concentrations are less than 1 µg/mL. A 0.75 mg/kg dose daily 
achieves a mean caspofungin Cmax of 11.0 µg/mL after the first dose and 14.7 µg/mL 
at steady-state, with average trough concentrations of approximately 4 µg/mL.  
 
Plots of the median and 90% CI’s of the predicted caspofungin concentrations over 
time are provided in Figure 4.4.  
 
Figure 4.4. Plots of caspofungin concentration over time. 
 
A) 0.75 mg/kg dosing daily for 7 days, B) 1 mg/kg dosing daily for 7 days, C) 1 mg/kg every 72 hours 
for 7 days. Solid black line indicates the median; shaded ribbon shows the 90% CI. Dashed black 
lines show the putative upper and lower Cmax targets. 
 
 
Figure 4.5 shows the predicted distribution of the Cmax:MEC ratio over time. The 
maximal percentage of animals with a Cmax:MEC ratio of 10 - 20 occurred at 0.75 
mg/kg once daily (q24 h) and 1 mg/kg every 3 days (q72 h). At the peak 
concentration on the first day of dosing with 0.75 mg/kg, 71% of animals were within 
the optimal Cmax: MEC, by the third and later daily doses this reached 97%. With 1 
mg/kg dosing, more than 96% of animals were within the target ratio after the first 
dose, and with continued q72 h dosing, this remained relatively constant for the 
remaining 7 days.  Despite almost all animals being above the lower threshold, 
 47 
continued daily dosing with 1 mg/kg (the regimen employed in the original trial), 
resulted in fewer animals within the target window after subsequent doses, reducing 
to 76% on the second day, and 57% after the 7th daily dose, due to 43% of animals 
having a Cmax:MEC ratio greater than 20.  
 
Figure 4.5. Plots of caspofungin Cmax:MEC ratio over time. 
 
A) 0.75 mg/kg dosing daily for 7 days, B) 1 mg/kg daily dosing for 7 days, C) 1 mg/kg every 72 hours 
for 7 days. Red solid line indicates the median, shaded ribbons show the 95%, 90%, 75% and 50% 
CI’s in decreasingly dark shading. Dashed black lines show the putative upper and lower Cmax:MEC 
ratio limits. 
 
A loading dose regimen, utilising 1 mg/kg of caspofungin on day 1 followed by 0.75 
mg/kg daily thereafter, resulted in 98% of cats falling within the optimal Cmax:MEC 
ratio from the first dose until the end of the study. Figure 4.6 shows the predicted 
distribution of the Cmax:MEC ratio over time for the loading dose regimen.    
 
The differences between the regimens in terms of time-course of concentration 
relative to the MEC are highlighted in Table 4.3, demonstrating that the 1 mg/kg 
q72 h regimen results in a 50% lower AUC>MEC compared to the 0.75 mg/kg q24 h 
regimen. 
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Figure 4.6. Plots of caspofungin Cmax:MEC ratio over time utilising a 1mg/kg 
loading dose on day 1 followed by 0.75 mg/kg daily thereafter. 
 
 
Red solid line indicates the median, shaded ribbons show the 95%, 90%, 75% and 50% CI's in 
increasingly dark shading. Dashed black lines show the putative upper and lower Cmax:MEC ratio 
limits. 
 
 
 
 
 
 
 
 
 
 49 
Chapter 5 
DISCUSSION 
 
This study investigated the pharmacokinetics of caspofungin in healthy adult cats, 
finding that it is well tolerated and reaches therapeutic plasma levels at the dosing 
regimen studied. The over-arching goal of antifungal therapy is to achieve adequate 
drug concentration at the site of infection for the appropriate duration. Using a 
modelling and simulation approach we have also shown that doses of 0.75 mg/kg or 
1 mg/kg once daily, as well as 1 mg/kg every 72 hours, will reach target therapeutic 
levels within serum. 98% of cats will also achieve the target therapeutic level after 
the first dose when a loading dose of 1 mg/kg is given on day 1 followed by 0.75 
mg/kg daily. It has previously been shown that the outcomes of infection at other 
tissue sites correlates well with plasma concentrations of the drug [279].   
 
The intravenous caspofungin concentration-time data in cats were best described by 
a linear population pharmacokinetic model which was in agreement with data 
collected from other species including rodents (mice, rats), lagomorphs (rabbits) and 
primates (chimpanzees, rhesus monkeys and humans) [213, 280]. It reaches 
maximal serum concentration levels at the end of the intravenous infusion. This was 
further supported by the population model. As expected, the elimination half-life of 
caspofungin in cats (14.5 ± 0.96 h) was longer than that in healthy human adults 
administered an equivalent 70 mg dose (9.29 ± 1.96 h) [212]. Steady state was 
achieved at approximately 72 h with trough concentrations of caspofungin in cats at 
1 mg/kg and 0.75 mg/kg daily of approximately 5 µg/mL and 4 µg/mL respectively. In 
contrast, humans given 70 mg/kg daily reportedly only achieved steady state during 
the third week of administration with a lower trough concentration of 2.57 ± 0.34 
µg/mL, as a result of a much longer terminal half-life in humans (40 – 50 h) 
compared to cats (15 h) [212]. The clearance reported in this study, in the typical 4kg 
cat (18 mL/min) is larger on a per kg basis than that reported in the typical 70 kg 
human (10 mL/min). As Stone, Holland (212) did not report the volume of distribution 
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a direct comparison cannot be made, however it would appear that humans likely 
have a greater volume of distribution per kg compared to cats.     
 
Studies conducted in humans and rats have shown that following initial distribution 
caspofungin is taken up by the liver and slowly metabolised; primarily in the liver, as 
well as the adrenal glands and spleen [210]. Furthermore, metabolism of 
caspofungin to inactive metabolites occurs by non-enzymatic hydrolysis and N-
acetylation [45, 210, 214].  The OATP-1B1 transporter pathway is responsible for 
hepatic uptake of caspofungin in rats, as well as the transport of bile which 
eliminates the degradation products of caspofungin [210, 215]. Cats are deficient in 
NAT2 and possess a single NAT similar to human NAT1 but with lower affinity and 
activity; therefore, it is likely that other pathways are involved in its metabolism and 
this warrants further investigation [42, 49]. Metabolic deficiencies in cats have been 
shown to occur mostly in phase II metabolism, such as with 
glucuronidation, acetylation, and sulfation reactions. Hence a proposed mechanism 
of feline caspofungin metabolism may be through enhanced phase I metabolism via 
hydrolysis or other mechanisms [42].   
 
Caspofungin exerts its antifungal activity on the b-glucans, i.e. glucose polymers that 
are a major cell wall structural component in fungi, plants and some bacteria, but not 
in mammals. Hence adverse effects in mammalian species are expected to be low 
[281]. In this study, caspofungin was well tolerated by cats with only two adverse 
events observed – transient fever and diarrhoea. Adverse events in healthy humans 
are minimal and are mostly due to infusion reactions such as fever, gastrointestinal 
signs, phlebitis and headache [1, 41, 214]. Histamine – mediated symptoms; 
including anaphylaxis, rashes, facial swelling, pruritus, bronchospasm and cardiac 
arrhythmias; have rarely been reported [208, 242, 282]. Manifestations of acute 
anaphylaxis are species-dependent. Thus, animal-models of disease need to 
account for such species differences and prospective studies of the effect of 
caspofungin in cats with active fungal infections are warranted.  
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Liver enzyme elevations did not occur in any cats in this study and were uncommon 
in healthy caspofungin-treated humans [212]. However, adverse events have been 
shown to be higher in patients with invasive fungal infections, co-morbidities and 
altered drug metabolism. For example, rabbits in a model of invasive aspergillosis 
had significantly slower clearance of anidulafungin associated with a higher plasma 
concentration of drug at the end of the dosing interval compared to healthy 
individuals [283]. Hepatotoxicity, manifesting as elevated liver enzymes (ALT, AST or 
ALP),  and infusion reactions are common in human patients with invasive fungal 
infections treated with caspofungin [284]. The most common clinical adverse events 
were fever (7.5%), chills (5.3%), nausea or vomiting (5.3%) and phlebitis (3.5%) 
[284].  
 
Caspofungin is also registered for use in patients that are unable to tolerate other 
antifungals due to hepatic or renal insufficiency, as well as for empirical therapy for 
presumed fungal infections in febrile neutropenic patients [41, 116]. Studies in 
humans and rodents have shown that caspofungin is not metabolised or excreted via 
the renal system [85, 212, 213]. It may, therefore, be a good option in elderly cats 
with renal insufficiency, or cats experiencing adverse effects from amphotericin B or 
azole therapy, however the route of metabolism and excretion requires further 
evaluation in cats. Poor clearance of antifungal drugs in sick patients may also affect 
patient outcome and predispose to the development of paradoxical growth or trailing 
effect at drug concentrations greater than the MIC/MEC, leading to increased growth 
of fungus and negative patient outcomes [199, 285, 286].  
 
The fungi responsible for feline sino-orbital aspergillosis are from the Aspergillus 
viridinutans complex, within Aspergillus section Fumigati [287]. A. felis, a cryptic 
species of A. virdinutans, is most commonly implicated as the causative agent, and 
has also been associated with invasive aspergillosis in humans and dogs [31]. 
Antifungal susceptibility was tested for thirteen A. felis isolates from cats by Barrs, 
van Doorn (31), caspofungin displayed a MEC of less than 0.06 µg/mL in all but one 
isolate which was 2 µg/mL. The majority of isolates had MICs greater than 0.06 
µg/mL for both amphotericin B and the azoles tested; for voriconazole MICs were 
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greater than 1 µg/mL in 9/13 isolates [31]. In the current study, at a dose of 1 mg/kg 
q24 h Cmax and Cmin were well in excess of the highest MECs reported for Aspergillus 
viridinutans complex species. However, other cryptic species in section Fumigati 
reported to cause invasive aspergillosis in humans and cats have shown decreased 
susceptibility to caspofungin, including some pathogenic isolates of A. lentulus from 
human cases which had MECs of caspofungin of 4 - >32 µg/mL [34].  
 
The trough plasma caspofungin concentration in this study was no less than 2.78 
µg/mL for all animals for the duration of the study period, which is above the MEC 
reported for Aspergillus Section Fumigati isolates, as well as greater than the 
recommended plasma concentration (1 µg/mL) in humans [34, 35, 221, 288]. In the 
pharmacokinetic model utilising this dose, 95% of the population achieved a trough 
concentration of approximately 3.75 μg/L, with the average around 5 μg/L, which is 
well above the MEC and recommended plasma concentrations. As previously 
mentioned, paradoxical growth effect can lead to negative patient outcomes. Thus, it 
is important to utilise a dosing regimen which does not greatly exceed the MEC for 
the isolate and to perform appropriate susceptibility testing and therapeutic 
monitoring. 
 
Appropriate plasma concentration of caspofungin is a potential predictor of efficacy, 
as it has been shown to have concentration-dependent activity against Aspergillus 
spp., unlike the azoles which are time-dependent [231]. Utilising the Wiederhold, 
Kontoyiannis (231) target for therapeutic doses of caspofungin, the simulated data 
shows that an optimal Cmax: MEC of 10-20 is achieved using 0.75 mg/kg q24 h or 1 
mg/kg q3 days. In the regimen initially studied (1 mg/kg q24 h), and extrapolated 
from the human dosage, the Cmax:MEC ratio is too high in a significant number of 
cats (42.6% greater than 20 after 7 consecutive doses). At this dose with a 3-day 
inter-dosing interval, Cmin was shown to be well below 1 μg/mL in more than 95% of 
the population as the prolonged dosing interval does not allow for drug accumulation.  
 
Using a daily dose of 0.75 mg/kg, the Cmax: MEC is below 20 and Cmin is greater than 
2.5 μg/mL for more than 95% of the population. This difference in exposure between 
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doses is also highlighted by the 50% reduction in the cumulative AUC above the 
MEC for the 1 mg/kg q72h regimen compared to 0.75 mg/kg q24h. One week of 
treatment was considered a long enough time to ensure plasma concentrations were 
at steady-state. Measuring the plasma concentrations at steady state is clinically 
relevant as fungal infections typically require long-term treatment to achieve 
resolution [41]. Although both 1 mg/kg q72h and 0.75 mg/kg q24h provide very 
similar results for Cmax: MEC, the former regimen in vastly superior in regard to AUC 
> MEC. The Cmax:MEC ratio appears promising utilising a dosage of 1 mg/kg every 
72 h, potentially to improve treatment compliance; however this regimen does not 
appear appropriate when considering trough plasma concentration and drug 
accumulation to achieve steady state. Therefore based on the modelling data, a daily 
dose of 0.75 mg/kg is most likely to meet the ideal Cmax:MEC, and provide consistent 
drug exposure between doses, thus improving patient outcomes. Alternatively, 
utilising a loading dose regimen of 1 mg/kg on day 1, followed by 0.75 mg/kg daily 
will rapidly achieve steady state, as well as provide continual exposure between 
dosing.  
 
The use of pharmacokinetic modelling aimed to reduce the bias associated with the 
small number of individuals in the original pharmacokinetic study. The visual 
predictive check shows that the pharmacokinetic data presented here is a good 
representation of the population. The two-stage method was utilised for the 
pharmacokinetic study in order to minimise bias associated with pharmacokinetic 
calculations, such as the naïve pooled data method, which do not take into account 
inter- and intra- individual variability. However, as the data was estimated from each 
individual concentration versus time curve some upward bias could not be avoided. 
The two-stage approach is resource intensive and requires repeated studies in 
different populations, for example feline breed differences have not been taken into 
account in our study design and thus a pharmacokinetic model is a superior method 
of assessing the drugs utility in a healthy cat population and allows for a more 
accurate dosing regimen to be achieved.  
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The relationship between antifungal in vivo susceptibility, dosages, drug 
concentrations within various body compartments and toxicological effects are not 
completely understood. Although our pharmacokinetic analyses have attempted to 
predict a regimen appropriate for safe and effective use of caspofungin using in vitro 
MEC values, inherent biological factors can affect therapeutic outcome. For 
example, in SOA systemic therapy may not be sufficient to penetrate the site of 
infection and reduce fungal burden. In addition, this work is based upon total plasma 
concentrations, and not unbound drug, which may further confound the results as   
caspofungin is highly protein bound (>95%) [85, 210]. The plasma free fraction in the 
cat is unknown. Nevertheless, the current clinical regimen provides total plasma 
concentrations consistent with the Cmax:MEC ratio proposed in the present analyses, 
suggesting that the simulations are likely to be clinically relevant. Further 
pharmacodynamic studies are, therefore, required which can be linked with the 
pharmacokinetic data presented here, prior to a robust prospective clinical study to 
document clinical efficacy and safety of the proposed regimens in feline patients 
affected by sino-orbital aspergillosis.   
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Abstract
Cats are the most common mammal to develop invasive fungal rhinosinusitis caused by
cryptic species in Aspergillus section Fumigati that are resistant to azoles but susceptible to
caspofungin. In this study nonlinear mixed-effects pharmacokinetic modeling and simulation
was used to investigate caspofungin pharmacokinetics and explore dosing regimens in cats
using caspofungin minimum effective concentrations (MECs). Plasma concentrations in
healthy cats were determined using HPLC-MS/MS after administration of a single and
seven consecutive daily intravenous doses of 1 mg/kg caspofungin. In the final pharmacoki-
netic model an optimum maximum concentration (Cmax): MEC ratio of 10–20 was used to
guide caspofungin efficacy. Simulations were performed for dosing regimens (doses 0.25–2
mg/kg and 6–72 h dosing intervals) with and without inclusion of a loading dose. Using a 1
mg/kg dose Cmax first dose was 14.8 μg/mL, Cmax at steady state was 19.8 μg/mL, Cmin was
5 μg/mL and Cmax: MEC was >20 in 42.6% of cats after multiple doses. An optimal Cmax:
MEC ratio was achieved in caspofungin simulations using 0.75 mg/kg q 24 h or 1 mg/kg q
72h. However, at 1 mg/kg q 72h, Cmin was <MEC (<1 μg/mL) in over 95% of the population.
Using a loading dose of 1 mg/kg and a daily dose of 0.75 mg/kg thereafter, the Cmax: MEC
was optimal and Cmin was > 2.5 μg/mL for 98% of the population. Based on the modeling
data this dosing regimen is likely to achieve target therapeutic concentrations, meet the pro-
posed Cmax: MEC window and provide consistent exposure between doses.
Introduction
Cats are the most common mammal to develop naturally occurring invasive fungal rhinosinu-
sitis caused by cryptic species of Aspergillus in section Fumigati [1]. Sino-orbital aspergillosis
occurs in immunocompetent cats, is usually fatal and is most frequently caused by two
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emerging pathogens in the Aspergillus viridinutans species complex, A. felis and A. udagawae
[1]. These cryptic species in section Fumigati also cause invasive fungal infection (IFIs) in
humans, usually in the form of invasive pulmonary aspergillosis [1–3].
In both humans and cats A. udagawae and A. felis cause infections with a protracted clinical
course that spread across anatomical planes to involve contiguous tissues and are refractory to
standard therapy [2, 4]. The minimum inhibitory concentrations (MICs) of azole and polyene
antifungal agents against Aspergillus viridinutans complex species are higher than those for A.
fumigatus [3]. Caspofungin is an approved echinocandin for treatment of human patients with
invasive aspergillosis refractory to other antifungal therapy [5–12] and was used to cure a
case of feline sino-orbital aspergillosis caused by A. felis that failed treatment with azoles and
amphotericin B [4]. The pharmacokinetics of caspofungin have been evaluated in rodents,
lagomorphs and primates [13, 14]. Among companion animals, the pharmacokinetics of mica-
fungin, but not caspofungin have been determined in dogs and no echinocandins have been
evaluated in felines [15].
The pharmacokinetics of caspofungin in cats cannot be extrapolated from other mammals
studied thus far since cats have substantial differences in drug metabolism compared to other
mammals, including deficiencies in multiple phase II metabolic pathways including N-acetyl-
transferase (NAT) [16]. Our objective was to determine the pharmacokinetics of caspofungin
in healthy cats after an intravenous dose of 1 mg/kg and after 7 consecutive daily doses. This
study used a modeling and simulation approach to explore caspofungin dosing regimens in
cats designed to examine Cmax: MEC ratios after intravenous caspofungin infusions.
Materials and methods
Pharmacokinetic study
Animals. Eight healthy adult desexed domestic shorthair cats (4 females, 4 males) with
mean age and body weight of 3.94 ± 1.84 years and 4.4 ± 0.56 kg, respectively were recruited
for the study. The cats were healthy cats from a research colony owned by Eurofins SCEC
Pty Ltd. (www.scec.net.au) and were returned at the completion of the study in good health.
Results of a complete blood count, serum biochemical analyses and urine specific gravity per-
formed 5 days prior to the start of the study were within reference intervals for all cats. Cats
were housed individually and acclimatized to the clinical environment for three days prior to
the start of the study with free access to food and water. The study was approved by the Animal
Ethics Committee (AEC) of The University of Sydney (Approval no. 2015/775, 6th March,
2015).
Drug administration and blood sampling. For blood sampling, a 20-guage 8 cm triple-
lumen central venous catheter (MILACATH1, MILA International, Inc., Kentucky, USA)
was inserted into the jugular vein using a modified Seldinger technique after sedation with IV
medetomidine (10 μg/kg; Domitor1, Pfizer Animal Health Australia, West Ryde, NSW) and
butorphanol (0.1 mg/kg; Ilium Butorgesic1, Troy Laboratories Pty Limited, Glendenning,
NSW), 24 h prior to starting the study. For drug administration, a peripheral catheter (22G IV
radiopaque catheter; OPTIVA1, Smiths Medical International Ltd, Lanchashire, UK) was
placed into a cephalic vein. For the single dose study (n = 8 cats) caspofungin acetate (Canci-
das1, Merck Sharp & Dohme (Australia) PTY Limited, South Granville, NSW) was adminis-
tered by IV infusion (1 mg/kg), 0.2 mg/mL in sterile saline solution (0.9% sodium chloride,
Abbott Laboratories, Abbott Park, IL) over 1 h. For the multiple consecutive daily dosing
study (n = 6 cats, 3 male, 3 female) administration of caspofungin acetate (1 mg/kg IV infusion
over 1 h) was repeated once daily (at the same time each day) for a further 6 days.
Caspofungin pharmacokinetics in cats
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Blood (1 mL) was collected in lithium-heparin immediately before drug administration
(time 0), and after IV administration at 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 6, 9, 12, and 24 h. Blood sam-
ples were immediately centrifuged (12, 000 g for 5 min) and plasma was stored at -80˚C until
assay. For the multi-dose study, a single blood sample was collected before each daily infusion
(48, 72, 96 and 120 h after the first dose) to ascertain steady state plasma concentrations and
blood sampling was repeated at the same times as day 1 on day 7. Repeat biochemical analyses
were performed on Day 8, 24 h after the final caspofungin dose and pharmacokinetic blood
sample collection.
Analytical method. Caspofungin concentrations in cat plasma were determined using
HPLC-MS/MS (tandem mass spectrometry). Blood samples were prepared for assay using
protein precipitation by adding methanol (80 μL) to 20 μL of calibrators, controls (drug
free) and unknown samples using a stable isotope of caspofungin as internal standard (in
methanol). Analytical reference standard for caspofungin was supplied by Merck Sharp &
Dohme (Whitehouse Station, New Jersey 08889, USA). Chromatography and analysis was
performed on a Shimadzu UPLC coupled to an 8050 tandem mass spectrometer in positive
ion ESI mode, monitoring the transition 547.6 > 538.5 and internal standard transition
549.5 > 86.2. A Waters BEH C18 column was used with gradient elution with mobile phase
A (water with 0.1% formic acid) and mobile Phase B (acetonitrile containing 0.1% formic
acid). The mobile phase gradient involved 100% A for 0.5 minutes and a linear gradient to
0% A by 4.5 minutes. After raising the gradient to 100% B at 4.5 minutes it was held there for
0.5 minutes before returning to initial conditions for a further minute, making a total run
time of 6 minutes.
The assay was validated in accordance with the US FDA Guidelines for industry for bioana-
lytical method validation utilising pooled plasma from six untreated cats with known concen-
trations of caspofungin reference standard. Linearity was demonstrated over the caspofungin
concentration range of 0.1 to 10.0 μg/mL. The assay accuracy and precision (4 replicates on 3
occasions of spiked caspofungin plasma samples at 0.2 and 9.0 μg/mL) showed total precision
of 12.0 and 4.3% (expressed as co-efficient of variation), respectively. Accuracy was 103.4 and
96.7%, respectively. Carry-over was demonstrated to be no more than 1.0% of the lowest stan-
dard in blank matrix following injection of the highest standard (10.0 μg/mL).
Population pharmacokinetics analysis and dose regimen simulations
Methods software. Pharmacokinetic model development employed nonlinear mixed-
effects modeling using NONMEM version 7.3 [17], with the Wings for NONMEM 7.3interface
(http://wfn.sourceforge.net) and IFort compiler. Modeling was performed using a Dell Power-
Edge R910 server with 4 by 10 core Xeon 2.26-Ghz processors running Windows Server 2008
R2 Enterprise 64- bit software. Data manipulation and post-run processing of NONMEM
output was conducted using the R data analysis language (Version 3.2.2) and the packages
ggplot2, GGally, foreign, tidyr, Hmisc, gdata, doBy, plyr, grid, stringr with associated depen-
dencies [17–28].
General modeling strategy. The base pharmacokinetic model was developed in a step-
wise manner. Pharmacokinetic models were coded using the built-in ADVAN subroutines
of NONMEM. Linear kinetic models with 1 and 2 compartments were evaluated. The First
Order Conditional Estimation (FOCE) method was used to fit models. The base model was
selected on the basis of mechanistic plausibility, visual inspection of goodness-of-fit diagnostic
plots, the precision of parameter estimates (se%<30% for fixed, <50% for random effects
parameters), and the lowest value of the Akaike’s information criterion (AIC; Eq 1) in accor-
dance with the number of parameters and the final NONMEM derived objective function
Caspofungin pharmacokinetics in cats
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value (OBJ). The base model was also required to pass the covariance step.
AIC ¼ OBJ þ 2  number of parameters ð1Þ
Unless stated otherwise, population parameter variability (PPV) was represented using an
exponential error model (Eq 2):
Pj ¼ TVP  e
Zj ð2Þ
where Pj is the individual value for the parameter in the j
th individual, TVP is the typical popu-
lation value of P and ηj is an independent random variable with a mean of zero and variance
ω2. PPV was systematically examined on each fixed-effect parameter. Models with and without
covariance for P were investigated using the OMEGA BLOCK functionality of NONMEM.
A combined proportional (θprop) and additive (θadd) residual unexplained error model of
the caspofungin concentrations (C) was used, where estimation of a THETA was employed
and epsilon was fixed to zero (Eq 3):
Cij ¼ C^ij þ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
yprop
2  C^ij2 þ yadd2
q
ð3Þ
Cij is the ith concentration measured in the jth individual, C^ij is the model predicted Cij, and
θprop and θadd are parameters representing the proportional and additive residual error, respec-
tively. The influence of the additive component of the error was also examined by a compari-
son with a proportional only error model.
All base models were investigated with allometric scaling for total body weight (TBW) ref-
erenced to 4 kg and an exponent fixed of 0.75 for clearance parameters and 1 for volumes,
although during base model development models was explored without allometric scaling on
any parameter.
Covariate model building. The base model was screened for the influence of cat sex,
guided by plots of individual parameter random effects versus sex if shrinkage was low. Sex
was only retained in the model if there was a significant improvement in OBJ at the p<0.01
level.
Model evaluation. Visual Predictive Checks (VPC) were used to assess the appropriate-
ness of the candidate base and final models, faceted for any included covariates as appropriate.
For the VPC’s, the median, 5th and 95th percentiles of the prediction-corrected observations
were compared against the empirical 95% confidence intervals (CI) of the median, 5th and 95th
percentiles of caspofungin concentrations from 1000 simulations of the index (original) data-
set. The predictive performance of the model was considered acceptable if the median, 5th and
95th percentiles of the prediction-corrected observed and simulated data agreed well.
Caspofungin dose regimen simulations. The final pharmacokinetic model for caspofun-
gin in cats was used to perform dosing simulations designed to examine Cmax: minimum effec-
tive concentration (MEC) ratios following intravenous infusions of caspofungin. Simulations
were performed utilising total drug in serum rather than unbound drug, as published data
available for MEC values have only been reported for the total drug. Based on data from a
murine model of invasive pulmonary aspergillosis an optimum Cmax: MEC ratio of 10–20 was
chosen as a marker of caspofungin dose efficacy [29]. Simulations were performed for dosing
regimens of 0.25 mg/kg at 6 h intervals; 0.5 mg/kg at 6 h, 12 h and 24 h dosing intervals; 0.75
mg/kg and 1 mg/kg at 24 h, 48 h and 72 h intervals; 2 mg/kg at 48 h and 72 h dosing intervals.
Loading dose regimen simulations were also considered based upon the results of the con-
stant-dose regimens. A MEC value of 1 μg/mL was chosen based on the epidemiological cut-
off value (ECV) of caspofungin for wild type A. fumigatus sens. str [30] and on antifungal
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susceptibility MEC data from clinical human and feline isolates of A. felis [1] and A. udagawae
[2, 31, 32]. The duration of infusion was adjusted to 1, 2 and 4 h in the 1 mg/kg and 2 mg/kg
simulations. Concentrations were simulated at 0.1 h intervals for 1000 standard 4 kg cats for
each dose regimen for a total of 7 days of dosing. The percentage of animals with a Cmax:
MEC> 10, > 20 and 10–20 was calculated over the entire 7 days of dosing. Maximising the
percentage of animals with a Cmax: MEC of 10–20 was the criteria for “goodness” of a regimen.
Supplementary pharmacokinetic parameters were also derived from the model parameters:
AUCss (determined from dose and clearance), distribution (t1/2α) and terminal (t1/2β) half-life
(calculated from the individual values of the pharmacokinetic parameters for each animal),
Cmax (derived directly from the data as the concentration at the end of each infusion).
Results
All cats completed the pharmacokinetic study and no changes were seen on complete blood
counts and multiple biochemical analyses after consecutive daily dosing. Physical examination
parameters were normal throughout the study except for minor transient hyperthermia in one
cat (range 39.6–39.8˚C, reference range 37.5–39.1˚C) during the first caspofungin transfusion
only and mild transient diarrhoea that resolved within 24 h of the final caspofungin infusion
on Day 8 in another.
Pharmacokinetic modeling
The two-compartment linear model provided the best (ΔOBJ>200) description of the plasma
concentration-time profiles of caspofungin in cats compared to a 1-compartment pharmacoki-
netic model. The two-compartment base model included both proportional and additive resid-
ual error terms, and random effects on clearance (CL) and the central volume of distribution
(V1). Clearance and V1 were highly correlated. This was best described using a scale factor for
the PPV on V1 as a function of the PPV on CL (ΔOBJ> 100) in order to prevent very high
shrinkage on V1. Inclusion of PPV on the peripheral volume of distribution (V2) and the
inter-compartmental clearance (Q) had no effect on the OBJ (ΔOBJ> 0.1), gave very low esti-
mates for PPV and resulted in failure of the covariance step. Removal of allometric scaling for
weight resulted in a worsening of model fit (ΔOBJ> 6), and so was retained in the final model.
No covariates demonstrated evidence of predictive performance, and none were included in
the final model. The population pharmacokinetic parameter estimates of the final pharmacoki-
netic model for caspofungin in cats are presented in Table 1.
All model parameters were estimated with very good precision (7–21% RSE). The inter-
individual variability for clearance was low (18%) and had minimal shrinkage (< 1%). There
was good agreement between the observed and predicted population as well as individually
predicted concentrations, with no evidence of bias, consistent with unbiased plots of condi-
tional weighted residuals versus concentration and time after dose.
The visual predictive check based on 1000 simulations of the final PK model suggested
acceptable fit of the model to the caspofungin plasma concentration-time data. Fig 1 shows the
visual predictive check for simulations based on initial 24 h and final dose on day 7.
Caspofungin dose regimen simulations. Table 2 summarises the caspofungin model-
independent pharmacokinetic parameters and exposure indices from the “best” simulations,
as well as the regimen employed in the original study (1 mg/kg every q24 h). While increasing
the infusion duration from 1 h to 2 h or 4 h had some impact on the observed Cmax, this has
minimal impact of the different dose regimens in the ability to achieve target exposures. As a
result, only the results from 1 h caspofungin infusions are presented here. Data for other dose
regimens and infusion durations are presented in supporting material (S1 Table). Similarly,
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doses above 1mg/kg resulted in excessively high exposures, which were less able to meet the
target Cmax:MEC ratio, and are not presented here. Data for other dose regimens and infusion
durations are presented in supporting material (S1 Table).
In the typical 4 kg cat, a 1 mg/kg daily caspofungin dose results in a Cmax of 14.8 μg/mL on
the first dose while this is 19.8 μg/mL at steady-state, with trough concentrations of caspofungin
approximately 5 μg/mL. In contrast, when given every 3 days, a 1 mg/kg dose reaches a mean
Table 1. Population pharmacokinetic parameters for caspofungin in cats.
Parameter (units) Estimate %RSE
Structural
CL (mL/h) * (WT/4)0.75 17.5 7
V1 (mL) * (WT/4) 214 8.6
V2 (mL) * (WT/4) 143 8.3
Q (mL/h) * (WT/4)0.75 150 20
Between subject variability (BSV) %CV (% shrinkage)
CL 18 (0) 21
V/F BSV scale factor 1.05 (na) 8.4
Residual unexplained variability (RUV)
Proportional (%CV) 7.8 18
Additive (SD, μg/mL) 0.61 20
CL, clearance; V1, central volume of distribution; V2, peripheral volume of distribution; Q, inter-
compartmental clearance; RSE, relative standard error.
https://doi.org/10.1371/journal.pone.0178783.t001
Fig 1. Visual predictive check plot for 1000 simulations of the final pharmacokinetic model and
observed data. Solid lines are the median and dashed lines represent the upper and lower confidence
intervals of the observed data (black) and prediction intervals of the final model (red). Circles are the raw
observed data.
https://doi.org/10.1371/journal.pone.0178783.g001
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Cmax of 15.4 μg/mL and the average trough caspofungin concentrations are less than 1 μg/mL.
A 0.75 mg/kg dose daily achieves a mean caspofungin Cmax of 11.0 μg/mL after the first dose,
14.7 μg/mL at steady-state, with average trough concentrations of approximately 4 μg/mL.
Plots of the median and 90% CI’s of the predicted caspofungin concentrations over time are
provided in Fig 2, while Fig 3 shows the predicted distribution of the Cmax:MEC ratio over
time. The maximal percentage of animals with a Cmax:MEC ratio of 10–20 occurred at 0.75
mg/kg once daily (q24 h) and 1 mg/kg every 3 days (q72 h). At the peak concentration on the
first day of dosing with 0.75 mg/kg, 71% of animals were within the optimal Cmax: MEC, by
the third and later daily doses this reached 97%. With 1 mg/kg dosing,> 96% of animals were
within the target ratio after the first dose, and with continued q72 h dosing, this remained rela-
tively constant for the remaining 7 days. Despite almost all animals being above the lower
threshold, continued daily dosing with 1 mg/kg (the regimen employed in the original trial),
resulted in fewer animals within the target window after subsequent doses, reducing to 76% on
the second day, and 57% after the 7th daily dose due to 43% of animals having a Cmax:MEC
ratio greater than 20. A loading dose regimen, utilising 1mg/kg of caspofungin on day 1 fol-
lowed by 0.75mg/kg q 24 h thereafter, resulted in 98% of cats falling within the optimal Cmax:
MEC ratio from the first dose until the end of the study. Fig 4 shows the predicted distribution
of the Cmax:MEC ratio over time for the loading dose regimen.
The differences between the regimens in terms of time-course of concentration relative to
the MEC are highlighted in Table 2, demonstrating that the 1 mg/kg q72 h regimen results in a
50% lower AUC > MEC compared to the 0.75 mg/kg q24 h regimen.
Table 2. Summary of caspofungin model-independent pharmacokinetic parameters and exposure indices from simulations which result in the
maximum % animals 10 <Cmax/MEC < 20 ratio for three dosing regimens administered as 1 h duration infusions (0.75 mg/kg q 24 h, 1 mg/kg q 24 h
and 1 mg/kg q72 h).
Metric Regimen Mean Median SD Minimum Maximum
Distribution t1/2 (hr) 0.388 0.387 0.0287 0.280 0.481
Terminal t1/2 (hr) 14.5 14.5 0.963 12.0 19.4
AUCss,0-T (μg.h/mL)* 1 mg/kg 232 230 40.7 125 436
AUCss,0-T (μg.h/mL) 0.75 mg/kg 173 170 30.7 88.8 287
First dose
Cmax first dose (μg/mL) 1 mg/kg 14.8 15.0 2.11 8.55 23.8
Cmax first dose (μg/mL) 0.75 mg/kg 11.0 10.8 1.61 6.01 16.6
AUC >MEC first dose (μg.h/mL)** 1 mg/kg q 24 h 133 133 22.0 69.0 227
AUC >MEC first dose (μg.h/mL)** 1mg/kg q72 h 163 159 36.4 75.9 313
AUC >MEC first dose (μg.h/mL)** 0.75mg/kg q 2 4h 93.2 92.5 16.6 42.7 148
Last dose
Cmax last dose (μg/mL) 1 mg/kg q 24 h 19.8 19.6 3.23 10.9 34.2
Cmax last dose (μg/mL) 1 mg/kg q 72 h 15.4 15.3 2.38 9.27 23.8
Cmax last dose (μg/mL) 0.75 mg/kg q24 h 14.7 14.2 2.42 7.94 22.9
AUC >MEC last dose (μg.h/mL)*** 1 mg/kg q24 h 1350 1340 253 662 2560
AUC >MEC last dose (μg.h/mL)*** 1 mg/kg q72 h 472 464 102 227 891
AUC >MEC last dose (μg.h/mL)*** 0.75mg/kg q24 h 958 945 191 424 1650
* AUCss,0-T = the AUC within an inter-dosing interval (0-T), at steady-state, which is also equivalent to the AUC0-infinity if only a single dose were given. This
is identical for regimens that employ the same total dose (ie. the 1mg/kg q24h and 1mg/kg q72h).
**AUC >MEC first dose: this is the AUC >MIC for the first dosing interval. For the q24 regimens this is 24h. For the Q72h regimen this is 72h. The
AUC >MEC in the first 24h for the q72h 1mg/kg regimen will be identical to that for the q24h 1mg/kg regimen as they both employ the same 1mg/kg dose.
***AUC >MEC last dose: this is the cumulative AUC>MIC during the entire 7 day dosing period.
https://doi.org/10.1371/journal.pone.0178783.t002
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Discussion
This study has investigated the pharmacokinetics of caspofungin in healthy adult cats, finding
that it is well tolerated and reaches therapeutic plasma levels at the dosing regimen studied.
Using an innovative modeling and simulation approach we have shown that doses of 0.75 mg/
kg or 1 mg/kg once daily, as well as 1 mg/kg every 72 hours, will reach target therapeutic levels.
We have also shown that a loading dose of 1 mg/kg followed by 0.75mg/kg daily will enable
98% of cats to achieve the target therapeutic level after the first-dose.
Caspofungin exhibits linear pharmacokinetics in cats after intravenous administration of a
single 1 mg/kg dose as demonstrated in other mammals including rodents (mice, rats), lago-
morphs (rabbits) and primates (chimpanzees, rhesus monkeys and humans) [13, 14]. In
humans, hepatic degradation of caspofungin to inactive metabolites occurs by non-enzymatic
Fig 2. Plots of caspofungin concentration over time. A) 0.75mg/kg dosing daily for 7 days, B) 1mg/kg dosing daily for 7 days, C) 1mg/kg every 72
hours for 7 days. Solid black line indicates the median, shaded ribbon shows the 90% CI. Dashed black lines show the putative upper and lower Cmax
targets.
https://doi.org/10.1371/journal.pone.0178783.g002
Fig 3. Plots of caspofungin Cmax:MEC ratio over time. A) 0.75mg/kg dosing daily for 7 days, B) 1mg/kg daily dosing for 7 days, C) 1mg/kg every 72
hours for 7 days. Red solid line indicates the median, shaded ribbons show the 95%, 90%, 75% and 50% CI’s in increasingly dark shading. Dashed black
lines show the putative upper and lower Cmax:MEC ratio limits.
https://doi.org/10.1371/journal.pone.0178783.g003
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hydrolysis and N-acetylation [33–35]. Cats are deficient in NAT2 and possess a single NAT
similar to human NAT1 but with lower affinity and activity [16]. Whether this is the major
pathway of caspofungin metabolism in the cat is not known. The elimination half-life of caspo-
fungin in cats (14.5 ± 0.96 h) was longer than that in healthy human adults administered an
equivalent 70 mg dose (9.29 ± 1.96 h) [35].
Steady state was achieved at approximately 72 h with trough concentrations of caspofungin
in cats at 1 mg/kg and 0.75 mg/kg daily of approximately 5 μg/mL and 4 μg/mL, respectively.
In contrast, humans given 70 mg/kg of caspofungin daily reportedly only achieved steady state
during the third week of administration with a lower trough concentration of 2.57 ± 0.34 μg/
mL, as a result of a much longer terminal half-life in humans (40–50 h) compared to cats (15
h) [36]. The clearance we report in the typical 4 kg cat (18 mL/min) is larger on a per kg basis
than that reported in the typical 70 kg human (10mL/min). We cannot comment on a compar-
ison of volume of distribution as Stone et al [36] did not report this parameter, although it
would appear that humans most likely have a larger volume of distribution per kg compared
to cats.
Caspofungin was well tolerated by cats with only two adverse events (AE) observed—tran-
sient fever and diarrhoea. Since caspofungin exerts its fungicidal activity on the β-glucans,
which are essential glucose polymer cell wall components of fungi but not mammals, AE in
mammalian species are expected to be low compared to other antifungals [37]. AE in healthy
humans administered caspofungin are minimal and mostly comprise infusion reactions [36].
Liver enzyme elevations did not occur in any cats in this study and were uncommon in healthy
caspofungin-treated humans [36]. However, AE are higher in patients because of co-morbidi-
ties and altered drug metabolism. Rabbits in an IFI model had significantly slower clearance of
Fig 4. Plots of caspofungin Cmax:MEC ratio over time utilising a 1mg/kg loading dose on day 1
followed by 0.75 mg/kg daily thereafter. Red solid line indicates the median, shaded ribbons show the 95%,
90%, 75% and 50% CI’s in increasingly dark shading. Dashed black lines show the putative upper and lower
Cmax:MEC ratio limits.
https://doi.org/10.1371/journal.pone.0178783.g004
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anidulafungin associated with a higher plasma concentration of drug at the end of the dosing
interval compared to healthy individuals [38]. For human patients with IFIs treated with cas-
pofungin, hepatotoxicity and infusion reactions are most common AEs [39]. In caspofungin-
treated patients with candidemia liver enzyme elevations (ALT, AST or ALP) were the most
frequent laboratory abnormalities (13.9%) and the most common clinical AE were fever
(7.5%), chills (5.3%), nausea or vomiting (5.3%) and phlebitis (3.5%) [39]. Other reported infu-
sion reactions to echinocandins in humans, including rash, pruritus, facial swelling and ana-
phylaxis are mediated by histamine release [40].
Manifestations of acute anaphylaxis are species-dependent and directly related to the loca-
tions of the largest population of mast cells, which are the heart and lungs in humans, gastroin-
testinal tract and liver in dogs, and lungs in cats [41–48]. Thus, animal-models of disease need
to account for such species differences and the effect of caspofungin in cats with IFIs needs to
be evaluated in prospective studies.
Echinocandins have concentration-dependent activity against Aspergillus spp [49]. In this
study, at a dose of 1 mg/kg q 24 h Cmax and Cmin were well in excess of the highest MECs
reported for Aspergillus viridinutans complex species. Caspofungin had MECs of less than
0.06 μg/mL for clinical isolates of A. felis from cats with invasive aspergillosis, except for one
isolate in which the MEC was 2 μg/mL [1]. However, other cryptic species in section Fumigati
reported to cause invasive aspergillosis in humans and cats have shown decreased susceptibil-
ity to caspofungin, including some pathogenic isolates of A. lentulus which had MECs of cas-
pofungin of 4 –>32 μg/mL [32].
In a murine model of invasive pulmonary aspergillosis caspofungin dose escalation and
dose fractionation was evaluated and Cmax: MEC ratio was the parameter most strongly associ-
ated with reduced fungal burden, with an optimal value of 10–20. Mice dosed with 1 mg/kg
q24 h or 2 mg/kg q48 h had a significantly lower fungal burdens than mice dosed with 1 mg/kg
q6 h [29]. At higher doses of 4 mg/kg, correlating to a Cmax: MEC >20 there was a paradoxical
effect on fungal growth resulting in increased burdens in mice. This paradoxical effect on fun-
gal growth of A. fumigatus has also been observed in vitro for caspofungin [49], and both in
vitro and in vivo for other first and second generation echinocandins [50, 51].
Although not proven in clinical trials, the paradoxical growth effect of caspofungin at Cmax:
MEC> 20 in vivo has led to concerns about possible reduced clinical efficacy using dosing
regimens where the Cmax greatly exceeds the MEC [29]. In this study, using a dose regimen of
1 mg/kg q24 h, Cmax: MEC was > 20 in 42.6% of cats after multiple doses. Our simulated data
shows that an optimal Cmax: MEC of 10–20 is achieved using 0.75 mg/kg q 24 h or 1 mg/kg q 3
days. However, at the higher dose with a 3 day inter-dosing interval, Cmin is well below 1 μg/
mL in more than 95% of the population as the prolonged dosing interval does not allow for
drug accumulation. Using a daily dose of 0.75 mg/kg, the Cmax: MEC is below 20 and Cmin is
greater than 2.5 μg/mL for more than 95% of the population. This difference in exposure
between doses is also highlighted by the 50% reduction in the cumulative AUC above the MEC
for the 1 mg/kg q 72 h regimen compared to 0.75 mg/kg q 24 h. Although both 1 mg/kg q 72 h
and 0.75 mg/kg q 24 h provide very similar results for Cmax: MEC, the latter regimen is vastly
superior in regard to AUC> MEC. Thus, based on the modeling data, a daily dose of 0.75 mg/
kg daily is likely to best meet the proposed Cmax: MEC window, as well as provide more consis-
tent exposure between doses. Alternatively, utilising a loading dose regimen of 1mg/kg on day
1, followed by 0.75mg/kg daily will rapidly achieve steady state, as well as provide continual
exposure between dosing.
The relationship between antifungal in vivo susceptibility, dosages, drug concentrations
within various body compartments and toxicological effects are not completely understood.
Although our pharmacokinetic analyses have attempted to predict a regimen appropriate for
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safe and effective use of caspofungin using in vitro MEC values, inherent biological factors can
affect therapeutic outcome. For example, in sino-orbital aspergillosis systemic therapy may not
be sufficient to penetrate the site of infection and reduce fungal burden. In addition, our work
here is based upon total plasma concentrations, and not unbound drug, which may further
confound the results. The echinocandins are highly protein bound, and this does not appear to
vary across mammalian species investigated [14, 15, 33, 52]. The unique properties of caspo-
fungin create a challenge in determining the precise level of protein binding [14]. However,
studies have shown that caspofungin is bound to albumin in serum and that binding in mouse
and human serum is equivalent, with an unbound fraction of caspofungin of 3–4%, which is
concentration independent [14, 33]. Caspofungin has been shown to bind to albumin in
serum [14, 33]. The plasma unbound fraction of caspofungin in the cat was not determined in
this study, and although likely to be similar to that of humans and mice, based on similar albu-
min concentrations in these three species, this should be confirmed in future investigations.
The current regimen employed clinically provides total plasma concentrations consistent with
the Cmax:MEC ratio proposed in the present analyses, suggesting that our simulations are likely
to be clinically relevant. Further pharmacodynamic studies are therefore required which can
be linked with the pharmacokinetic data presented here, prior to a robust prospective clinical
study to document clinical efficacy and safety of the proposed regimens in feline patients
affected by sino-orbital aspergillosis.
Supporting information
S1 Table. Summary of caspofungin simulations.
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Summary of Caspofungin simulations
Each regimen has data provided for each dose of the 7 day regimen. This will be the 7th dose for the q 24h regimen and the 25th dose 
for the q 6h regimen.  However, for the q6h and q12h regimens only data for the last dose each day is provided. Note that for dose 
regimens, there are several infusion durations (1h, 2h and 4h).
Dose regimen Period Cmax/MIC
Dose
Dose 
Interval 
(h)
Infusion 
Duration 
(h) Time (h) Dose Number
Ratio > 10 
(%) Ratio > 20 (%)
10 > Ratio > 20 
(%)
0.25mg/kg q6 1h 1 First Dose 0 0 0
0.25mg/kg q6 1h 25 Fifth Dose 27.5 0 27.5
0.25mg/kg q6 1h 49 Ninth Dose 65.6 0 65.6
0.25mg/kg q6 1h 73 Thirteenth Dose 76.4 0 76.4
0.25mg/kg q6 1h 97 Seventeenth Dose 77.9 0 77.9
0.25mg/kg q6 1h 121 Twenty first Dose 78.5 0 78.5
0.25mg/kg q6 1h 145 Twenty fifth Dose 78.7 0 78.7
0.5mg/kg q12 1h 1 First Dose 2.40 0 2.40
0.5mg/kg q12 1h 25 Third Dose 88.6 0 88.6
0.5mg/kg q12 1h 49 Fifth Dose 95.5 0.600 94.9
0.5mg/kg q12 1h 73 Seventh Dose 97.5 2.00 95.5
0.5mg/kg q12 1h 97 Ninth Dose 97.7 2.60 95.1
0.5mg/kg q12 1h 121 Eleventh Dose 97.7 2.70 95.0
0.5mg/kg q12 1h 145 Thirteenth Dose 97.7 2.70 95.0
0.5mg/kg q24 1h 1 First Dose 2.10 0 2.10
0.5mg/kg q24 1h 25 Second Dose 25.2 0 25.2
0.5mg/kg q24 1h 49 Third Dose 44.3 0 44.3
0.5mg/kg q24 1h 73 Fourth Dose 44.3 0 44.3
0.5mg/kg q24 1h 97 Fifth Dose 44.3 0 44.3
0.5mg/kg q24 1h 121 Sixth Dose 44.3 0 44.3
0.5mg/kg q24 1h 145 Seventh Dose 44.3 0 44.3
0.5mg/kg q6 1h 1 First Dose 2.20 0 2.20
0.5mg/kg q6 1h 25 Fifth Dose 100 27.8 72.2
0.5mg/kg q6 1h 49 Ninth Dose 100 68.6 31.4
0.5mg/kg q6 1h 73 Thirteenth Dose 100 76.7 23.3
0.5mg/kg q6 1h 97 Seventeenth Dose 100 78.8 21.2
0.5mg/kg q6 1h 121 Twenty first Dose 100 79.5 20.5
0.5mg/kg q6 1h 145 Twenty fifth Dose 100 79.8 20.2
0.75mg/kg q24 1h 1 First Dose 70.9 0 70.9
0.75mg/kg q24 1h 25 Second Dose 97.4 0.300 97.1
0.75mg/kg q24 1h 49 Third Dose 98.4 1.60 96.8
0.75mg/kg q24 1h 73 Fourth Dose 98.4 1.60 96.8
0.75mg/kg q24 1h 97 Fifth Dose 98.5 1.70 96.8
0.75mg/kg q24 1h 121 Sixth Dose 98.5 1.80 96.7
0.75mg/kg q24 1h 145 Seventh Dose 98.5 1.90 96.6
0.75mg/kg q48 1h 1 First Dose 72.8 0 72.8
0.75mg/kg q48 1h 49 Second Dose 86.0 0 86.0
0.75mg/kg q48 1h 97 Third Dose 87.1 0 87.1
0.75mg/kg q48 1h 145 Third Dose 88.3 0 88.3
0.75mg/kg q72 1h 1 First Dose 72.6 0 72.6
0.75mg/kg q72 1h 73 Second Dose 79.0 0 79.0
0.75mg/kg q72 1h 145 Third Dose 80.9 0 80.9
1mg/kg q24 1h 1 First Dose 99.3 0.700 98.6
1mg/kg q24 1h 25 Second Dose 100 24.3 75.7
1mg/kg q24 1h 49 Third Dose 100 32.5 67.5
1mg/kg q24 1h 73 Fourth Dose 100 39.7 60.3
1mg/kg q24 1h 97 Fifth Dose 100 41.5 58.5
1mg/kg q24 1h 121 Sixth Dose 100 42.1 57.9
1mg/kg q24 1h 145 Seventh Dose 100 42.6 57.4
1mg/kg q24 2h 1 First Dose 1.60 0 1.60
1mg/kg q24 2h 25 Second Dose 96.1 0 96.1
1mg/kg q24 2h 49 Third Dose 99.8 6.50 93.3
1mg/kg q24 2h 73 Fourth Dose 100 14.6 85.4
1mg/kg q24 2h 97 Fifth Dose 100 17.7 82.3
1mg/kg q24 2h 121 Sixth Dose 100 19.3 80.7
1mg/kg q24 2h 145 Seventh Dose 100 20.0 80.0
1mg/kg q24 4h 1 First Dose 0 0 0
1mg/kg q24 4h 25 Second Dose 80.4 0 80.4
1mg/kg q24 4h 49 Third Dose 99.3 0.700 98.6
1mg/kg q24 4h 73 Fourth Dose 99.5 2.70 96.8
1mg/kg q24 4h 97 Fifth Dose 99.5 3.80 95.7
1mg/kg q24 4h 121 Sixth Dose 99.5 4.60 94.9
1mg/kg q24 4h 145 Seventh Dose 99.5 5.40 94.1
1mg/kg q48 1h 1 First Dose 99.8 2.10 97.7
1mg/kg q48 1h 49 Second Dose 99.9 5.70 94.2
1mg/kg q48 1h 97 Third Dose 99.9 5.70 94.2
1mg/kg q48 1h 145 Third Dose 99.9 5.80 94.1
1mg/kg q48 2h 1 First Dose 0.900 0 0.900
1mg/kg q48 2h 49 Second Dose 96.1 0 96.1
1mg/kg q48 2h 97 Third Dose 97.8 0.200 97.6
1mg/kg q48 2h 145 Third Dose 98.2 0.300 97.9
1mg/kg q48 4h 1 First Dose 0 0 0
1mg/kg q48 4h 49 Second Dose 79.2 0 79.2
1mg/kg q48 4h 97 Third Dose 90.1 0 90.1
1mg/kg q48 4h 145 Third Dose 91.4 0 91.4
1mg/kg q72 1h 1 First Dose 99.1 1.70 97.4
1mg/kg q72 1h 73 Second Dose 99.2 2.80 96.4
1mg/kg q72 1h 145 Third Dose 99.2 3.80 95.4
1mg/kg q72 2h 1 First Dose 2.20 0 2.20
1mg/kg q72 2h 73 Second Dose 96.4 0 96.4
1mg/kg q72 2h 145 Third Dose 97.2 0.300 96.9
1mg/kg q72 4h 1 First Dose 0 0 0
1mg/kg q72 4h 73 Second Dose 80.8 0 80.8
1mg/kg q72 4h 145 Third Dose 84.0 0 84.0
2mg/kg q48 1h 1 First Dose 100 99.6 0.400
2mg/kg q48 1h 49 Second Dose 100 99.7 0.300
2mg/kg q48 1h 97 Third Dose 100 99.7 0.300
2mg/kg q48 1h 145 Third Dose 100 99.7 0.300
2mg/kg q48 2h 1 First Dose 100 1.50 98.5
2mg/kg q48 2h 49 Second Dose 100 96.6 3.40
2mg/kg q48 2h 97 Third Dose 100 99.4 0.600
2mg/kg q48 2h 145 Third Dose 100 99.4 0.600
2mg/kg q48 4h 1 First Dose 2.20 0 2.20
2mg/kg q48 4h 49 Second Dose 100 76.7 23.3
2mg/kg q48 4h 97 Third Dose 100 90.1 9.90
2mg/kg q48 4h 145 Third Dose 100 91.0 9.00
2mg/kg q72 1h 1 First Dose 100 98.9 1.10
2mg/kg q72 1h 73 Second Dose 100 99.4 0.600
2mg/kg q72 1h 145 Third Dose 100 99.4 0.600
2mg/kg q72 2h 1 First Dose 99.0 1.00 98.0
2mg/kg q72 2h 73 Second Dose 100 94.7 5.30
2mg/kg q72 2h 145 Third Dose 100 95.9 4.10
2mg/kg q72 4h 1 First Dose 1.80 0 1.80
2mg/kg q72 4h 73 Second Dose 100 78.1 21.9
2mg/kg q72 4h 145 Third Dose 100 82.2 17.8
 102 
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S-WPC-MK0991-IV-102016 1 
PRODUCT INFORMATION 
 
 
CANCIDAS ® 
(caspofungin acetate) 
 
 
DESCRIPTION 
 
CANCIDAS® is a sterile, lyophilised product for intravenous infusion that contains a 
semisynthetic lipopeptide (echinocandin) compound synthesised from a fermentation 
product of Glarea lozoyensis.  CANCIDAS is the first of a new class of antifungal 
drugs (echinocandins) that inhibit the synthesis of  (1,3)-D-glucan, an integral 
component of the fungal cell wall. 
 
CANCIDAS (caspofungin acetate) is 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-
dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-
ornithine]pneumocandin B0 diacetate (salt).  In addition to the active ingredient 
caspofungin acetate, CANCIDAS contains the following inactive ingredients: sucrose, 
mannitol, acetic acid, glacial, and sodium hydroxide.  Caspofungin acetate is a 
hygroscopic, white to off-white powder.  It is freely soluble in water and methanol, 
and slightly soluble in ethanol.  The pH of a saturated aqueous solution of 
caspofungin acetate is approximately 6.6.  The empirical formula is 
C52H88N10O15•2C2H4O2 and the formula weight is 1213.42.  The CAS No is 179463-
17-3.  The structural formula is: 
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PHARMACOLOGY 
 
Mechanism of Action 
Caspofungin acetate, the active ingredient of CANCIDAS, inhibits the synthesis of  
 (1,3)-D-glucan, an essential component of the cell wall of many filamentous fungi 
and yeast.   (1,3)-D-glucan is not present in mammalian cells. 
 
Microbiology 
Activity in vitro 
Caspofungin has in vitro activity against: 
Aspergillus species (including Aspergillus fumigatus, Aspergillus flavus, Aspergillus 
niger, Aspergillus nidulans, Aspergillus terreus and Aspergillus candidus)  
Candida species (including Candida albicans, Candida dublinensis, Candida 
glabrata, Candida guilliermondii, Candida kefyr, Candida krusei, Candida lipolytica, 
Candida lusitaniae, Candida parapsilosis, Candida rugosa, and Candida tropicalis).  
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Susceptibility testing was performed according to a modification of both the Clinical 
and Laboratory Standards Institute (CLSI, formerly known as the National Committee 
for Clinical Laboratory Standards (NCCLS) method M38-A2 (for Aspergillus species) 
and method M27-A3 (for Candida species).   
 
Interpretive standards (or breakpoints) for caspofungin against Candida species are 
applicable only to tests performed using CLSI microbroth dilution reference method 
M27-A3 for minimum inhibitory concentrations (MIC) read as a partial inhibition 
endpoint at 24 hours. The MIC values for caspofungin using CLSI microbroth dilution 
reference method M27-A3 should be interpreted according to the criteria provided in 
Table 1 below (CLSI M27-S3). 
TABLE 1 
Susceptibility Interpretive Criteria for Caspofungin against Candida species 
 
 
Pathogen 
Broth Microdilution MIC*, † (g/mL) at 24  
hours 
 Susceptible Indeterminate Resistant Non-susceptible 
Candida species 2 - - ≥2 
* A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound 
in the blood reaches the concentrations usually achievable. 
† There is no Resistant category assigned for the echinocandin agents; isolates with higher MICs may be 
described as Non-susceptible.  
 
There are no established breakpoints for caspofungin against Candida species using 
the European Committee for Antimicrobial Susceptibility Testing (EUCAST) method. 
 
Standardised techniques for susceptibility testing have been established for yeasts 
by EUCAST. No standardised techniques for susceptibility testing or interpretive 
breakpoints have been established for Aspergillus species and other filamentous 
fungi using either the CLSI or EUCAST method. 
 
Activity in vivo 
Caspofungin was active when parenterally administered to immune-competent and 
immune-suppressed animals with disseminated infections of Aspergillus and Candida 
for which the endpoints were prolonged survival of infected animals (Aspergillus and 
Candida) and clearance of fungi from target organs (Candida).  Caspofungin was 
also active in immunodeficient animals after disseminated infection with C. glabrata, 
C. krusei, C. lusitaniae, C. parapsilosis, or C. tropicalis in which the endpoint was 
clearance of Candida from target organs.  Caspofungin has been reported to be 
active in the prevention and treatment of pulmonary aspergillosis in a rat model.  
 
Cross-resistance 
Caspofungin acetate is active against strains of Candida with intrinsic or acquired 
resistance to fluconazole, amphotericin B, or flucytosine consistent with their different 
mechanisms of action.  
 
Drug Resistance 
A caspofungin MIC of 2 g/mL (“Susceptible” per Table 1) using the CLSI M27-A3 
method indicates that the Candida isolate is likely to be inhibited if caspofungin 
therapeutic concentrations are achieved. Breakthrough infections with Candida 
isolates requiring caspofungin concentrations 2 g/mL for growth inhibition have 
developed in a mouse model of C. albicans infection. Isolates of Candida with 
reduced susceptibility to caspofungin have been identified in a small number of 
patients during treatment (MICs for caspofungin >2 g/mL using standardised MIC 
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testing techniques approved by the CLSI). Some of these isolates had mutations in 
the FKS1/FKS2 gene. Although the incidence is rare, these cases have been 
routinely associated with poor clinical outcomes. 
 
Development of in vitro resistance to caspofungin by Aspergillus species has been 
identified. In clinical experience, drug resistance in patients with invasive 
aspergillosis has been observed. The mechanism of resistance has not been 
established.   
 
The incidence of drug resistance in various clinical isolates of Candida and 
Aspergillus species is rare. 
 
 
Pharmacokinetics 
 
Absorption 
Absorption is not relevant since caspofungin acetate is administered intravenously. 
 
Distribution 
Plasma concentrations of caspofungin decline in a polyphasic manner following 
single 1-hour IV infusions.  A short -phase occurs immediately post-infusion, 
followed by a -phase (half-life of 9 to 11 hours) that characterises much of the 
profile and exhibits clear log-linear behaviour from 6 to 48 hours post-dose (during 
which the plasma concentration decreases by an order of magnitude).  An additional, 
longer half-life (-) phase, also occurs with a half-life of 40-50 hours.  
 
Distribution, rather than excretion or biotransformation, is the dominant mechanism 
influencing plasma clearance.  Caspofungin is extensively bound to albumin (~97%), 
and distribution into red blood cells is minimal.  Mass balance results showed that 
approximately 92% of the [3H] label was found in tissues 36 to 48 hours after a single 
70 mg dose of [3H] caspofungin acetate.  There is little excretion or biotransformation 
of caspofungin during the first 30 hours after administration. 
 
Metabolism 
Caspofungin is slowly metabolised by hydrolysis and N-acetylation.  Caspofungin 
also undergoes spontaneous chemical degradation to an open-ring peptide 
compound, L-747969.  At later time points (5 days post-dose), there is a low level ( 
7 picomoles/mg protein, or  1.3% of administered dose) of covalent binding of 
radiolabel in plasma, following single-dose administration of [3H] caspofungin acetate.  
This may be due to two reactive intermediates formed during the chemical 
degradation of caspofungin to L-747969.  Additional metabolism involves hydrolysis 
into constitutive amino acids and their degradates, including dihydroxyhomotyrosine 
and N-acetyl-dihydroxyhomotyrosine.  These two tyrosine derivatives are found only 
in urine, suggesting rapid clearance of these derivatives by the kidneys. 
 
Excretion 
Two single-dose radiolabelled pharmacokinetic studies were conducted.  In one 
study, plasma, urine, and faeces were collected over 27 days, and in the second 
study, plasma was collected over six months.  Approximately 75% of the radioactivity 
was recovered: 41% in urine and 34% in faeces.  Plasma concentrations of 
radioactivity and of caspofungin were similar during the first 24 to 48 hours post-
dose; thereafter drug levels fell more rapidly.  In plasma, caspofungin concentrations 
fell below the limit of quantitation after 6 to 8 days post-dose, while radio-label fell 
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below the limit of quantitation at 22.3 weeks post-dose.  A small amount of 
caspofungin is excreted unchanged in urine (~1.4% of dose).  Renal clearance of 
parent drug is low (~0.15 mL/min). 
 
Special Populations 
Gender 
The plasma concentration of caspofungin was similar in healthy men and women on 
Day 1 following a single 70 mg dose.  After 13 daily 50 mg doses, the area under the 
curve (AUC) for caspofungin was elevated slightly (approximately 20%) in women 
relative to men.  No dosage adjustment is necessary based on gender. 
 
Geriatric 
Plasma concentrations of caspofungin in healthy older men and women (65 years of 
age) were increased slightly (approximately 28% in area under the curve [AUC]) 
compared to young healthy men.  In patients who were treated empirically or who 
had invasive candidiasis, a similar modest effect of age was seen in older patients 
relative to younger patients.  No dosage adjustment is necessary for the elderly.  
 
Race 
No clinically significant differences in the pharmacokinetics of caspofungin were seen 
among Caucasians, Blacks, Hispanics, and persons of mixed race.  No dosage 
adjustment is necessary on the basis of race. 
 
Renal Insufficiency 
In a clinical study of single 70 mg doses, caspofungin pharmacokinetics were similar 
in volunteers with mild renal insufficiency (creatinine clearance 50 to 80 mL/min) and 
control subjects.  Moderate (creatinine clearance 31 to 49 mL/min), advanced 
(creatinine clearance 5 to 30 mL/min), and end-stage (creatinine clearance <10 
mL/min and dialysis dependent) renal insufficiency moderately increased 
caspofungin plasma concentrations after single-dose administration (range: 30 to 
49% for AUC).  However, in patients with invasive aspergillosis who received multiple 
daily doses of CANCIDAS 50 mg, there was no significant effect of mild to advanced 
renal impairment on caspofungin trough concentrations.  No dosage adjustment is 
necessary for patients with renal insufficiency.  Caspofungin is not dialysable, thus 
supplementary dosing is not required following haemodialysis. 
 
Hepatic Insufficiency 
Plasma concentrations of caspofungin after a single 70 mg dose in patients with mild 
hepatic insufficiency (Child-Pugh score 5 to 6) were increased by approximately 55% 
in AUC compared to healthy control subjects.  In a 14-day multiple-dose study (70 
mg on Day 1 followed by 50 mg daily thereafter), plasma concentrations in patients 
with mild hepatic insufficiency were increased modestly (21 to 26% in AUC) on Days 
7 and 14 relative to healthy control subjects.  No dosage adjustment is recommended 
for patients with mild hepatic insufficiency.  Patients with moderate hepatic 
insufficiency (Child-Pugh score 7 to 9) who received a single 70 mg dose of 
CANCIDAS had an average plasma caspofungin increase of 76% compared to 
control subjects.   
 
A dosage reduction is recommended for patients with moderate hepatic insufficiency 
(see DOSAGE AND ADMINISTRATION).  There is no clinical experience in patients 
with severe hepatic insufficiency (Child-Pugh score >9). 
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Paediatric Patients 
CANCIDAS has been studied in five prospective studies involving paediatric patients 
under 18 years of age, including three paediatric pharmacokinetic studies (initial 
study in adolescents [12-17 years of age]  and children [2-11 years of age] followed 
by a study in younger patients [3-23 months of age] and then followed by a study in 
neonates and infants [<3 months]).  
 
 In adolescents (ages 12 to 17 years) receiving caspofungin at 50 mg/m2 daily 
(maximum 70 mg daily), the caspofungin plasma AUC0-24hr was generally 
comparable to that seen in adults receiving caspofungin at 50 mg daily. All 
adolescents received doses >50 mg daily, and, in fact, 6 of 8 received the 
maximum dose of 70 mg/day. The caspofungin plasma concentrations in these 
adolescents were reduced relative to adults receiving 70 mg daily, the dose most 
often administered to adolescents.   
 In children (ages 2 to 11 years) receiving caspofungin at 50 mg/m2 daily 
(maximum 70 mg daily), the caspofungin plasma AUC0-24hr after multiple doses 
was comparable to that seen in adults receiving caspofungin at 50 mg/day. On the 
first day of administration, AUC0-24hr was somewhat higher in children than adults 
for these comparisons (37% increase for the 50 mg/m2/day to 50 mg/day 
comparison).   
 In young children and toddlers (ages 3 to 23 months) receiving caspofungin at 50 
mg/m2 daily (maximum 70 mg daily), the caspofungin plasma AUC0-24hr after 
multiple doses was comparable to that seen in adults receiving caspofungin at 50 
mg daily. As in the older children, these young children who received 50 mg/m2 
daily had slightly higher AUC0-24 hr values on Day 1 relative to adults receiving the 
standard 50-mg daily dose. The caspofungin pharmacokinetic results from the 
young children (3 to 23 months of age) that received 50 mg/m2 caspofungin daily 
were similar to the pharmacokinetic results from older children (2 to 11 years of 
age) that received the same dosing regimen.  
 In neonates and infants (<3 months) receiving caspofungin at 25 mg/m2 daily, 
caspofungin peak concentration (C1 hr) and caspofungin trough concentration (C24 
hr) after multiple doses were comparable to that seen in adults receiving 
caspofungin at 50 mg daily. On Day 1, C1 hr was comparable and C24 hr modestly 
elevated (36%) in these neonates and infants relative to adults. AUC0-24hr 
measurements were not performed in this study due to the sparse plasma 
sampling. Of note, the efficacy and safety of CANCIDAS has not been adequately 
studied in prospective clinical trials involving neonates and infants under 3 months 
of age. 
 
Based on population pharmacokinetic analyses including data from the 2 efficacy 
studies in paediatric population and in comparison with healthy adults and adult 
patients, the caspofungin C1 hr was significantly increased (50 – 163%) in paediatric 
patients of all age groups, whereas C24 hr was significantly increased (25-109%) in 
older children (2 – 11 years) and adolescents (12 – 17 years), but was similar to 
adults in young children (3 – 24 months). The estimated increase in AUC0-24 hr was 
38 – 41% in paediatric patients of all age groups compared with adult patients. 
 
Overall, the available pharmacokinetic, efficacy, and safety data are limited in 
patients 3 to 10 months of age. Pharmacokinetic data from one 10-month old child 
receiving the 50 mg/m2 daily dose indicated an AUC0-24hr within the same range as 
that observed in older children and adults at the 50 mg/m2 and the 50 mg dose, 
respectively, while in one 6-month old child receiving the 50 mg/m2 dose, the AUC0-
24hr was somewhat higher. 
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Clinical Trials 
 
The results of the adult clinical studies are presented by each indication below, 
followed thereafter by the results of paediatric clinical trials. 
 
Empirical Therapy in febrile, neutropenic patients 
A multicentre, double-blind study enrolled 1111 febrile, neutropenic, adult patients 
(mean age 48 years, range 16-83; 56% male) who were randomised to treatment 
with daily doses of CANCIDAS (50 mg/day following a 70 mg loading dose on Day 1) 
or AmBisome®
1
 (liposomal amphotericin for injection, 3.0 mg/kg/day).  Eligible 
patients had received chemotherapy for malignancy or had undergone 
haematopoietic stem-cell transplantation (HSCT), and presented with neutropenia 
(<500 cells/mm3 for 96 hours) and fever (>38.0°C) that had not responded to 
antibacterial therapy.  Any patient known to have a documented fungal infection was 
excluded from entering the study.  Patients were to be treated until resolution of 
neutropenia, with a maximum treatment duration of 28 days.  However, patients 
found to have a documented fungal infection could be treated longer.  If the drug was 
well tolerated but the patient’s fever persisted and clinical condition deteriorated 
following 5 days of therapy, the dosage of study drug could be increased to 70 
mg/day for CANCIDAS (13.3% of patients treated) or to 5.0 mg/kg/day for AmBisome 
(14.3% of patients treated). 
 
Patients were stratified based on risk category [high-risk patients had undergone 
allogeneic HSCT (7.0% total) or had relapsed acute leukaemia (17.7% total)] and on 
receipt of prior antifungal prophylaxis.  The percentage of patients in the high-risk 
stratum at entry was 26.6% for the CANCIDAS group and 22.9% for the AmBisome 
group.  In both groups a similar percentage of patients had received antifungal 
prophylaxis.  The most frequent diagnoses were acute myelogenous leukaemia, 
acute lymphocytic leukaemia, and non-Hodgkin’s lymphoma. 
 
Patients who met the entry criteria and received at least one dose of study therapy 
were included in the modified intention-to-treat (MITT) population (556 treated with 
CANCIDAS and 539 treated with AmBisome).  The mean duration of study therapy 
was 13 days.  An overall favourable response required meeting each of 5 criteria: 1) 
successful treatment of any baseline fungal infection, 2) no breakthrough fungal 
infections during administration of study drug or within 7 days after completion of 
treatment, 3) survival for 7 days after completion of study therapy, 4) no 
discontinuation of the study drug because of drug-related toxicity or lack of efficacy, 
and 5) resolution of fever during the period of neutropenia. 
 
An independent expert panel adjudicated blinded data from all patients identified as 
having a suspected invasive fungal infection.  The panel assessed the presence of 
invasive fungal infection, timing of onset (baseline or breakthrough), causative 
pathogen, and, for baseline infections, response to study treatment.  The only fungal 
infections considered to be present for purposes of statistical analysis were those 
classified by the expert panel as either probable or proven.  Approximately 5% of 
patients were found to have baseline fungal infections, of which the majority were 
due to Aspergillus or Candida species. 
 
The proportion of MITT patients with an overall favourable response and the 
proportion of MITT patients with favourable responses to the individual criteria are 
shown in Table 2. 
                                                          
1 Registered trademark of Gilead Sciences, Inc. 
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Table 2 
Favourable Response of Patients with Persistent Fever and Neutropenia 
  
CANCIDAS* 
 
AmBisome* 
% Difference 
(Confidence 
Interval) ** 
Number of Patients (Modified Intention-
To-Treat) 
556 539  
Overall Favourable Response  190 (33.9%) 181 (33.7%) 0.2 (-5.6, 6.0) 
1. Successful treatment of any baseline 
fungal infection 
14/27 
(51.9%) 
7/27 
(25.9%) 
25.9 (0.9, 51.0)† 
2. No breakthrough fungal infection 527 (94.8%) 515 (95.5%) -0.8 (-3.3, 1.8) 
3. Survival 7 days after end of treatment 515 (92.6%) 481 (89.2%) 3.4 (0.0, 6.8) 
4. No discontinuation due to toxicity or 
lack of efficacy 
499 (89.7%) 461 (85.5%) 4.2 (0.3, 8.1)† 
5. Resolution of fever during neutropenia 229 (41.2%) 223 (41.4%) -0.2 (-6.0, 5.6) 
* CANCIDAS: 70 mg on Day 1, then 50 mg daily for the remainder of treatment (daily dose 
increased to 70 mg for 73 patients);  
 AmBisome: 3.0 mg/kg/day (daily dose increased to 5.0 mg/kg for 74 patients). 
** Overall Response (primary efficacy endpoint): estimated % difference adjusted for strata and 
expressed as CANCIDAS – AmBisome (95.2% CI);, based on all 5 criteria  
 Individual Criteria: % difference calculated as CANCIDAS – AmBisome (95% CI).  
† Statistically significant difference. 
 
 
Based on overall favourable response rates, CANCIDAS was as effective as 
AmBisome in empirical therapy of persistent febrile neutropenia.  CANCIDAS had 
significantly higher favourable response rates than AmBisome for the following 
criteria: successful treatment of any baseline fungal infection (CANCIDAS 51.9%, 
AmBisome 25.9%) and absence of premature discontinuation from study therapy due 
to toxicity or lack of efficacy (CANCIDAS 89.7%, AmBisome 85.5%).  CANCIDAS 
was comparable to AmBisome for the other criteria (absence of a breakthrough 
fungal infection, survival for 7 days after the end of treatment, and resolution of fever 
during neutropenia).  
 
Overall favourable response rates were comparable in high-risk patients (CANCIDAS 
43.2%, AmBisome 37.7%) and low-risk patients (CANCIDAS 31.0%, AmBisome 
32.4%).  Rates were also comparable in patients who had received prior antifungal 
prophylaxis (CANCIDAS 33.5%, AmBisome 32.9%) and those who had not 
(CANCIDAS 35.0%, AmBisome 34.5%). 
 
The majority of baseline infections were due to Aspergillus or Candida species. 
Response rates to CANCIDAS and AmBisome for baseline infections caused by 
Aspergillus species were, respectively, 41.7% (5/12) and 8.3% (1/12), and by 
Candida species were 66.7% (8/12) and 41.7% (5/12). 
 
Invasive Candidiasis 
In an initial Phase III randomised, double-blind study, patients with a proven 
diagnosis of invasive candidiasis received daily doses of CANCIDAS (50 mg/day 
following a 70-mg loading dose on Day 1) or amphotericin B deoxycholate (0.6 to 0.7 
mg/kg/day for non-neutropenic patients and 0.7 to 1.0 mg/kg/day for neutropenic 
patients).  Patients were stratified by both neutropenic status and APACHE II score.  
Patients who met the entry criteria and received one or more doses of IV study 
therapy were included in the primary (modified intention-to-treat [MITT]) analysis of 
response at the end of IV study therapy.  A predefined analysis to support the MITT, 
the evaluable-patients assessment, included patients who met entry criteria, received 
IV study therapy for 5 or more days and had a full efficacy evaluation at the end of IV 
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study therapy.  A favourable response required both symptom resolution and 
microbiological clearance of the Candida infection. 
 
Of the 239 patients enrolled, 224 (109 treated with CANCIDAS and 115 treated with 
amphotericin B) met the criteria for inclusion in the MITT analysis.  Of these patients, 
185 (88 treated with CANCIDAS and 97 treated with amphotericin B) met the criteria 
for inclusion in the evaluable-patients analysis.  The most frequent diagnoses were 
bloodstream infections (candidaemia) (83%) and Candida peritonitis (10%), patients 
with Candida endocarditis, osteomyelitis or meningitis were excluded from this study.  
Most infections were caused by C. albicans (45%), followed by C. parapsilosis (19%), 
C. tropicalis (16%), C. glabrata (11%), and C. krusei (2%). The favourable response 
rates at the end of IV study therapy are shown in Table 3. 
 
Table 3 
Favourable Response Rates to IV Study Therapy 
Among Patients with Invasive Candidiasis (and Candidaemia) 
 
 CANCIDAS 50 mg* 
% (n/m**) 
[95% CI] 
Amphotericin B 
% (n/m) 
[95% CI] 
Difference (%) after 
Adjusting for strata 
[95.6% CI] 
ALL PATIENTS WITH INVASIVE CANDIDIASIS 
 
  
MITT analysis  73.4% (80/109) 
[65.1, 81.7] 
 
61.7% (71/115) 
[52.8, 70.7] 
12.7% 
[-0.7, 26.0] 
Neutropenic patients 
(ANC  500L)  
 
50% (7/14) 
 
 
40% (4/10) 
 
 
 
APACHE II scores 
>20 at study entry 
 
57.1% (12/21) 
 
 
43.5% (10/23) 
 
 
 
Evaluable-patients analysis  
 
80.7% (71/88) 
[72.4, 89.0] 
 
64.9% (63/97) 
[55.4, 74.5] 
 
15.4% 
[1.1, 29.7] 
 
 
PATIENTS WITH CANDIDAEMIA 
 
  
MITT analysis  
 
71.7% (66/92) 
[62.5, 81.0] 
 
62.8% (59/94) 
[52.9, 72.6] 
 
10.0% 
[-4.5, 24.5] 
 
Evaluable-patients analysis 80.3% (57/71) 
[71.0, 89.6] 
 
64.6% (51/79) 
[53.9, 75.2] 
15.2% 
[-0.6, 31.0] 
* Patients received CANCIDAS 70 mg on Day 1, then 50 mg daily for the remainder of their treatment. 
** Number of patients with favourable response at the end of IV study therapy/number of patients included in analysis 
 
Response rates were also consistent across all identified Candida species.  For all 
other efficacy time points (Day 10 of IV study therapy, end of all antifungal therapy, 2-
week post-therapy follow-up, and 6- to 8-week post-therapy follow-up), CANCIDAS 
was as effective as amphotericin B.  CANCIDAS was also comparable to 
amphotericin B with regard to relapse or survival rates, with an overall mortality 
among MITT patients during the study treatment period and 6 to 8-week follow-up 
period of 33.0% in the CANCIDAS group and 30.4% in the amphotericin B group. 
CANCIDAS was comparable to amphotericin B in the treatment of invasive 
candidiasis at the end of IV study therapy in the primary (MITT) efficacy analysis.  In a 
predefined efficacy analysis of evaluable patients to support the MITT, CANCIDAS 
was statistically superior to amphotericin B at the end of IV study therapy. 
 
S-WPC-MK0991-IV-102016 9 
Of the 224 patients from the invasive candidiasis study who met the criteria for 
inclusion in the MITT analysis, 186 patients (92 treated with CANCIDAS and 94 
treated with amphotericin B) had candidaemia.  Of these patients, 150 (71 treated 
with CANCIDAS and 79 treated with amphotericin B) met the criteria for inclusion in 
the evaluable-patients analysis.  The favourable response rates at the end of IV 
study therapy for patients with candidaemia are shown in Table 3. 
In both the MITT and evaluable-patients efficacy analyses, CANCIDAS was 
comparable to amphotericin B in the treatment of candidaemia at the end of IV study 
therapy. 
 
In a second Phase III randomised, double-blind study, patients with a proven 
diagnosis of invasive candidiasis received daily doses of CANCIDAS 50 mg/day 
(following a 70-mg loading dose on Day 1) or CANCIDAS 150 mg/day. The 
diagnostic criteria, efficacy time points, and efficacy endpoints used in this study 
were similar to those employed in the prior study. Efficacy was a secondary endpoint 
in this study. Patients who met the entry criteria and received one or more doses of 
caspofungin study therapy were included in the efficacy analysis. The favorable 
overall response rates at the end of CANCIDAS therapy were similar in the 2 
treatment groups: 72% (73/102) and 78% (74/95) for the CANCIDAS 50-mg and 150-
mg treatment groups, respectively (difference 6.3% [95% CI -5.9, 18.4]). 
 
Oesophageal Candidiasis 
A total of 393 patients with oesophageal candidiasis were enrolled in three 
comparative studies to evaluate the efficacy of CANCIDAS for the treatment of 
oesophageal candidiasis.  Patients were required to have symptoms and 
microbiological documentation of oesophageal candidiasis; and most patients were 
significantly immunocompromised.  Disease severity was determined by 
oesophagoscopy (endoscopy).  
 
In the randomised, double-blind study comparing CANCIDAS 50 mg/day (n=83) 
versus IV fluconazole 200 mg/day (n=94) for the treatment of oesophageal 
candidiasis, patients were treated for 7 to 21 days.  A favourable overall response 
required both complete resolution of symptoms and significant endoscopic 
improvement 5 to 7 days following discontinuation of study therapy.  The definition of 
endoscopic response was based on severity of disease at baseline using a 4 grade 
scale and required at least a two grade reduction from baseline endoscopic score or 
reduction to grade 0 for patients with a baseline score of 2 or less.  The proportion of 
patients with a favourable response to CANCIDAS was comparable to that seen with 
fluconazole, as demonstrated in Table 4. 
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Table 4 
Oesophageal Candidiasis study: CANCIDAS v fluconazole 
Proportion of patients with a favourable response 
    
 CANCIDAS 50 mg 
n/m (%) 
[95% Confidence Interval] 
Fluconazole 200 mg 
n/m (%) 
[95% Confidence Interval] 
Observed Difference 
(%) 
[95% Confidence 
Interval] 
Favourable Overall 
Combined Response 
(Symptoms and 
Endoscopy 
66/81 (81.5) 
[71.3, 89.2] 
80/94 (85.1) 
[76.3, 91.6] 
-3.6 
[-14.7, 7.5] 
    
Symptom Response 73/81 (90.1) 
[81.5, 95.6] 
84/94 (89.4) 
[81.3, 94.8] 
0.8 
[-8.2, 9.8] 
    
Endoscopy Response 69/81 (85.2) 
[75.6, 92.1] 
81/94 (86.2) 
[77.5, 92.4] 
-1.0 
[-11.4, 9.4] 
    
*n/m=number of patients with a favourable assessment/patients with data at 5 to 7 day follow-up visit 
 
In addition, two double-blind, comparative dose-ranging studies evaluated 3 different 
doses of CANCIDAS (35, 50, 70 mg/day) and amphotericin B (0.5 mg/kg/day).  
These clinical studies support the use of CANCIDAS 50 mg daily in the treatment of 
oesophageal candidiasis.  Increasing doses of CANCIDAS above 50 mg daily 
provided no additional benefit in the treatment of oesophageal candidiasis. 
 
Invasive Aspergillosis 
Sixty nine patients between the ages of 18 and 80 with invasive aspergillosis were 
enrolled in an open-label, non-comparative study to evaluate the safety, tolerability, 
and efficacy of CANCIDAS.  Enrolled patients had previously been refractory to or 
intolerant of other antifungal therapy.  Refractory patients were classified as those 
who had disease progression or failed to improve despite therapy for at least 7 days 
with amphotericin B, lipid formulations of amphotericin B, itraconazole, or an 
investigational azole (voriconazole) with reported activity against Aspergillus.  
Intolerance to previous therapy was defined as a doubling of creatinine (or creatinine 
> 2.5 mg/dL while on therapy), other acute reactions, or infusion-related toxicity.  
 
To be included in the study, patients with pulmonary disease must have had definite 
(positive tissue histopathology or positive culture from tissue obtained by an invasive 
procedure) or probable (positive radiographic or computed tomographic evidence 
with supporting culture from bronchoalveolar lavage or sputum, galactomannan 
enzyme-linked immunosorbent assay, and/or polymerase chain reaction) invasive 
aspergillosis.   
 
Patients with extrapulmonary disease had to have definite invasive aspergillosis.  
The definitions were modelled after the Mycoses Study Group Criteria.  Patients were 
administered a single 70 mg loading dose of CANCIDAS and subsequently dosed 
with 50 mg daily.  The mean duration of therapy was 33.7 days, with a range of 1 to 
162 days.  
 
An independent expert panel evaluated patient data, including diagnosis of invasive 
aspergillosis, response and tolerability to previous antifungal therapy, treatment 
course on CANCIDAS, and clinical outcome.  
 
A favourable response was defined as either complete resolution (complete 
response) or clinically meaningful improvement (partial response) of all signs and 
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symptoms and attributable radiographic findings.  Stable, nonprogressive disease 
was considered to be an unfavourable response. 
 
Among the 69 patients enrolled in the study, 63 met entry diagnostic criteria and had 
outcome data; and of these, 52 patients received treatment for >7 days.  Fifty-three 
(84%) were refractory to previous antifungal therapy and 10 (16%) were intolerant. 
Forty five patients had pulmonary disease and 18 had extrapulmonary disease. 
Underlying conditions were haematologic malignancy (N=24), allogeneic bone 
marrow transplant or stem cell transplant (N=18), organ transplant (N=8), solid 
tumour (N=3), or other conditions (N=10).  Fourteen patients were neutropenic (ANC 
< 500/L) at baseline; two of these patients had a favourable response to 
caspofungin therapy and evidence of their clinical response was seen prior to 
recovery of their neutrophil  counts.  In addition, 3 patients who had become 
neutropenic during caspofungin therapy all had a favourable response.  None of the 
7 patients who were persistently neutropenic had a favourable response. 
 
All patients in the study received concomitant therapies for their other underlying 
conditions. Eighteen patients received tacrolimus and CANCIDAS concomitantly, (of 
whom 8 also received mycophenolate mofetil); 5 of these 18 patients had a 
favourable response.  Among the 23 patients receiving high-dose corticosteroids, 8 
had a favourable response, including 5 who continued on high-dose steroids.  
Overall, the expert panel determined that 41% (26/63) of patients receiving at least 
one dose of CANCIDAS had a favourable response.  For those patients who 
received >7 days of therapy with CANCIDAS, 50% (26/52) had a favourable 
response.  The favourable response rates for patients who were either refractory to 
or intolerant of previous therapies were 36% (19/53) and 70% (7/10), respectively.  
The response rates among patients with pulmonary disease and extrapulmonary 
disease were 47% (21/45) and 28% (5/18), respectively.  Among patients with 
extrapulmonary disease, 2 of 8 patients who also had definite, probable, or possible 
CNS involvement had a favourable response.  
 
A medical chart review of 206 patients with invasive aspergillosis was also conducted 
to assess the response to standard (non-investigational) therapies.  Patient 
characteristics and important risk factors in this review were similar to those of 
patients enrolled in the open-label non-comparative study (see above), and the same 
rigorous definitions of diagnosis and outcome were used.  To be included in this 
study, patients had to have had invasive aspergillosis and to have received at least 7 
days of standard antifungal therapy.  The favourable response rate from this 
historical control study was 17% (35/206) for standard therapy compared to the 
favourable response rate of 41% (26/63) for CANCIDAS in the open-label non-
comparative study (the odds ratio was approximately 3).  
 
Paediatric Patients 
The safety and efficacy of CANCIDAS was evaluated in paediatric patients 3 months 
to 17 years of age in two prospective, multicentre clinical trials.  
 
The first study, which enrolled 82 patients between 2 to 17 years of age, was a 
randomised, double-blind study comparing CANCIDAS (50 mg/m2 IV once daily 
following a 70-mg/m2 loading dose on Day 1 [not to exceed 70 mg daily]) to 
AmBisome (3 mg/kg IV daily) in a 2:1 treatment fashion (56 on caspofungin, 26 on 
AmBisome) as empirical therapy in paediatric patients with persistent fever and 
neutropenia. The study design and criteria for efficacy assessment were similar to 
the study in adult patients (see Clinical Trials, Empirical Therapy in febrile, 
neutropenic patients). Patients were stratified based on risk category (high-risk 
patients had undergone allogeneic stem cell transplantation or had relapsed acute 
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leukaemia). Twenty-seven percent of patients in both treatment groups were high 
risk. The overall success rates in the MITT analysis, adjusted for strata, were as 
follows: 46% (26/56) for CANCIDAS and 32% (8/25) for AmBisome. For those 
patients in the high risk category, the favourable overall response rate was 60% 
(9/15) in the CANCIDAS group and 0% (0/7) in the AmBisome group.  
 
The second study was a prospective, open-label, non-comparative study estimating 
the safety and efficacy of caspofungin in paediatric patients (ages 3 months to 17 
years) with invasive candidiasis, oesophageal candidiasis, and invasive aspergillosis 
(as salvage therapy). The study employed diagnostic criteria which were based on 
established EORTC/MSG criteria of proven or probable infection; these criteria were 
similar to those criteria employed in the adult studies for these various indications. 
Similarly, the efficacy time points and endpoints used in this study were similar to 
those employed in the corresponding adult studies (see Clinical Trials, Invasive 
Candidiasis, Candidaemia, Oesophageal Candidiasis, Invasive Aspergillosis). All 
patients received CANCIDAS at 50 mg/m2 IV once daily following a 70-mg/m2 loading 
dose on Day 1 (not to exceed 70 mg daily). Among the 49 enrolled patients who 
received CANCIDAS, 48 were included in the MITT analysis. Of these 48 patients, 37 
had invasive candidiasis, 10 had invasive aspergillosis, and 1 patient had 
oesophageal candidiasis. The favourable response rate, by indication, at the end of 
caspofungin therapy was as follows in the MITT analysis:  81% (30/37) in invasive 
candidiasis, 50% (5/10) in invasive aspergillosis, and 100% (1/1) in oesophageal 
candidiasis. 
 
INDICATIONS 
 
CANCIDAS is indicated for: 
 Empirical therapy for presumed fungal infections in febrile, neutropenic  patients 
whose fever has failed to respond to broad-spectrum antibiotics 
 
 Treatment of: 
 -Invasive Candidiasis, including candidaemia 
 -Oesophageal Candidiasis 
 -Invasive Aspergillosis in patients who are refractory to or intolerant of other 
 therapies. 
 
CONTRAINDICATIONS 
 
CANCIDAS is contraindicated in patients with hypersensitivity to any component of 
this product.   
 
PRECAUTIONS 
 
General 
 
Anaphylaxis has been reported during administration of CANCIDAS. If this occurs, 
CANCIDAS should be discontinued and appropriate treatment administered. Possibly 
histamine-mediated adverse reactions, including rash, facial swelling, angioedema, 
pruritus, sensation of warmth, or bronchospasm have been reported and may require 
discontinuation and/or administration of appropriate treatment.  
 
Cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) 
have been reported after post marketing use of caspofungin.  Caution should apply in 
patients with history of allergic skin reactions. 
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Safety information on treatment durations longer than 4 weeks is limited, however 
available data suggest that CANCIDAS continues to be well tolerated with longer 
courses of therapy. 
 
Laboratory abnormalities in liver function tests have been seen in healthy volunteers 
and in adult and paediatric patients treated with CANCIDAS. In some adult and 
paediatric patients with serious underlying conditions who were receiving multiple 
concomitant medications with CANCIDAS, isolated cases of clinically significant 
hepatic dysfunction, hepatitis, and hepatic failure have been reported; a causal 
relationship to CANCIDAS has not been established. Patients who develop abnormal 
liver function tests during CANCIDAS therapy should be monitored for evidence of 
worsening hepatic function and evaluated for risk/benefit of continuing CANCIDAS 
therapy.  
 
Carcinogenesis / Mutagenesis / Impairment of Fertility 
 
No long-term studies in animals have been performed to evaluate the carcinogenic 
potential of caspofungin. 
 
Caspofungin did not show evidence of genotoxic potential when evaluated in assays 
for gene mutation [bacterial (Ames) and mammalian cell (V79 Chinese hamster lung 
fibroblasts) assays] and chromosomal damage (Chinese hamster ovary cells in vitro 
and the mouse bone marrow chromosomal assay).  Caspofungin was also negative 
in the alkaline elution/rat hepatocytes DNA strand break test. 
 
Fertility and reproductive performance were not affected by the intravenous 
administration of caspofungin to rats at IV doses of up to 5 mg/kg/day.  At 5 
mg/kg/day, drug exposures (AUC) were similar to those seen in patients treated with 
the 70 mg dose. 
 
Use in Pregnancy (Category B3) 
 
CANCIDAS was shown to be weakly embryotoxic in rats and rabbits.  In rats, 
CANCIDAS was shown to cause the complete ossification of the skull and torso and 
an increased incidence of cervical rib.  Caspofungin also produced increases in 
resorptions in rats and rabbits and pre-implantation losses in rats.  These findings 
were observed at doses that produced drug exposures similar to those seen in 
patients treated with a 70 mg dose (1-2 fold clinical exposure at the maximum 
recommended dose, based on AUC).  Caspofungin crossed the placental barrier in 
rats and rabbits and was detected in the plasma of foetuses of pregnant animals 
dosed with CANCIDAS.  There were no adequate and well-controlled studies in 
pregnant women.  CANCIDAS should be used in pregnancy only if the potential 
benefit justifies the potential risk to the foetus. 
 
Use in Lactation 
 
Caspofungin was found in the milk of lactating, drug-treated rats.  It is not known 
whether caspofungin is excreted in human milk.  Because many drugs are excreted 
in human milk, women receiving CANCIDAS should not breast-feed. 
 
Use in children 
 
The use of caspofungin in paediatric patients 3 months to 17 years of age is 
supported by efficacy/safety studies in adults, pharmacokinetic studies in paediatric 
patients (see Pharmacokinetics subsection) and two prospective efficacy studies in 
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paediatric patients (see Clinical Trials section). 
 
The efficacy and safety of caspofungin has not been studied in prospective clinical 
trials involving neonates and infants under 3 months of age. 
 
Caspofungin has not been studied in paediatric patients with endocarditis, 
osteomyelitis, and meningitis due to Candida. Caspofungin has also not been studied 
as initial therapy for invasive aspergillosis in paediatric patients.  
 
The pharmacokinetic, efficacy, and safety data for patients aged 3 to 12 months of 
age are limited. Caution is advised when treating this age group. 
 
Interactions with Other Drugs 
Table 5 
Co-administered drug CANCIDAS 
dose 
N Results 
Cyclosporin A  
4 mg/kg as a single dose 
70 mg daily for 
11 days 
19 Approximately 35% increase in 
CANCIDAS AUC when co-
administered with Cyclosporin A*; no 
effect of CANCIDAS on cyclosporin 
A 
Amphotericin B  
0.25 mg/kg as a single dose 
50 mg daily for 
11 days 
21 No effect of Amphotericin B on 
CANCIDAS; no effect of CANCIDAS 
on Amphotericin B 
Itraconazole 
200mg/d, multiple doses 
50 mg daily for 
14 days 
47 No effect of itraconazole on 
CANCIDAS; no effect of CANCIDAS 
on itraconazole 
Mycophenolate 
1.5g as a single dose 
50 mg daily  for 
16 days 
18 No effect of mycophenolate on 
CANCIDAS; no effect of CANCIDAS 
on mycophenolate 
Tacrolimus 
0.1 mg/kg, doses on days 1 
and 10 
70 mg or 50 mg 
daily 
51 No effect of tacrolimus on 
CANCIDAS; 20% decrease in AUC 
for tacrolimus when co-administered 
with CANCIDAS.  
Rifampicin  
600 mg oral dose daily 
When CANCIDAS added 
to pre-existing rifampicin 
(i.e. steady state) 
therapy 
 
When CANCIDAS and 
rifampicin initiated on the 
same day 
 
 
50 mg daily for 
14 days (for both 
studies)  
 
14 
 
 
 
 
 
10 
 
Approximately 30 % decrease in 
trough concentrations of CANCIDAS, 
but with little change in AUC for 
CANCIDAS.  No effect of 
CANCIDAS on rifampicin. 
 
Approximately 60% increase in AUC 
for CANCIDAS on Day 1.  No effect 
of CANCIDAS on rifampicin. 
 
Refer to Dosage and Administration 
section 
 
Nelfinavir  
1250 mg oral dose twice 
daily 
50 mg daily for 
14 days 
9 No effect of nelfinavir on 
CANCIDAS. 
*Refer below for trial description  
Cyclosporin 
Concomitant use of CANCIDAS with cyclosporin has been evaluated in healthy adult 
volunteers and in adult patients. In one clinical study, 3 of 4 healthy adult subjects 
who received CANCIDAS 70 mg on Days 1 through 10, and also received two 3 
mg/kg doses of cyclosporin 12 hours apart on Day 10, developed transient elevations 
of alanine transaminase (ALT) on Day 11 that were 2 to 3 times the upper limit of 
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normal (ULN).  In a separate panel of adult subjects in the same study, 2 of 8 who 
received CANCIDAS 35 mg daily for 3 days and cyclosporin (two 3 mg/kg doses 
administered 12 hours apart) on Day 1 had small increases in ALT (slightly above the 
ULN) on Day 2.  In both groups, elevations in aspartate transaminase (AST) 
paralleled ALT elevations, but were of lesser magnitude (see ADVERSE 
REACTIONS, Laboratory Abnormalities).   
 
In the above two clinical studies, cyclosporin increased the AUC of caspofungin by 
approximately 35%.  These AUC increases are probably due to reduced uptake of 
caspofungin by the liver.  CANCIDAS did not increase the plasma levels of 
cyclosporin.  Refer to Table 5. 
 
A retrospective study was conducted of 40 adult patients treated during marketed 
use with CANCIDAS and cyclosporin for 1 to 290 days (median 17.5 days).  The 
majority of patients had allogeneic haematopoietic stem cell transplants (82.5%) or 
solid organ transplants (10%).  The majority of patients received caspofungin 50 mg 
daily after 70 mg on Day 1. No serious hepatic adverse events were noted during this 
study.  As expected in this population, hepatic enzyme abnormalities occurred 
commonly; however, no patient had elevations in ALT that were considered drug 
related.  Elevations in AST considered at least possibly related to therapy with 
CANCIDAS and/or cyclosporin occurred in 5 patients, but all were less than 3.6 times 
the ULN.  Discontinuations due to laboratory abnormalities in hepatic enzymes from 
any cause occurred in 4 patients.  Of these, 2 were considered possibly related to 
therapy with CANCIDAS and/or cyclosporin as well as other possible causes.  In the 
prospective invasive aspergillosis and compassionate use studies, there were 6 
patients treated with CANCIDAS and cyclosporin for 2 to 56 days; none of these 
patients experienced increases in hepatic enzymes.   
 
These data suggest that CANCIDAS can be used in patients receiving cyclosporin 
when the potential benefit outweighs the potential risk. 
 
Tacrolimus 
Clinical studies in healthy adult volunteers show that the pharmacokinetics of 
CANCIDAS are not altered by tacrolimus.  CANCIDAS reduced the blood AUC of 
tacrolimus by approximately 20%, maximal blood concentration (Cmax) by 16%, and 
12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 
doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 
70 mg daily, as compared to results from a control period in which tacrolimus was 
administered alone.  For patients receiving both therapies, standard monitoring of 
tacrolimus blood concentrations and appropriate tacrolimus dosage adjustments are 
recommended. Refer to Table 5. 
 
Effect of caspofungin on the P450 (CYP) system 
Studies in vitro show that caspofungin is not an inhibitor of cytochrome P450 (CYP) 
mediated reactions.  In clinical studies, caspofungin did not induce the CYP3A4 
metabolism of other drugs.  Caspofungin is not a substrate for P-glycoprotein, and 
metabolism by cytochrome P450 was not observed in vitro. 
 
Other Drugs 
Clinical studies in healthy adult volunteers show that the pharmacokinetics of 
CANCIDAS are not altered by itraconazole, amphotericin B, nelfinavir or 
mycophenolate.  CANCIDAS has no effect on the pharmacokinetics of itraconazole, 
amphotericin B, rifampicin or the active metabolite of mycophenolate. Refer to Table 
5. 
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Population pharmacokinetic screening of caspofungin concentrations in adult patients 
receiving other concomitant medications indicate that elevations in plasma 
caspofungin levels due to drug interactions, as was seen in the formal drug 
interaction study with cyclosporin, are uncommon.  Results from two clinical drug 
interaction studies indicate that rifampicin both induces and inhibits caspofungin 
disposition with net induction at steady state.  In one study, rifampicin and 
caspofungin were co-administered for 14 days with both therapies initiated on the 
same day.  In the second study, rifampicin was administered alone for 14 days to 
allow the induction effect to reach steady state, and then rifampicin and caspofungin 
were co-administered for an additional 14 days.  When the induction effect of 
rifampicin was at steady state, there was little change in caspofungin AUC or end-of-
infusion concentration, but caspofungin trough concentrations were reduced by 
approximately 30%.  The inhibitory effect of rifampicin was demonstrated when 
rifampicin and caspofungin treatments were initiated on the same day, and a 
transient elevation in caspofungin plasma concentrations occurred on Day 1 
(approximately 60% increase in AUC).  This inhibitory effect was not seen when 
caspofungin was added to pre-existing rifampicin therapy, and no elevation in 
caspofungin concentrations occurred.  Refer to Table 5.  In addition, results from the 
population pharmacokinetic screening suggest that co-administration of other 
inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone or 
carbamazepine) with CANCIDAS may also result in clinically meaningful reductions 
in caspofungin concentrations. Available data suggest that the inducible drug 
clearance mechanism involved in caspofungin disposition is likely an uptake 
transport process, rather than metabolism.  
 
When CANCIDAS is co-administered in adult patients with inducers of drug 
clearance, such as efavirenz, nevirapine, phenytoin, rifampicin, dexamethasone, or 
carbamazepine, use of a daily dose of 70 mg CANCIDAS should be considered.  
 
In paediatric patients, results from regression analyses of pharmacokinetic data 
suggest that co-administration of dexamethasone with caspofungin may result in 
clinically meaningful reductions in caspofungin trough concentrations. This finding 
may indicate that paediatric patients will have similar reductions with inducers as 
seen in adults. When caspofungin is co-administered to paediatric patients with 
inducers of drug clearance, such as rifampicin, efavirenz, nevirapine, phenytoin, 
dexamethasone, or carbamazepine, a caspofungin dose of 70-mg/m2 daily (not to 
exceed an actual daily dose of 70 mg) may need to be considered depending on the 
clinical response. 
 
ADVERSE EFFECTS 
 
General 
Hypersensitivity reactions have been reported (see PRECAUTIONS).  
 
Clinical Adverse Experiences in Adult Patients 
The overall safety of caspofungin was assessed in 1865 adult individuals who 
received single or multiple doses of caspofungin acetate: 564 febrile, neutropenic 
patients (empirical therapy study), 382 patients with invasive candidiasis, 297 
patients with oesophageal and/or oropharyngeal candidiasis, 228 patients with 
invasive aspergillosis and 394 individuals in phase I studies.  In the empirical therapy 
study, patients had received chemotherapy for malignancy or had undergone 
haematopoietic stem-cell transplantation.  In the studies involving patients with 
documented Candida infections, the majority of the patients had serious underlying 
medical conditions (e.g. haematologic or other malignancy, recent major surgery, 
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HIV) requiring multiple concomitant medications.  Patients in the non-comparative 
Aspergillus study often had serious predisposing medical conditions (e.g., bone 
marrow or peripheral stem cell transplants, haematologic malignancy, solid tumours 
or organ transplants) requiring multiple concomitant medications. 
 
Empirical Therapy in Febrile, Neutropenic Patients 
In the randomised, double-blinded empirical therapy study, patients received either 
CANCIDAS 50 mg/day (following a 70 mg loading dose) or AmBisome  
(3 mg/kg/day).  Drug-related clinical adverse experiences occurring in  2% of the 
patients in either treatment group are presented in Table 6. 
 
Table 6 
Drug-Related* Clinical Adverse Experiences Among Patients with Persistent 
Fever and Neutropenia 
Incidence  2% for at least one treatment group by Body System 
 CANCIDAS** 
N=564 (percent) 
AmBisome*** 
N=547 (percent) 
Body as a Whole   
Abdominal Pain 1.4 2.4 
Chills 13.8 24.7 
Fever 17.0 19.4 
Flushing 1.8 4.2 
Perspiration/Diaphoresis 2.8 2.2 
Cardiovascular System   
Hypertension 1.1 2.0 
Tachycardia 1.4 2.4 
Digestive System   
Diarrhoea 2.7 2.4 
Nausea 3.5 11.3 
Vomiting 3.5 8.6 
Metabolism and Nutrition   
Hypokalaemia 3.7 4.2 
Musculoskeletal System   
Back Pain 0.7 2.7 
Nervous System & Psychiatric   
Headache 4.3 5.7 
Respiratory System   
Dyspnoea 2.0 4.2 
Tachypnoea 0.4 2.0 
Skin & Skin Appendage   
Rash 6.2 5.3 
* Determined by the investigator to be possibly, probably, or definitely drug-related. 
** 70 mg on Day 1, then 50 mg daily for the remainder of treatment; daily dose was increased to 
70 mg for 73 patients. 
*** 3.0 mg/kg/day; daily dose was increased to 5.0 mg/kg for 74 patients. 
 
 
The proportion of patients who experienced an infusion-related adverse event was 
significantly lower in the group treated with CANCIDAS (35.1%) than in the group 
treated with AmBisome (51.6%). 
 
To evaluate the effect of CANCIDAS and AmBisome on renal function, nephrotoxicity 
was defined as doubling of serum creatinine relative to baseline or an increase of 
1 mg/dL in serum creatinine if baseline serum creatinine was above the upper limit 
of the normal range.  Among patients whose baseline creatinine clearance was 
>30 mL/min, the incidence of nephrotoxicity was significantly lower in the group 
treated with CANCIDAS (2.6%) than in the group treated with AmBisome (11.5%)  
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Invasive Candidiasis 
In an initial randomised, double-blinded invasive candidiasis study, patients received 
either CANCIDAS 50 mg/day (following a 70-mg loading dose) or amphotericin B, 0.6 
to 1.0 mg/kg/day.  Drug-related clinical adverse experiences occurring in 2% of the 
patients in either treatment group are presented in Table 7. 
 
Table 7 
Drug-Related Clinical Adverse Experiences Among Patients with Invasive 
Candidiasis* 
Incidence 2% for at least one treatment group by Body System 
 
 CANCIDAS 50 mg** 
N=114 (percent) 
Amphotericin B 
N=125 (percent) 
Body as a Whole   
Chills 5.3 26.4 
Fever 7.0 23.2 
Cardiovascular System   
Hypertension 1.8 6.4 
Hypotension 0.9 2.4 
Tachycardia 1.8 10.4 
Peripheral Vascular System   
Phlebitis/thrombophlebitis 3.5 4.8 
Digestive System   
Diarrhoea 2.6 0.8 
Jaundice 0.9 3.2 
Nausea 1.8 5.6 
Vomiting 3.5 8.0 
 
Metabolic/Nutritional/Immune   
Hypokalaemia 0.9 5.6 
Nervous System & Psychiatric   
Tremor 1.8 2.4 
Respiratory System   
Tachypnoea 0.0 10.4 
Skin & Skin Appendage   
Erythema 0.0 2.4 
Rash 0.9 3.2 
Sweating 0.9 3.2 
Urogenital System   
Renal insufficiency 0.9 5.6 
Renal insufficiency, acute 0.0 5.6 
*  Determined by the investigator to be possibly, probably, or definitely drug related. 
** Patients received CANCIDAS 70 mg on Day 1, then 50 mg daily for the remainder of their 
treatment. 
 
The incidence of drug-related clinical adverse experiences was significantly lower 
among patients treated with CANCIDAS (28.9%) than among patients treated with 
amphotericin B (58.4%).  Also, the proportion of patients who experienced an 
infusion-related adverse event was significantly lower in the CANCIDAS group 
(20.2%) than in the amphotericin B group (48.8%). 
 
In a second randomised, double-blinded invasive candidiasis study, patients received 
either CANCIDAS 50 mg/day (following a 70-mg loading dose) or CANCIDAS 150 
mg/day. The primary endpoint for this study was the proportion of patients developing 
a significant drug-related adverse experience (defined as a serious drug-related 
adverse experience or a drug-related adverse experience leading to caspofungin 
discontinuation). The proportion of patients with a significant drug-related adverse 
experience was comparable in the 2 treatment groups: 1.9% (2/104) vs. 3.0% (3/100) 
in the CANCIDAS 50 mg/day and 150 mg/day groups, respectively (difference 1.1% 
[95% CI -4.1, 6.8]). The proportion of patients who experienced any drug-related 
adverse experience was also similar in the 2 treatment groups. Drug-related clinical 
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adverse experiences occurring in 2.0% of the patients in either treatment group are 
presented in Table 8. 
 
TABLE 8 
Drug-Related* Clinical Adverse Experiences among Patients with Invasive 
Candidiasis 
Incidence ≥2.0% for at Least One Treatment Group by System Organ Class or 
Preferred Term 
 
Adverse Experience 
(MedDRA v11.0 System Organ Class and 
Preferred Term) 
CANCIDAS 50 mg† 
N=104 (percent) 
CANCIDAS 150 mg 
N=100 (percent) 
 All Systems, Any Adverse Experience  13.5 14.0 
 General Disorders and Administration 
Site Conditions                
 6.7  7.0 
   Injection site erythema                                                            0.0     2.0   
   Injection site phlebitis                                                        3.8     2.0   
   Injection site swelling                                                            1.0     2.0   
 Metabolism and Nutrition Disorders                                  1.9  2.0 
   Hypokalemia                                                       1.0    2.0    
Nervous System Disorders                                          0.0  2.0 
   Headache                                                      0.0     2.0    
* Determined by the investigator to be possibly, probably, or definitely drug-related. Within any 
system organ class, individuals may experience more than 1 adverse experience 
† Patients received CANCIDAS 70 mg on Day 1, then 50 mg daily for the remainder of their     
treatment 
 
 
Oesophageal and/or oropharyngeal candidiasis 
Drug-related clinical adverse experiences occurring in 2% of patients with 
oesophageal and/or oropharyngeal candidiasis are presented in Table 9. 
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TABLE 9 
Drug-related Clinical Adverse Experiences among Patients with Oesophageal 
and/or Oropharyngeal Candidiasis* 
Incidence 2% for at least one treatment dose (per comparison) by Body System 
  
CANCIDAS  
50 mg 
(N=83) 
percent 
 
Fluconazole 
IV 200mg  
(N=94) 
percent 
 
CANCIDAS  
50 mg 
(N=80) 
percent 
 
CANCIDAS  
70 mg 
(N=65) 
percent 
 
Amphotericin B 
0.5 mg/kg 
(N=89) 
percent 
Body as a Whole      
Asthenia/fatigue  0.0 0.0 0.0 0.0 6.7 
Chills  0.0 0.0 2.5 1.5 75.3 
Oedema/swelling  0.0 0.0 0.0 0.0 5.6 
Oedema, facial  0.0 0.0 0.0 3.1 0.0 
Fever  3.6 1.1 21.3 26.2 69.7 
Flu-like illness  0.0 0.0 0.0 3.1 0.0 
Malaise  0.0 0.0 0.0 0.0 5.6 
Pain  0.0 0.0 1.3 4.6 5.6 
Pain, abdominal  3.6 2.1 2.5 0.0 9.0 
Warm sensation  0.0 0.0 0.0 1.5 4.5 
Peripheral Vascular 
System  
     
Infused vein complication  12.0 8.5 2.5 1.5  0.0 
Phlebitis/thrombophlebitis  15.7 8.5 11.3 13.8 22.5 
Cardiovascular System      
Tachycardia  0.0 0.0 1.3 0.0 4.5 
Vasculitis 0.0 0.0 0.0 0.0 3.4 
Digestive System       
Anorexia 0.0 0.0 1.3 0.0 3.4 
Diarrhoea  3.6 2.1 1.3 3.1 11.2 
Gastritis 0.0 2.1 0.0 0.0 0.0 
Nausea  6.0 6.4 2.5 3.1 21.3 
Vomiting  1.2 3.2 1.3 3.1 13.5 
Haemic & Lymphatic 
System  
     
Anaemia  0.0 0.0 3.8 0.0 9.0 
Musculoskeletal System       
Myalgia  1.2 0.0 0.0 3.1 2.2 
Pain, back 0.0 0.0 0.0 0.0 2.2 
Pain, musculoskeletal  0.0 0.0 1.3 0.0 4.5 
Metabolic/Nutritional 
/Immune 
     
Anaphylaxis 0.0 0.0 0.0 0.0 2.2 
Nervous System & 
Psychiatric  
     
Dizziness 0.0 2.1 0.0 1.5 1.1 
Headache  6.0 1.1 11.3 7.7 19.1 
Insomnia 1.2 0.0 0.0 0.0 2.2 
Paraesthesia  0.0 0.0 1.3 3.1 1.1 
Tremor  0.0 0.0 0.0 0.0 7.9 
Respiratory System       
Tachypnoea  0.0 0.0 1.3 0.0 4.5 
Skin & Skin Appendage       
Erythema  1.2 0.0 1.3 1.5 7.9 
Induration  0.0 0.0 0.0 3.1 6.7 
Pruritus 1.2 0.0 2.5 1.5 0.0 
Rash  0.0 0.0 1.3 4.6 3.4 
Sweating  0.0 0.0 1.3 0.0 3.4 
*Relationship to drug was determined by the investigator to be possibly, probably or 
definitely drug-related.  Patients who received CANCIDAS 35 mg daily in these 
studies are not included in this table. 
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Invasive aspergillosis 
In the open-label, non-comparative aspergillosis study, in which 69 patients received 
CANCIDAS (70-mg loading dose on Day 1 followed by 50 mg daily), the following 
drug-related clinical adverse experiences were observed with an incidence of 2%: 
fever (2.9%), infused-vein complications (2.9%), nausea (2.9%), vomiting (2.9%) and 
flushing (2.9%).  Also reported infrequently in this patient population were pulmonary 
oedema, adult respiratory distress syndrome (ARDS), and radiographic infiltrates. 
 
Clinical Adverse Experiences in Paediatric Patients 
The overall safety of caspofungin was assessed in 171 paediatric patients who 
received single or multiple doses of CANCIDAS: 104 febrile, neutropenic patients; 56 
patients with invasive candidiasis; 1 patient with oesophageal candidiasis; and 
10 patients with invasive aspergillosis. The overall clinical safety profile of 
CANCIDAS in paediatric patients is comparable to that in adult patients. Table 10 
shows the incidence of drug-related clinical adverse experiences reported in 2.0% 
of paediatric patients in clinical studies. The most common drug-related clinical 
adverse experiences in paediatric patients treated with CANCIDAS were fever 
(11.7%), rash (4.7%), and headache (2.9%). 
 
TABLE 10 
Drug-Related Clinical Adverse Experiences among Paediatric Patients* 
Incidence 2% for at least one treatment dose by Body System 
  
CANCIDAS 
Any Dose** 
N=171 
(percent) 
 
CANCIDAS 
50 mg/m2*** 
N=56 
(percent) 
 
AmBisome                      
3 mg/kg*** 
N=26 
(percent) 
Cardiac Disorders    
  Tachycardia  1.2 1.8 11.5 
Gastrointestinal Disorders     
  Nausea  0.0 0.0 3.8 
   Vomiting  0.6 1.8 7.7 
General Disorders  & Administration Site 
Conditions 
   
  Adverse Drug Reaction  0.0 0.0 3.8 
  Catheter Site Pain 1.2 3.6 0.0 
   Chills 1.8 1.8 7.7 
   Fever  11.7 28.6 23.1 
Hepatobiliary Disorders    
  Hepatitis, toxic   0.0 0.0 3.8 
   Hyperbilirubinemia 0.0 0.0 3.8 
   Jaundice 0.0 0.0 3.8 
Metabolism & Nutrition Disorders    
  Hypokalemia 0.6 0.0 3.8 
Nervous System Disorders    
  Headache 2.9 8.9 0.0 
Respiratory, Thoracic, & Mediastinal 
Disorders 
   
  Dyspnea 0.0 0.0 3.8 
   Laryngospasm 0.0 0.0 3.8 
Skin & Subcutaneous Tissue Disorders    
  Angioneurotic edema  0.0 0.0 3.8 
   Circumoral edema 0.0 0.0 3.8 
   Pruritus 1.8 3.6 0.0 
   Rash 4.7 8.9 0.0 
Vascular Disorders    
  Flushing 1.8 3.6 0.0 
  Hypotension 1.8 3.6 3.8 
                     * Relationship to drug was determined by the investigator to be possibly, probably or definitely drug-related. 
                    ** Derived from all paediatric clinical studies. 
                    ***Derived from Phase II comparator-controlled clinical study of empirical therapy.   
 
S-WPC-MK0991-IV-102016 22 
One patient (0.6%) receiving CANCIDAS and three patients (11.5%) receiving 
AmBisome developed a serious drug-related clinical adverse experience. Two 
patients (1.2%) were discontinued from CANCIDAS and three patients (11.5%) were 
discontinued from AmBisome due to a drug-related clinical adverse experience. The 
proportion of patients who experienced an infusion-related adverse event was 21.6% 
in the group treated with CANCIDAS and 34.6% in the group treated with AmBisome. 
 
Laboratory values:  
Adult Patients 
Empirical Therapy in Febrile, Neutropenic Patients 
 
Drug-related laboratory adverse experiences occurring in  2% of the patients in 
either treatment group are presented in Table 11. 
 
 
TABLE 11 
Drug-Related* Laboratory Adverse Experiences among Patients with 
Persistent Fever and Neutropenia 
Incidence  2% for at least one treatment group by Laboratory Test Category 
 CANCIDAS** 
N=564 (percent) 
AmBisome*** 
N=547 (percent) 
Blood Chemistry   
Alanine aminotransferase increased 8.7 8.9 
Alkaline phosphatase increased 7.0 12.0 
Aspartate aminotransferase increased 7.0 7.6 
Direct serum bilirubin increased 2.6 5.2 
Total serum bilirubin increased 3.0 5.2 
Hypokalemia 7.3 11.8 
Hypomagnesemia 2.3 2.6 
Serum creatinine increased 1.2 5.5 
* Determined by the investigator to be possibly, probably, or definitely drug-related. 
** 70 mg on Day 1, then 50 mg daily for the remainder of treatment; daily dose was increased to 
70 mg for 73 patients. 
*** 3.0 mg/kg/day; daily dose was increased to 5.0 mg/kg for 74 patients. 
 
The percentage of patients with either a drug-related clinical or a drug-related 
laboratory adverse experience was significantly lower among patients receiving 
CANCIDAS (54.4%) than among patients receiving AmBisome (69.3%). 
Furthermore, the incidence of discontinuation due to a drug-related clinical or 
laboratory adverse experience was significantly lower among patients treated with 
CANCIDAS (5.0%) than among patients treated with AmBisome (8.0%). 
 
Invasive Candidiasis 
Drug-related laboratory adverse experiences occurring in 2% of the patients in an 
initial invasive candidiasis study are presented in Table 12. 
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Table 12 
Drug-Related Laboratory Adverse Experiences among Patients with Invasive 
Candidiasis* 
Incidence 2% for at least one treatment group by Laboratory Test Category 
 
 CANCIDAS 50 mg** 
N=114 (percent) 
Amphotericin B 
N=125 (percent) 
Blood Chemistry   
ALT increased 3.7 8.1 
AST increased 1.9 9.0 
Blood urea increased 1.9 15.8 
Direct serum bilirubin increased 3.8 8.4 
Serum alkaline phosphatase increased 8.3 15.6 
Serum bicarbonate decreased 0.0 3.6 
Serum creatinine increased 3.7 22.6 
Serum phosphate increased 0.0 2.7 
Serum potassium decreased 9.9 23.4 
Serum potassium increased 0.9 2.4 
Total serum bilirubin increased 2.8 8.9 
Haematology   
Haematocrit decreased 0.9 7.3 
Haemoglobin decreased 0.9 10.5 
Urinalysis   
Urine protein increased 0.0 3.7 
*  Determined by the investigator to be possibly, probably, or definitely drug related. 
** Patients received CANCIDAS 70 mg on Day 1, then 50 mg daily for the remainder of their    
treatment. 
 
The incidence of drug-related laboratory adverse experiences was significantly lower 
among patients receiving CANCIDAS (24.3%) than among patients receiving 
amphotericin B (54.0%). 
 
The percentage of patients with either a drug-related clinical adverse experience or a 
drug-related laboratory adverse experience was significantly lower among patients 
receiving CANCIDAS (42.1%) than among patients receiving amphotericin B 
(75.2%).  Furthermore, a significant difference between the two treatment groups 
was observed with regard to incidence of discontinuation due to drug-related clinical 
or laboratory adverse experience; 3/114 (2.6%) in the CANCIDAS group and 29/125 
(23.2%) in the amphotericin B group. 
 
To evaluate the effect of CANCIDAS and amphotericin B on renal function, 
nephrotoxicity was defined as doubling of serum creatinine relative to baseline or an 
increase of 1 mg/dL in serum creatinine if baseline serum creatinine was above the 
upper limit of the normal range. In a subgroup of patients whose baseline creatinine 
clearance was >30 mL/min, the incidence of nephrotoxicity was significantly lower in 
the CANCIDAS group than in the amphotericin B group. 
 
In a second randomised, double-blinded invasive candidiasis study, patients received 
either CANCIDAS 50 mg/day (following a 70-mg loading dose) or CANCIDAS 150 
mg/day. Drug-related laboratory adverse experiences occurring in 2.0% of the 
patients in either treatment group are presented in Table 13. 
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TABLE 13 
Drug-Related* Laboratory Adverse Experiences among Patients with 
Invasive Candidiasis 
Incidence ≥2.0% for at Least One Treatment Group by System Organ Class or 
Preferred Term 
 
Adverse Experience 
(MedDRA v11.0 System Organ Class and 
Preferred Term) 
CANCIDAS 50 mg† 
N=104 (percent) 
CANCIDAS 150 mg 
N=100 (percent) 
 All Systems, Any Adverse Experience   7.8  7.1 
   Alanine Aminotransferase Increased                                 2.0  2.0 
   Alkaline Phosphatase Increased                             6.9  2.0 
   Aspartate Aminotransferase Increased                             4.0  2.0 
* Determined by the investigator to be possibly, probably, or definitely drug-related. Within any 
system organ class, individuals may experience more than 1 adverse experience 
† Patients received CANCIDAS 70 mg on Day 1, then 50 mg daily for the remainder of their 
treatment 
 
Oesophageal and/or oropharyngeal candidiasis 
Drug-related laboratory abnormalities occurring in 2% of patients with oesophageal 
and/or oropharyngeal candidiasis are presented in Table 14. 
 
TABLE 14 
Drug-related Laboratory Abnormalities Reported among Patients with 
Oesophageal and/or Oropharyngeal Candidiasis (comparative studies)* 
Incidence 2% (for at least one treatment dose) by Laboratory Test Category 
 CANCIDAS 
50 mg 
CANCIDAS 
70 mg 
Fluconazole  
200 mg 
Amphotericin 
B  
0.5 mg/Kg 
 (N=163 ) (N=65 ) (N=94 ) (N=89 ) 
 (percent) (percent) (percent) (percent) 
Blood Chemistry      
   ALT increased  10.6 10.8 11.8 22.7 
   AST increased  13.0 10.8 12.9 22.7 
   Blood urea increased  0.0 0.0 1.2 10.3 
   Direct serum bilirubin increased 0.6 0.0 3.3 2.5 
   Serum albumin decreased  8.6 4.6 5.4 14.9 
   Serum alkaline phosphatase increased 10.5 7.7 11.8 19.3 
   Serum bicarbonate decreased 0.9 0.0 0.0 6.6 
   Serum calcium decreased  1.9 0.0 3.2 1.1 
   Serum creatinine increased  0.0 1.5 2.2 28.1 
   Serum potassium decreased  3.7 10.8 4.3 31.5 
   Serum potassium increased 0.6 0.0 2.2 1.1 
   Serum sodium decreased  1.9 1.5 3.2 1.1 
   Serum uric acid increased  0.6 0.0 0.0 3.4 
   Total serum bilirubin increased 0.0 0.0 3.2 4.5 
   Total serum protein decreased  3.1 0.0 3.2 3.4 
Haematology      
   Eosinophils increased  3.1 3.1 1.1 1.1 
   Haematocrit decreased  11.1 1.5 5.4 32.6 
   Haemoglobin decreased  12.3 3.1 5.4 37.1 
   Lymphocytes increased 0.0 1.6 2.2 0.0 
   Neutrophils decreased  1.9 3.1 3.2 1.1 
   Platelet count decreased  3.1 1.5 2.2 3.4 
   Prothrombin time increased 1.3 1.5 0.0 2.3 
   WBC count decreased  6.2 4.6 8.6 7.9 
Urinalysis      
   Urine blood increased  0.0 0.0 0.0 4.0 
   Urine casts increased  0.0 0.0 0.0 8.0 
   Urine pH increased  0.8 0.0 0.0 3.6 
   Urine protein increased  1.2 0.0 3.3 4.5 
   Urine RBC's increased  1.1 3.8 5.1 12.0 
   Urine WBC's increased  0.0 7.7 0.0 24.0 
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* Relationship to drug was determined by the investigator to be possibly, probably, or definitely 
drug-related. Patients who received CANCIDAS 35 mg daily in these studies are not included in this 
table. 
 
Invasive aspergillosis 
Drug-related laboratory abnormalities reported with an incidence 2% in patients 
treated with CANCIDAS in the non-comparative aspergillosis study were: serum 
alkaline phosphatase increased (2.9%), serum potassium decreased (2.9%), 
eosinophils increased (3.2%), urine protein increased (4.9%), and urine RBCs 
increased (2.2%). 
 
The safety and efficacy of multiple doses up to 150 mg daily (range: 1 to 51 days; 
median: 14 days) have been studied in 100 adult patients with invasive candidiasis. 
CANCIDAS was generally well tolerated in these patients receiving CANCIDAS at 
this higher dose; however, the efficacy of CANCIDAS at this higher dose was 
generally similar to patients receiving the 50-mg daily dose of CANCIDAS. 
 
Paediatric Patients 
Table 15 shows the incidence of drug-related laboratory adverse experiences 
reported in 2.0% of paediatric patients in clinical studies. The overall laboratory 
safety profile in paediatric patients is comparable to that in adult patients. The most 
common drug-related laboratory adverse experiences in paediatric patients treated 
with CANCIDAS were increased ALT (6.5%) and increased AST (7.6%). None of the 
patients receiving CANCIDAS or AmBisome developed a serious drug-related 
adverse event or were discontinued from therapy due to a drug-related laboratory 
adverse experience.  
 
TABLE 15 
Drug-Related Laboratory Adverse Experiences among Paediatric Patients* 
Incidence 2% for at least one treatment dose by Body System 
  
CANCIDAS 
Any Dose** 
N=171 
(percent) 
 
CANCIDAS 
50 mg/m2*** 
N=56 
(percent) 
 
AmBisome                      
3  mg/kg*** 
N=26 
(percent) 
Blood Chemistry Test     
  Alanine aminotransferase (ALT) increased 6.5 3.6  0.0 
  Aspartate aminotransferase (AST) 
increased 
7.6 1.8 0.0 
  Blood bilirubin increased 0.6 1.8 4.0 
  Blood phosphorus decreased 2.0 1.8 0.0 
  Blood potassium decreased 3.5 3.6 11.5 
  Blood sodium decreased 0.0 0.0 3.8 
  Direct bilirubin increased  0.0 0.0 6.3 
                     * Relationship to drug was determined by the investigator to be possibly, probably or definitely drug-related. 
                    **Derived from all paediatric clinical studies. 
                  ***Derived from Phase II comparator-controlled clinical study of empirical therapy.   
 
Post-marketing experience 
The following post-marketing adverse events have been reported:  
 
Hepatobiliary: rare cases of hepatic dysfunction 
Skin and subcutaneous tissue disorders: toxic epidermal necrolysis and Steven-
Johnson syndrome  
Cardiovascular: swelling and peripheral oedema 
Metabolic: hypercalcaemia; gamma-glutamyltransferase increased. 
 
 
S-WPC-MK0991-IV-102016 26 
DOSAGE AND ADMINISTRATION 
 
Dosage Recommendations 
 
CANCIDAS should be administered in adult patients by slow intravenous 
infusion over approximately 1 hour (refer to Reconstitution section for dilution 
recommendations). 
 
Table 16 
Dosing Recommendations in Adult Patients 
 
 Loading Dose  Maintenance dose 
Empirical Therapy   
Normal hepatic function or 
mild hepatic insufficiency* 
70 mg on day 1 50 mg daily 
Moderate hepatic 
insufficiency ** 
70 mg on day 1 35 mg daily 
   
Invasive candidiasis 
Normal hepatic function or 
mild hepatic insufficiency* 
70 mg on day 1 50 mg daily 
Moderate hepatic 
insufficiency ** 
70 mg on day 1 35 mg daily 
   
Oesophageal  
Normal hepatic function or 
mild hepatic insufficiency* 
Not required 50 mg daily 
Moderate hepatic 
insufficiency** 
Not required 35 mg daily 
   
Invasive aspergillosis 
Normal hepatic function or 
mild hepatic insufficiency* 
70 mg on day 1 50 mg daily 
Moderate hepatic 
insufficiency ** 
70 mg on day 1 35 mg daily 
  *Mild hepatic insufficiency: Child-Pugh score 5 to 6 
**Moderate hepatic insufficiency: Child Pugh score 7 to 9 
 
 
General Recommendations in Adult Patients 
 
Empirical Therapy 
Duration of treatment should be based on the patient’s clinical response.  Empirical 
therapy should be continued until resolution of neutropenia, which is generally 
expected to occur within 28 days.  Patients found to have a fungal infection should be 
treated for a minimum of 14 days; treatment should continue for at least 7 days after 
both neutropenia and clinical symptoms are resolved.  If the 50-mg dose is well 
tolerated but does not provide an adequate clinical response, the daily dose can be 
increased to 70 mg.  Although an increase in efficacy with 70 mg daily has not been 
demonstrated, safety data suggest that an increase in dose to 70 mg daily is well 
tolerated. 
 
Candidiasis 
 Invasive:  Duration of treatment of invasive candidiasis should be dictated by the 
patient’s clinical and microbiological response.  In general, antifungal therapy 
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should continue for at least 14 days after the last positive culture.  Patients who 
remain persistently neutropenic may warrant a longer course of therapy pending 
resolution of the neutropenia. 
 Oesophageal: Increasing doses of CANCIDAS above 50 mg daily provided no 
additional benefit in the treatment of oesophageal candidiasis. 
 
Invasive Aspergillosis 
Duration of treatment should be based upon the severity of the patient’s underlying 
disease, recovery from immunosuppression, and clinical response. The efficacy of a 
70-mg dose regimen in patients who are not clinically responding to the 50-mg daily 
dose is not known. Safety data suggest that an increase in dose to 70 mg daily is 
well tolerated. The efficacy of doses above 70 mg has not been adequately studied in 
patients with invasive aspergillosis.  
 
Concomitant Therapy with Inducers of Drug Clearance 
When CANCIDAS is co-administered in adult patients with inducers of drug 
clearance, such as efavirenz, nevirapine, phenytoin, rifampicin, dexamethasone or 
carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered. 
 
Hepatic Insufficiency 
 Adult patients with mild hepatic insufficiency (Child-Pugh score 5 to 6) do not 
need a dosage adjustment.   
 Adult patients with moderate hepatic insufficiency (Child-Pugh score 7 to 9), 
require an adjustment to maintenance dosage-refer to Table16.   
 There is no clinical experience in adult patients with severe hepatic insufficiency 
(Child-Pugh score >9) (see PHARMACOLOGY, Pharmacokinetics, Special 
Populations) and in paediatric patients with any degree of hepatic insufficiency. 
 
Renal Insufficiency 
No dosage adjustment is necessary for patients with renal insufficiency.  
Caspofungin is not dialysable, thus supplementary dosing is not required following 
haemodialysis (see PHARMACOLOGY, Pharmacokinetics, Special Populations). 
 
Paediatric Patients 
CANCIDAS should be administered in paediatric patients (3 months to 17 years of 
age) by slow IV infusion over approximately 1 hour. Dosing in paediatric patients (3 
months to 17 years of age) should be based on the patient’s body surface area (see 
Instructions for Use in Paediatric Patients, Mosteller2 Formula).  
 
For all indications, a single 70-mg/m2 loading dose (not to exceed an actual dose of 
70 mg) should be administered on Day 1, followed by 50 mg/m2 daily thereafter (not 
to exceed an actual dose of 70 mg daily). Duration of treatment should be 
individualised to the indication, as described for each indication in adults (see 
General Recommendations in Adult Patients). 
 
If the 50-mg/m2 daily dose is well tolerated but does not provide an adequate clinical 
response, the daily dose can be increased to 70 mg/m2 daily (not to exceed an actual 
daily dose of 70 mg). Although an increase in efficacy with 70 mg/m2 daily has not 
been demonstrated, limited safety data suggest that an increase in dose to 70 mg/m2 
daily is well tolerated. 
 
The efficacy and safety of CANCIDAS have not been sufficiently studied in clinical 
trials involving neonates and infants below 12 months of age. Caution is advised 
                                                          
2 Mosteller RD: Simplified Calculation of Body Surface Area. N Engl J Med 1987 Oct 22;317(17): 1098 (letter)  
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when treating this age group. Limited data suggest that CANCIDAS at 25 mg/m2 daily 
in neonates and infants (less than 3 months of age) and 50 mg/m2 daily in young 
children (3 to 11 months of age) can be considered. 
 
When CANCIDAS is co-administered to paediatric patients with inducers of drug 
clearance, such as rifampicin, efavirenz, nevirapine, phenytoin, dexamethasone, or 
carbamazepine, use of a CANCIDAS dose of 70-mg/m2 daily (not to exceed an 
actual daily dose of 70 mg) may need to be considered depending on the clinical 
response. 
   
Reconstitution of CANCIDAS 
 
The reconstituted vial of CANCIDAS must be further diluted prior to 
administration.  DO NOT USE DILUENTS CONTAINING GLUCOSE as 
CANCIDAS is not stable in diluents containing glucose.  
 
CANCIDAS should be administered by slow IV infusion of approximately 1 
hour.  It contains no antimicrobial agent.  Product is for single use in one 
patient only.  Discard any residue.  
 
Do not mix or co-infuse CANCIDAS with other medications as there is no data 
available on the compatibility of CANCIDAS with other intravenous substances, 
additives, or medications.  
 
INSTRUCTIONS FOR USE IN ADULTS 
 
Step 1:  Reconstitution of vials  
To reconstitute the powdered drug, bring the refrigerated vial of CANCIDAS to room 
temperature and aseptically add 10.5 mL of 0.9% Sodium Chloride Injection or Water 
for Injections.  The concentrations of the reconstituted vials will be: 7.2 mg/mL (70 
mg vial) or 5.2 mg/mL (50 mg vial).  
 
The white to off-white compact powder will dissolve completely.  Mix gently until a 
clear solution is obtained.  Reconstituted solutions should be visually inspected for 
particulate matter or discolouration.  This reconstituted solution is chemically and 
physically stable for up to 1 hour when held below 25°C.  However, to reduce 
microbiological hazard, use as soon as practicable after dilution and if storage is 
necessary, hold at 2-8C for not more than 1 hour. 
 
Step 2: Addition of reconstituted CANCIDAS to infusion solution  
The patient infusion solution is prepared by aseptically adding the appropriate 
amount of reconstituted drug (as shown in Table17) to a 250 mL intravenous PVC 
bag or glass bottle of 0.9% Sodium Chloride Injection.  Reduced volume infusions in 
100 mL may be used, when medically necessary, for 50 mg or 35 mg daily doses.  
 
Visually inspect the infusion solution for particulate matter or discolouration.  Do not 
use if the solution is cloudy or precipitated.  This infusion solution is chemically and 
physically stable for 24 hours when stored below 25C.  However, to reduce 
microbiological hazard, use as soon as practicable after dilution and if storage is 
necessary, hold at 2-8C for not more than 24 hours.  CANCIDAS should be 
administered by slow intravenous infusion over approximately 1 hour.  It contains no 
antimicrobial agent.  Use once only and discard any residue.  
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Table 17:  
Preparation of the patient infusion solutions 
 
 
 
DOSE* 
Volume of 
reconstituted 
CANCIDAS for 
transfer to 
intravenous bag 
or bottle 
Typical Preparation 
(reconstituted 
CANCIDAS added to 
250 mL infusion 
sodium chloride 0.9%) 
final concentration 
Reduced Volume 
Infusion 
(reconstituted CANCIDAS 
added to 100mL infusion 
sodium chloride 0.9% 
final concentration 
70 mg  
(from one 70 
mg vial) 
10 mL 0.28 mg/mL not recommended 
70 mg  
(from two 50 
mg vials)** 
14 mL 0.28 mg/mL not recommended 
50 mg 
(from one 50 
mg vial) 
10 mL 0.20 mg/mL 0.47 mg/mL 
35 mg  
(from one 50 
mg vial) 
7 mL 0.14 mg/mL 0.34 mg/mL 
35 mg  
(from one 70 
mg vial) 
5 mL 0.14 mg/mL 0.34 mg/mL 
* 10.5 mL should be used for reconstitution of all vials 
**If 70 mg vial is not available, the 70 mg dose can be prepared from two 50 mg vials 
 
 
INSTRUCTIONS FOR USE IN PAEDIATRIC PATIENTS 
 
Calculation of Body Surface Area (BSA) for paediatric dosing 
Before preparation of infusion, calculate the body surface area (BSA) of the patient 
using the following formula: (Mosteller Formula) 
 
Preparation of the 70 mg/m2 infusion for paediatric patients 3 months of age or 
older (using a 70-mg vial) 
1. Determine the actual loading dose to be used in the paediatric patient by using 
the patient's BSA (as calculated above) and the following equation: 
   BSA (m2)  X  70 mg / m2  =  Loading Dose 
The maximum loading dose on Day 1 should not exceed 70 mg regardless of the 
patient's calculated dose. 
2. Equilibrate the refrigerated vial of CANCIDAS to room temperature. 
3. Aseptically add 10.5 mL of 0.9% Sodium Chloride Injection or Sterile Water for 
Injectiona This reconstituted solution may be stored for up to one hour at ≤25°C.b 
This will give a final caspofungin concentration in the vial of 7.2 mg/mL. 
4. Remove the volume of drug equal to the calculated loading dose (Step 1) from the 
vial. Aseptically transfer this volume (mL)c of reconstituted CANCIDAS to an IV 
bag (or bottle) containing 250 mL  of 0.9%, 0.45%, or 0.225% Sodium Chloride 
Injection, or Lactated Ringers Injection. Alternatively, the volume (mL)c of 
reconstituted CANCIDAS can be added to a reduced volume of 0.9%, 0.45%, or 
0.225% Sodium Chloride Injection or Lactated Ringers Injection, not to exceed a 
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final concentration of 0.5 mg/mL. This infusion solution must be used within 24 
hours if stored at ≤25°C or within 24 hours if stored refrigerated at 2 to 8°C.  
5. If the calculated loading dose is <50 mg, then the dose may be prepared from the 
50-mg vial [follow Steps 2-4 from Preparation of the 50 mg/m2 infusion for 
paediatric patients 3 months of age or older (using a 50-mg vial)]. The final 
caspofungin concentration in the 50-mg vial after reconstitution is 5.2 mg/mL. 
 
Preparation of the 50 mg/m2 infusion for paediatric patients 3 months of age or 
older (using a 50-mg vial) 
1. Determine the daily maintenance dose to be used in the paediatric patient by 
using the patient's BSA (as calculated above) and the following equation: 
   BSA (m2)  X  50 mg/m2  =  Daily Maintenance Dose (mg) 
The daily maintenance dose should not exceed 70 mg regardless of the patient's 
calculated dose. 
2. Equilibrate the refrigerated vial of CANCIDAS to room temperature. 
3. Aseptically add 10.5 mL of 0.9% Sodium Chloride Injection or Sterile Water for 
Injectiona This reconstituted solution may be stored for up to one hour at ≤25°C.b 
This will give a final caspofungin concentration in the vial of 5.2 mg/mL. 
4. Remove the volume of drug equal to the calculated loading dose (Step 1) from the 
vial. Aseptically transfer this volume (mL)c of reconstituted CANCIDAS to an IV 
bag (or bottle) containing 250 mL  of 0.9%, 0.45%, or 0.225% Sodium Chloride 
Injection, or Lactated Ringers Injection. Alternatively, the volume (mL)c of 
reconstituted CANCIDAS can be added to a reduced volume of 0.9%, 0.45%, or 
0.225% Sodium Chloride Injection or Lactated Ringers Injection, not to exceed a 
final concentration of 0.5 mg/mL. This infusion solution must be used within 24 
hours if stored at ≤25°C or within 24 hours if stored refrigerated at 2 to 8°C. 
5. If the actual daily maintenance dose is > 50 mg, then the dose may be prepared 
from the 70-mg vial [follow steps 2-4 from Preparation of the 70 mg/m2 infusion for 
paediatric patients 3 months of age or older (using a 70-mg vial)]. The final 
caspofungin concentration in the 70-mg vial after reconstitution is 7.2 mg/L. 
 
Preparation notes:  
 
a. The white to off-white cake will dissolve completely. Mix gently until a clear 
solution is obtained. 
 
b. Visually inspect the reconstituted solution for particulate matter or discolouration 
during reconstitution and prior to infusion. Do not use if the solution is cloudy or 
has precipitated. 
 
c. CANCIDAS is formulated to provide the full labelled vial dose (70 mg or 50 mg) 
when 10 mL is withdrawn from the vial. 
 
OVERDOSAGE 
In clinical studies the highest dose was 210 mg, which was administered as a single 
dose to 6 healthy subjects and was generally well tolerated.  In addition, 150 mg daily 
up to 51 days has been administered to 100 healthy patients and was generally well-
tolerated.  Caspofungin is not dialysable. 
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PRESENTATION AND STORAGE CONDITIONS 
 
CANCIDAS is available as a white to off white lyophilised compact powder for 
infusion in single use vials of 50 mg and 70 mg.   
 
The lyophilised vials of CANCIDAS should be stored at 2-8C, refrigerate, do not 
freeze.  
 
Reconstituted vials of CANCIDAS may be stored for one hour prior to preparation of 
the infusion solution, and the final patient infusion solution in the IV bag or bottle can 
be stored for up to 24 hours.  To reduce microbiological hazard, it is recommended to 
use as soon as practicable after reconstitution/dilution and if storage is necessary, to 
hold at 2-8C. 
 
SPONSOR 
 
MERCK SHARP & DOHME (AUSTRALIA) PTY LIMITED 
LEVEL 1, BUILDING A, 26 TALAVERA ROAD 
MACQUARIE PARK NSW 2113 
 
POISONS SCHEDULE 
 
Schedule 4 – Prescription Medicine 
 
This document was approved by the Therapeutic Goods Administration on 4 
November 2010. Date of most recent amendment: 9 February 2017 
 
 
